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“Para ser grande, sê inteiro: nada 
 Teu exagera ou exclui. 
Sê todo em cada coisa. Põe quanto és 
 No mínimo que fazes. 
Assim em cada lago a lua toda 
 Brilha, porque alta vive.” 
 
Ricardo Reis  
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SUMMARY 
 
B lymphocytes are important players in adaptive immunity and the main targets of 
current vaccination strategies, with the interaction between B and T cells being fundamental to 
generate long-term immunity. B cells also play a key role in linking innate and adaptive immunity 
by expressing receptors that recognize both specific antigens and microbial patterns.  
The general aim of this work was to investigate the interplay between B cells and other 
components of the immune system through the study of B-cell immunodeficiencies, namely 
Common Variable Immunodeficiency (CVID), characterized by impaired antibody production due 
to defective mature B-cell differentiation, and Congenital Agammaglobulinemia, where early B-
cell development is abrogated, commonly resulting in the absence of peripheral B cells. 
We found BAFF-R expression to be reduced in CVID, particularly in patients with low 
memory B cells, and associated with high serum levels of BAFF, while TACI expression was 
significantly increased. BAFF induced BAFF-R down-regulation in vitro, both in healthy individuals 
and CVID patients. However, the degree of modulation in CVID was impaired, suggesting that 
these dynamics are affected, with a possible impact in B-cell homeostasis. 
We also observed that CVID was associated with monocyte activation, irrespective of LPS 
levels, but in direct association with T-cell activation and B-cell imbalances.  
To explore the mechanisms underlying chronic immune activation, we studied the role 
of IL-17, a major pro-inflammatory cytokine implicated in autoimmunity and inflammatory 
conditions, frequently found in CVID. However, no increase in TH17 cells was found and their 
frequency was inversely correlated with markers of germinal centre impairment. TH17 cells were 
severely reduced in Congenital Agammaglobulinemia and directly associated with switched-
memory B cells in healthy subjects. Our data support a link between B-cell differentiation and 
TH17 homeostasis, with implications for the understanding of the pathogenesis of 
inflammatory/autoimmune diseases and the physiology of B-cell depleting therapies. 
 
Keywords: Primary B-cell immunodeficiencies, CVID, Congenital Agammaglobulinemia, B 
cells, BAFF-R, BAFF, Monocyte activation, T-cell activation, TH17 cells, IL-17. 
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SUMÁRIO 
 
Linfócitos B têm um papel preponderante na imunidade adaptativa e são os principais 
alvos das estratégias de vacinação, sendo a interacção entre linfócitos B e T fundamental para 
desenvolver imunidade a longo prazo. Linfócitos B têm também um papel importante no 
estabelecimento da ponte entre imunidade inata e adaptativa. 
O objectivo principal deste trabalho foi investigar o diálogo entre linfócitos B e outros 
elementos do sistema imunitário, através do estudo da Imunodeficiência Comum Variável 
(IDCV), caracterizada por produção deficiente de anticorpos resultante de defeitos na maturação 
de linfócitos B, e da Agamaglobulinémia Congénita, em que ocorre um bloqueio precoce no 
desenvolvimento de linfócitos B, resultando frequentemente na sua ausência em circulação. 
A expressão de BAFF-R encontrou-se diminuída na IDCV, particularmente em doentes 
que possuíam uma frequência baixa de linfócitos B de memória, associada a níveis séricos de 
BAFF elevados. BAFF induziu diminuição de expressão de BAFF-R in vitro, no entanto de forma 
alterada na IDCV, sugerindo que esta dinâmica está afectada, com possível impacto na 
homeostasia de linfócitos B.  
A IDCV associou-se com activação monocitária, não relacionada com níveis de LPS, mas 
com activaçãode de linfócitos T e alterações de linfócitos B. 
Para explorar os mecanismos subjacentes à activação imunitária crónica, estudámos o 
papel da IL-17, citocina pró-inflamatória envolvida em autoimunidade e manifestações 
inflamatórias, as quais são frequentemente associadas a IDCV. No entanto, não houve aumento 
de linfócitos TH17 e a sua frequência associou-se inversamente com evidências de defeitos de 
centros germinativos. Linfócitos TH17 estavam reduzidos na Agamaglobulinémia Congénita, e em 
indivíduos saudáveis encontravam-se associados com a frequência de linfócitos B de memória 
com switch. Estes resultados mostram que a homeostasia de linfócitos TH17 se associa à 
maturação de linfócitos B, com implicações para a compreensão da patogénese de doenças 
inflamatórias/autoimunes e da fisiologia de terapêuticas depletivas de linfócitos B. 
Palavras-Chave: Imunodeficiências de linfócitos B, IDCV, Agamaglobulinémia Congénita, 
Linfócitos B, BAFF-R, BAFF, Activação monocitária, Activação de linfócitos T, Linfócitos TH17, IL-
17. 
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This introduction will be divided in two main parts. In the first part will be made an 
overview of the development of B lymphocytes, as well as of the role they play in the generation 
of immune responses. In the second part, primary B-cell immunodeficiencies will be addressed, 
with a brief historical overview followed by a description of the major clinical complications 
involved, together with a perspective on the aetiology of the different diseases and a short 
outline of the therapeutic strategies that are currently used in such conditions. 
 
PART I 
B CELLS AT THE CROSSROAD OF IMMUNE RESPONSES 
 
a. ONTOGENY, DEVELOPMENT AND DIFFERENTIATION OF B LYMPHOCYTES 
B lymphocytes are a population of haematopoietic cells that mainly dedicated to the 
production of antibodies. Importantly, current vaccination strategies rely on memory B-cell 
generation and antibody production by B cells. B lymphocytes are thus at the crossroad of 
immune responses. In evolutionary terms, their origin goes back more than 500 million years to 
the adaptive immune system of jawed vertebrates1. The discovery of B cells was essentially 
simultaneous to the discovery of T cells. In the mid-1960s, pioneer work by Max Cooper and 
Robert Good implied that the adaptive immune system was composed of two different 
populations: one that was accountable for the production of antibodies and derived from the 
chicken bursa of Fabricius, and another deriving from the thymus that was required for delayed 
hypersensitivity and graft versus host reactions2,3. This functional characterization was also at 
the basis of the nomenclature used then on: T (thymus-derived) and B (bursa-derived) 
lymphocytes. In mammals, B lymphocytes are bone marrow derived, also suiting the 
classification.  
Earlier stages of B-cell development occur in primary lymphoid organs, such as the foetal 
liver and the bone marrow, and then differentiation proceeds in secondary lymphoid organs, 
such as the spleen and lymph nodes, where B cells achieve functional maturation (Figure 1). 
Haematopoietic stem cells (HSCs) generate lymphoid progenitors that give rise to the earliest 
cell committed to the B-cell lineage, the progenitor B cell or pro-B cell. Proliferation of pro-B 
cells in the bone marrow is accompanied by the sequential rearrangement of the 
immunoglobulin (Ig) heavy chain, originating pre-B cells. The rearranged Ig heavy chain forms, 
together with the surrogate light chains, 5 and VpreB, the pre-B cell receptor (BCR). 
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Figure 1. B-cell development. Outline of the events involved, depicting the bone marrow, antigen-independent phase, 
and the functional maturation in the periphery (adapted from Immunology, by Goldsby et al.
4
). 
 
The progeny of pre-B cells will then proceed with the rearrangement of the Ig light chain, 
developing into immature B cells expressing membrane IgM at their surface, in addition to a 
functional BCR5-7. At this stage, expression of an autoreactive BCR can direct the internalization 
of the self-antigen-BCR complexes and the activation of a pathway of intracellular signals that 
arrests differentiation and initiates a secondary rearrangement of the Ig light chain that will 
replace the original one. This process is called receptor editing and provides the first checkpoint 
on B-cell development for autoreactivity8,9. In addition to receptor editing, B cells with 
autoreactivities can be eliminated by clonal deletion, undergoing apoptosis if they recognize self-
antigens expressed in the bone marrow10,11. Even though IL-7 has been shown to be critically 
involved in murine B-cell development, promoting VDJ rearrangements and inducing 
proliferation and survival of B-cell precursors12, such role for IL-7 in human B-cell development 
remains elusive. Patients with severe combined immunodeficiency (SCID) due to mutations in 
the IL-7 receptor have normal levels of circulating B cells13, arguing against a major role for IL-7 
in this process.  
Following the bone marrow phase of development, immature B cells migrate into 
secondary lymphoid organs to integrate an antigen-dependent phase of maturation in the 
periphery7,14. Immature B cells, also termed transitional B cells, are fundamentally short-lived 
and migrate to the spleen through the bloodstream, where they develop into mature long-lived 
B cells. Upon exiting the bone marrow, transitional B cells acquire expression of markers such as 
IgD or CD21 (also known as complement receptor 2, CR2)14. CD21 is part of the 
CD19/CD81/CD21/CD225 complex, which is associated with signal transduction from the BCR, 
thus playing an important role in the bridging of innate and adaptive responses15. Transitional B 
cells have been mainly characterized in the murine system, where they can be subdivided into 
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T1 and T2 transitional populations. These two populations can be distinguished according to the 
expression of phenotypic markers, such as CD21 and IgD, with T1 cells being IgMbrightCD21-IgD- 
and T2 cells defined IgMbrightCD21brightIgDbright. However, some controversy remains regarding 
whether they are developmentally related or completely independent populations14. 
Transitional B cells have also been described in humans and have been proposed to include two 
populations expressing differential levels of CD21, which would correspond to the T1 and T2 
transitional B-cell populations in the mouse16,17. These two populations are thought to represent 
distinct developmental stages, based on the assessment of B-cell reconstitution following HSC 
transplantation (HSCT)17. A third, more mature, transitional B-cell subset has also been proposed 
in humans, possessing a more transient nature and rapidly differentiating into mature naïve B 
cells18. Importantly, in addition to BCR signalling, transitional T1 and T2 B-cell populations have 
differential requirements for B-cell Activating Factor of the TNF family (BAFF)-mediated survival 
signals, since BAFF-deficient mice present impaired B-cell maturation arrested at the transitional 
T1 stage19, while BAFF-transgenic mice have an accumulation of B cells at the transitional T2 
stage20. It is unclear whether this requirement is also observed for human transitional B cells16,21. 
The transitional B-cell stage is particularly relevant given that it includes a second checkpoint for 
autoreactivity, in the event of an autoreactive B cell escaping the first checkpoint in the bone 
marrow. BCR signalling at this stage induces apoptosis and is thus very important to remove 
autoreactivities22. B cells that recognize autoantigens can also be converted to a state where 
they can no longer respond to BCR engagement, in a process termed clonal anergy or functional 
unresponsiveness23,24. Importantly, human transitional B cells can respond to Toll-like receptor 
(TLR) 9 stimulation by differentiating into IgM-secreting plasma cells (PCs), arguing that 
transitional B cells can actually play an important role in building a rapid immune response 
against bacterial antigens25,26. 
Mature B cells recirculate between the follicles of the spleen and the lymph nodes, 
playing a crucial role in adaptive immune responses (Figure 2). In humans, five major 
populations are described in peripheral B-cell development: the abovementioned transitional B 
cells, naïve B cells that have not yet encountered antigen, germinal centre (GC) B cells that are 
found in peripheral lymphoid organs and are actively involved in ongoing immune responses, 
memory B cells, expressing the memory marker CD27, that are generated through GC reactions 
and survive for long periods of time, and PCs that produce antibodies, being the effector arm of 
the B-cell immune response7. 
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Figure 2. Peripheral B-cell differentiation. Simplified schematic outline, with the main B-cell subsets depicted. MZ: 
marginal zone; smB: switched-memory B cell. 
 
Naïve B cells constitute the major B-cell subset found in the peripheral blood of healthy 
adult individuals27. Full activation of naïve B cells requires BCR cross-linking by antigen 
recognition, together with signals coming from CD40 ligation and cytokine stimulation (to be 
discussed in the next sections) and stimulation by TLR agonists28 (Figure 3). Following activation, 
naïve B cells can either differentiate into short-lived IgM-producing PCs through extrafollicular 
reactions or they can enter B-cell follicles and participate in GC reactions, where they 
differentiate into long-lived memory B cells and PCs29. Memory B cells possess less stringent 
requisites for activation and rapidly produce specific IgG when they re-encounter the antigen, 
while persisting once the antigen is cleared. Surface expression of CD27 is currently accepted as 
the best marker for memory, antigen-experienced B cells27. PCs directly differentiate from 
plasmablasts that migrate from the secondary lymphoid organs to the bone marrow29. They are 
normally not found in the peripheral blood of healthy individuals.  
The main origin of IgM-expressing human memory B cells is the subject of great 
controversy. While some argue that they derive from GC reactions30, others actually propose 
them to be independent of the GC, since they are present in patients with impaired GC 
formation and class-switch recombination (CSR)31-34. In addition, it has also been suggested that 
this population includes B cells that are the circulating counterparts of splenic marginal zone 
(MZ) B cells, which are important in the responses against encapsulated bacteria, and that they 
would undergo somatic hypermutation (SHM) very early during ontogeny35,36. 
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Figure 3. The 3-signal model for naïve B-cell activation. Full activation of naïve B cells requires the integration of BCR 
stimulation (Signal 1), and help provided by T cells (Signal 2), both in the form of co-stimulation and cytokines. BCR 
stimulation drives the up-regulation of TLR expression
37
, which then provides Signal 3 for B-cell activation. 
 
In the mouse, follicular (also termed B2) B-cell differentiation is essentially similar to that 
described above for humans. In addition, two separate lineages of B cells have also been well 
characterized, with features that put them closer to the innate arm of the immune system: B1 B 
cells and the already mentioned MZ B cells38. While MZ B cells share developmental stages with 
B2 B cells39, B1 B cells develop from distinct B-cell progenitors in the foetal liver40. B1 B cells, 
originally identified as a population of CD5+ splenic B cells, are a self-renewing population and 
express germline-encoded antibodies that form the so-called natural antibody repertoire41. The 
terminology derives from the fact that these antibodies are generated in the absence of antigen 
exposure and hence the proximity to a more innate-like function41. B1 B cells are believed to 
play an important role in the suppression of inflammatory responses41,42. Even though human 
equivalents to mouse B1 B cells have been reported over time43-45, these cells are not resident in 
the peritoneal cavity46, unlike mouse B1 B cells. The recent report that the human equivalent to 
murine B1 B cells expresses CD27 and IgM, in addition to CD43, argues that at least some B cells 
that have been previously described as IgM-expressing memory B cells are in fact B1 B cells44. 
MZ B cells are, as the nomenclature indicates, located in the marginal zone of the spleen. They 
represent a distinct, non-circulating, lineage of murine splenic B cells, critical for the first line of 
defence against encapsulated bacteria47. Contrary to what is seen in the mouse, human MZ B 
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cells can recirculate and are thus found both in the spleen and the peripheral blood. In addition 
and as previously mentioned, they express the memory marker CD27 and have been described 
to undergo SHM in the absence of typical immune responses36,47,48. Nevertheless, it has been 
proposed that, similar to what happens in the murine system, MZ B cells are critical for the fast 
protective, T-independent response against encapsulated bacteria47. 
Peripheral B-cell survival and differentiation largely depend on two factors belonging to the 
TNF family, BAFF and A Proliferation Ligand (APRIL), and on their interaction with the receptors 
BAFF Receptor (BAFF-R), Transmembrane Activator and Calcium-modulating Cyclophilin Ligand 
Interactor (TACI), and B-cell Maturation Antigen (BCMA)49. BAFF signalling through BAFF-R is 
particularly relevant for the survival and maturation of peripheral B cells, while APRIL acting 
through BCMA appears to be critical for PC survival in the bone marrow50-53. BAFF-R stimulation 
by BAFF mainly activates the alternative Nuclear Factor-B (NF-B) pathway, mediated by the 
stabilization of the NF-B-inducing kinase (NIK) induced by TNF-receptor associated factor 
(TRAF) 3 degradation, thereby resulting in increased B-cell survival49,54-56. In addition, BAFF 
stimulation of BAFF-R also has an impact in the metabolic fitness of B cells by activating the 
mammalian target of rapamycin complex 1 (mTORC1), in a pathway that sequentially involves 
Phosphoinositide 3-kinase (PI3K) and Akt57,58. The activation of Akt in also critically involved in 
the up-regulation of the anti-apoptotic molecule myeloid cell leukemia sequence 1 (Mcl-1)54,58 
(Figure 4). The integration of the signals delivered through BAFF-R stimulation to these signalling 
pathways thus mediates the effects of BAFF on B-cell survival and metabolic fitness. 
 
 
Figure 4. Simplified schematic representation of BAFF-R-mediated signalling events. 
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b. B CELLS AND THE INNATE IMMUNE SYSTEM 
Whenever a pathogen enters the organism, an immune response needs to take place in 
order to clear it and prevent further damage. Given that failing to control the initial phase of an 
infection can have serious and even life-threatening outcomes, there is the need for immune 
defences that are ready-to-go. The innate immune system has the task of initiating a local 
inflammatory response at the place of pathogen entry, thereby limiting the extent of infection 
until an adaptive immune response is developed. In addition, the innate immune system also has 
a crucial role in the priming of the initial adaptive immune response. B cells have an important 
role in linking cell-intrinsic innate and adaptive immune responses, given the fact that they 
express both an antigen-specific BCR and TLRs59. TLRs are receptors that recognize microbial 
antigens and activate the innate immune system. The integration of signals coming from these 
two pathways thus determines the fine-tuning of the overall B-cell response. 
As previously mentioned, two subsets of B cells have characteristics that places them closer 
to the innate immune system: B1 B cells and MZ B cells. These B-cell subsets are crucially 
involved in T-independent immune responses, where they generate rapid although low-affinity 
antibody production60. Moreover, the BCRs expressed by B1 and MZ B cells are of limited 
diversity and preferentially recognize microbial antigens and self-peptides, and TLR signalling is 
important for their responses. In fact, B1 and MZ B cells show higher responsiveness to TLR 
signals than follicular B cells61,62. TLR stimulation induces the up-regulation of Blimp-1 specifically 
in B1 and MZ B cells, thus driving their differentiation into PCs61. In addition, B1 and MZ B cells 
are highly responsive to BAFF63,64, which is mainly produced by cells of the innate immune 
system, such as dendritic cells, monocytes, macrophages, neutrophils and FDCs, and can also be 
stimulated in response to TLR ligands49. Also, naïve and memory B cells respond differently to 
TLR stimulation, with memory B cells expressing constitutively higher levels of several TLRs37,65. 
This renders memory B cells able to differentiate into PCs through TLR stimulation bypassing the 
need for T-cell help37,66. 
Such innate-like immune responses of B cells are particularly important in the context of 
mucosal tissues. Especially in the intestine, B cells mediate immunity against commensal 
bacteria through the production of IgA by mucosal follicular and extrafollicular reactions67,68. At 
these sites, immune responses are highly dependent on TLR stimulation, as well as on factors 
such as BAFF, APRIL, TGF-, and IL-1069-71. 
TLR stimulation of innate cell types can also have an effect in the modulation of B-cell 
responses. Plasmacytoid dendritic cells (pDCs) were shown to have a better ability to support B-
cell differentiation when compared to myeloid dendritic cells (mDCs)72,73. Interestingly, TLR-
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stimulated mDCs and macrophages may play a suppressive role in controlling the activation of 
autoreactive B cells, through the secretion of IL-6 and soluble CD40L74,75. This suppressive effect 
was specific for autoreactive B cells, since the activation of naïve B cells was not affected in this 
system75. In line with this observation, patients with defects in TLR signalling (i.e., deficiencies in 
Myeloid Differentiation Factor 88 (MyD88), Interleukin-1 Receptor-associated Kinase 4 (IRAK4), 
and UNC93B) have an appearance of autoreactive mature naïve B cells in the peripheral blood76. 
Understanding how B cells translate the different signals around them, coordinating the 
innate and the adaptive immune systems, is of paramount importance, both for the 
development of adequate vaccination protocols and treatments for autoimmune diseases77.  
 
c. THE RELEVANCE OF T-B CELL INTERACTIONS FOR IMMUNE RESPONSES 
The interaction between B cells and T cells is fundamental to generate adaptive immune 
responses. The establishment of long-term humoral immunity, namely in vaccination strategies, 
relies on B cells receiving appropriate help from CD4 T cells in the context of GC reactions, with 
the generation of memory B cells and antibody-producing plasma cells78. It should also be 
appreciated that B cells themselves play a crucial role in the development and maintenance of 
the immune response, in addition to their effector function of antibody production, by acting as 
antigen-presenting cells (APCs), producing cytokines, recruiting and co-stimulating CD4 T cells7.  
 
i. ORGANIZATION OF GERMINAL CENTRES 
GCs are specific structures within B-cell follicles where antigen-driven SHM and CSR 
occur79. The GC reaction starts with the recruitment and expansion of antigen-experienced B 
cells to the B-cell follicles of secondary lymphoid organs, which have as main function bringing 
together APCs and lymphocytes in order to mount immune responses. Whether B cells 
differentiate into plasmablasts in extrafollicular reactions or seed the GC seems to be related to 
BCR primary affinity for the antigen. BCRs with high affinity most likely drive B cells into the 
extrafollicular reaction, whereas moderate or lower affinity will push B cells into the GC80,81. As 
the GC reaction develops, a defined anatomical structure comprising light and dark zones 
becomes apparent (Figure 5). The light zone is mainly occupied by follicular dendritic cell (FDC) 
processes, while lymphocytes are compacted in the dark zone. The chemokine receptors CXCR4 
and CXCR5 are crucial for the positioning of lymphocytes to the dark zone and the light zone. 
CXCL12, the ligand for CXCR4, is more abundant in the dark zone, while CXCL13, the ligand for 
CXCR5, is more abundant in the light zone79,82. GC B cells in the dark zone are called centroblasts 
and express high levels of CXCR4, while GC B cells present in the light zone are termed 
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centrocytes and express high levels of CXCR5. Different events of the GC reaction take place at 
different zones of the GC; SHM occurs in proliferating centroblasts in the GC dark zone, while it 
is in the light zone that interactions between T cells, centrocytes and FDCs happen79,82,83. During 
the GC reaction, B cells clonally expand to ultimately generate a high affinity BCR to the given 
antigen, with the locus of the Ig heavy chain undergoing CSR and its variable regions going 
through SHM. Both of these processes are mainly mediated by an enzyme termed activation-
induced cytidine deaminase (AID)84. 
 
 
Figure 5. Germinal Centre. Schematic representation of the structure of a germinal centre, with dark and light zones 
depicted. Somatic hypermutation occurs in the dark zone, while class-switch recombination is limited to the light 
zone, where B cells interact with follicular helper T cells (TFH) and follicular dendritic cells (FDC) (adapted from Klein 
and Dalla-Favera
84
). 
 
T-cell help is known to be essential to the induction and subsequent organization of GCs. 
This help is attributed to a particular subset of T cells, follicular helper T cells (TFH)
85,86, which are 
identified by the expression of the chemokine receptor CXCR5, necessary for their specific 
homing to B-cell follicles and within GCs87-89. In addition to CXCR5 expression, TFH cells are 
characterized by the expression of the co-stimulatory molecules CD40L and ICOS85,86, crucial for 
their function of B-cell help provision (see next section), and the inhibitory receptor 
Programmed Death-1 molecule (PD-1)90. A major function of TFH cells is the production of 
interleukin (IL)-2191, a cytokine involved in B-cell differentiation, survival and function (discussed 
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below). After a long standing debate regarding the functional relationship between other helper 
T-cell populations and TFH cells, they have been described as a separate lineage of helper T 
cells91-93, with its generation being governed by the transcription factor B-cell Lymphoma 6 (Bcl-
6)94-96. In B cells, Bcl-6 expression is restricted to the GC and it suppresses the differentiation into 
plasma cells, by inhibiting the expression of the transcription factor B Lymphocyte-induced 
Maturation Protein-1 (Blimp-1)97,98. In addition, Blimp-1 has also been shown to inhibit TFH cell 
differentiation and function96. Thus, Bcl-6 is crucial for GC development and function, both at the 
B-cell and the T-cell levels95. The lack of adequate T-cell help during the priming of B cells results 
in apoptosis, rather than their differentiation into GC B cells or plasma cells78,99,100. 
Despite the fact that much is known about the attributes of adaptive immune responses, 
the factors that govern the differentiation of memory B cells and their long-term maintenance 
remain largely unknown101.  
 
ii. CO-STIMULATORY MOLECULES 
The functional interaction between T cells and B cells within GCs rely on the expression 
of co-stimulatory molecules, such as CD40-CD40L and the Inducible Co-Stimulator (ICOS) 
molecule102.  
CD40 is a member of the tumour necrosis factor (TNF) receptor family and a co-
stimulatory molecule expressed on B cells that binds CD40L on the surface of activated T cells. 
This interaction activates B cells and, in combination with soluble cytokines, induces production 
of different classes of antibodies103,104. For instance, CD40 stimulation together with IL-4 induces 
preferential isotype switch to IgE105. Humoral responses are impaired in both mice106,107 and 
humans108-113 with defective CD40L function, underpinning the important role of CD40-CD40L 
interactions in GC generation, isotype switching and SHM. Also, blocking CD40-CD40L 
interactions impairs the formation of the GC structure and the proliferation of B cells114-116. 
Importantly, CD40 signals are essential to prevent centrocyte apoptosis99,100. 
ICOS, a member of the CD28 family of T-cell co-stimulatory molecules117, plays a critical 
role in the regulation of humoral immunity. ICOS expression is up-regulated on T cells following 
activation and is expressed at high levels on TFH cells
85,86,117. ICOS specifically binds to ICOS ligand 
(ICOSL), constitutively expressed on B cells118. ICOS co-stimulation induces IL-4 and, more 
specifically, IL-10 production by T cells, both of which have an important role in antibody 
production117 (discussed in the next section). Of note, ICOS co-stimulation also induces up-
regulation of CD40L expression117, further enhancing the B-cell helper capacity of the T cell. Both 
ICOS-deficient mice119-122 and human individuals31,123 exhibit profoundly defective isotype class-
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switch, as well as impaired GC formation. Homozygous deletion of the ICOS gene in humans 
leads to a phenotype of Common Variable Immunodeficiency (CVID), with low numbers of B 
cells, low serum antibody concentrations and lack of memory B cells31. It is noteworthy to 
mention that patients with defective ICOS or CD40L show a decreased frequency of circulating 
CXCR5+ CD4 T cells124, which are suggested to be the counterparts of TFH cells found in secondary 
lymphoid organs124,125. Together with the finding of reduced TFH cells in the spleens and lymph 
nodes of ICOS- and ICOSL-deficient mice124,126, this suggests that ICOS is important for the 
development of TFH cells. In line with these observations, ICOS has recently been shown to 
supply a vital signal for the early induction of Bcl6 on T cells, which then induces expression of 
CXCR5, committing cells to the TFH lineage
127. 
PD-1 expression by TFH cells also plays a critical role in the GC reaction. GC B cells up-
regulate the expression of the PD-1 ligands Programmed Death-1 molecule Ligand 1 (PD-L1) and 
Programmed Death-1 molecule Ligand 2 (PD-L2). The study of mice deficient for either of the 
molecules involved in this pathway showed that PD-1 expression on T cells and PD-L2 expression 
on B cells is in fact regulating TFH cell and PC numbers
128. PD-1 deficiency also resulted in lower 
production of IL-4 and IL-21. It has thus been proposed that PD-1 directs the development of 
long-lived PCs by regulating the survival and selection of B cells in the GC, through its role in the 
function of TFH cells
128. 
In addition to the aforementioned molecules, other factors that affect the interaction 
between T and B cells also have an impact in GC development and function101. One of such cases 
is the signaling lymphocytic activation molecule-associated protein (SAP), expressed on T cells, 
whose absence results in defective interaction between TFH and B cells, with a consequent 
inability of TFH cells to sustain GC reactions
129.  
 
iii. SOLUBLE FACTORS 
T-cell derived cytokines present during the events of B-cell activation are crucial in the 
modulation of the B-cell response, namely by regulating the CSR process and determining the 
class of antibody that the B cell will produce.  
IL-21 is probably the best example of cytokines involved in the functional interaction 
between T cells and B cells130-132. IL-21 was first described as having a critical role in the 
regulation of antibody production by B cells131,133,134. In addition, the GC requirement for IL-21 
was also found to reflect an intrinsic requisite for TFH maintenance, acting in an autocrine 
fashion132. Nevertheless, IL-21 is in fact a central player in the B helper function provided by TFH 
cells. IL-21 produced by TFH cells acts directly in a B-cell intrinsic fashion to induce Bcl-6 
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expression and thus has a crucial role in the development of GC responses135,136. In the absence 
of IL-21 signalling, GCs are reduced and the production of high-affinity plasma cells is 
impaired135,136. IL-21 production is induced by ICOS stimulation, through the regulation of the 
transcription factor c-Maf137. Paradoxically, IL-21 was also found to promote B-cell apoptosis138. 
This effect is however dependent on the activation signals provided to B cells and may thus 
represent an important role of IL-21 in regulating B-cell homeostasis138,139. 
IL-4, the master cytokine involved in Th2 responses, was originally identified as a B-cell 
stimulating factor140,141. IL-4 was shown to be critical for isotype switch to IgE and IgG1105,142, and 
also to cooperate with IL-21 in regulating isotype switch to different IgG subclasses and IgA131,143. 
Importantly, TFH cells have been shown to produce IL-4 upon immunization with given antigens, 
in particular with helminths144,145. 
IL-2 was initially described as promoting B-cell growth146,147. In addition, it has later been 
demonstrated to participate in the induction of antibody production148-152. However, recent data 
has challenged this view, with IL-2 administration being described to impair influenza-specific GC 
formation, long-term IgG responses and limiting the differentiation of TFH cells
153. However, 
other recent reports have identified T-cell derived IL-2 to be critically involved in human PC 
differentiation154,155. If these conflicting data represent an essential functional difference 
between the murine and the human systems is something that needs to be clarified. 
IL-6 is another T-cell derived cytokine with a role in the regulation of B-cell responses156,  
inducing plasma cell differentiation and antibody production152,157,158. Importantly, IL-6 was also 
shown to promote IL-21 production159,160 and to drive the differentiation of T cells with the 
ability to provide B-cell help160. 
IL-10 has a well recognized role in PC differentiation, especially in humans78,148,157,161,162. 
Along with Tumour Growth Factor (TGF)-, it mediates isotype switch to IgA163, particularly 
important at the mucosal sites. IL-10 seems to be especially relevant in stopping B-cell 
proliferation in the GC and inducing differentiation into PCs164. IL-10 production is enhanced by 
ICOS stimulation117,165,166, which is particularly relevant in the context of TFH cells. Accordingly, 
human TFH cells were found to produce IL-10 in an ICOS-dependent manner
167,168, which adds up 
to their function in providing B-cell help. Recent studies also suggest that IL-10 production by B 
cells, the so-called regulatory B-cell population, can be important to modulate T-cell 
responses169,170. 
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PART II 
PRIMARY B-CELL IMMUNODEFICIENCIES 
 
a. HISTORICAL PERSPECTIVE, CLINICAL MANIFESTATIONS, AETIOLOGY AND TREATMENT OF PRIMARY B-CELL 
IMMUNODEFICIENCIES 
Primary B-cell immunodeficiencies include several disorders that have as a common feature 
a defect in antibody. Currently, several classes of primary antibody deficiencies are considered - 
defective early B-cell development in the bone marrow; impairments in CSR, mainly comprising 
Hyper IgM (HIGM) syndromes; isotype or light chain deficiency, including selective IgA 
deficiency; specific antibody deficiency; and CVID. Given the fact that this work will be mainly 
focused on patients affected by defects in early B-cell development and CVID patients, the other 
classes will only be briefly mentioned. 
 
CSR defects, also referred to as HIGM syndromes, are observed in patients with 
recurrent infections that have normal or elevated serum levels of IgM, in the presence of 
reduced IgG, IgA, and IgE. In addition to the CSR defect, SHM can also be affected171. This group 
of genetic defects can be B-cell restricted or it can affect other cell types, such as T cells, 
macrophages or DCs. More than half of the patients with CSR defects present X-linked mutations 
in the gene encoding CD40L108-110,112,113, expressed by activated T cells. In this case, patients 
usually suffer from opportunistic infections and neutropenia, presenting a clinical picture that is 
more severe than the one seen in patients with pure humoral defects171. CD40 deficiency has 
also been identified, although in very rare cases, with a clinical phenotype identical to the CD40L 
deficiency172. In terms of CSR defects that are B-cell restricted, autosomal recessive mutations in 
AID account for the majority of the cases173,174. These patients have a later onset of disease, 
while frequently presenting adenopathies and a high incidence of autoimmunity175. Autosomal 
dominant mutations have also been described in a small number of patients176. In addition, 
autosomal recessive mutations in uracil-DNA glycosylase (UNG), an enzyme responsible for the 
deglycosylation and removal of uracil residues resulting from the action of AID, have also been 
described in very few cases of HIGM patients177. The clinical phenotype is similar to the one 
observed in AID-deficient patients. 
 
X-linked Agammaglobulinemia (XLA) was one of the first immunodeficiencies to be 
described and is often regarded as a prime example.  Back in 1952, Ogden C. Bruton reported a 
case of an 8-year-old male presenting recurrent pneumococcal sepsis with complete absence of 
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the serum gamma globulin fraction, with otherwise normal serum proteins178. These laboratory 
findings led to the use of tailored therapy, through the subcutaneous administration of human 
immune serum globulin, while completely explaining the clinical symptoms. In 1953, Charles A. 
Janeway and colleagues documented the same phenomena (agammaglobulinemia and recurrent 
infections) in an adult individual, in what was the first report of the nowadays termed CVID179. 
While having a similar outline, it was since early recognized that differences existed between the 
two observations. Agammaglobulinemia mainly affected males when presenting during 
childhood, often with an X-linked mode of inheritance, whereas in adults such pattern was not 
evident, with both females and males being equally affected179-184. Later on, it was established 
that patients with XLA presented virtually no circulating B lymphocytes, at the same time as 
adult CVID patients typically had close to normal numbers of B cells185-188. It was not until more 
than 40 years after the original description that the molecular defect underlying XLA was 
unveiled and shown to affect a cytoplasmic tyrosine kinase expressed at all stages of the B-cell 
lineage and in myeloid cells, later termed Bruton’s Tyrosine Kinase, or Btk189,190. Mutations in the 
Btk gene arrest early B-cell development in the bone marrow at the pre-B cell stage191-194, 
frequently, but not always195,196, leading to a complete absence of circulating mature B cells. This 
block in B-cell development results from defective signal transduction by Btk through the pre-
BCR and BCR197,198. 
Regarding clinical manifestations, the most common feature of XLA patients is recurrent 
infections of the respiratory tract that usually start between 3 and 18 months of age199-201. 
Although some problems can arise from viral infections at early ages, they are well dealt with by 
XLA patients once T-cell immunity is developed. The most frequent infectious agents are the 
encapsulated bacteria Streptococcus pneumoniae and Haemophilus influenza, in terms of 
respiratory tract infections, and the protozoan parasite Giardia, in what concerns 
gastrointestinal infections199.  
In addition to the X-linked form of agammaglobulinemia, autosomal recessive forms 
have also been identified, accounting for approximately 15% of the cases of patients suffering 
from early defects in B-cell development202 (Table 1). As happens with patients with XLA, all of 
these patients are characterized by presenting an onset of recurrent infections in the first 5 
years of life, severe hypogammaglobulinemia, remarkably reduced or absent circulating B cells, 
and a block in B-cell development in the bone marrow. 
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Table 1. Genetic defects underlying Congenital Agammaglobulinemia. 
GENETIC DEFECT ASSOCIATED FEATURES REFERENCES 
Btk deficiency 
Severe bacterial infections; 
Absence of circulating B cells; 
Normal numbers of pro-B cells in the bone 
marrow 
173, 176, 177 
 heavy chain deficiency 198 
5 deficiency 200 
Ig deficiency 201 
Ig deficiency 202, 203 
BLNK deficiency 204 
PI3K deficiency 
Severe bacterial infections; 
Absence of circulating B cells; 
Markedly reduced numbers of pro-B cells in 
the bone marrow 
205 
 
Autosomal recessive forms of agammaglobulinemia include mutations in the genes 
encoding for components of the pre-BCR or the BCR, or in the adaptor protein B cell Linker 
Protein (BLNK), which also plays a role in signal transduction from the BCR. Mutations in the  
heavy chain, which defines the IgM isotype and is part of the BCR, were identified to underlie a 
clinical picture similar to XLA203. However, the clinical manifestations found in these patients 
tend to be biased towards a more severe phenotype, with an earlier onset of disease and more 
clinical complications throughout life204. A smaller number of patients have been identified with 
mutations in the genes encoding 5205, Ig206, and Ig207,208, all of which are part of the pre-BCR 
complex. In addition, mutations in BLNK have also been described to give rise to a phenotype 
similar to XLA209. The vast part of the patients presents null mutations that abrogate protein 
function. In clinical terms, these patients are identical to XLA patients, even though they 
normally present an earlier onset of disease. Very recently, it has been described a case of a 
young female with agammaglobulinemia in the absence of circulating B cells that presented a 
mutation in PI3K, resulting in the absence of the p85 subunit210. Interestingly, the absence of 
p85 in the patient results in an early and striking defect in B-cell development in the bone 
marrow, but with a clinical picture restricted to colitis. The block in B-cell development was 
observed at the earliest stage of commitment to the B-cell lineage, earlier to what is seen for 
XLA or patients with other forms of autosomal recessive agammaglobulinemia210. 
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CVID is the most frequent primary immunodeficiency with clinical relevance, with  an 
estimated prevalence of 1:25,000 – 1:50,000 in the European population211. The age of disease 
onset has a bimodal distribution, with some patients being diagnosed during childhood while the 
majority presents in early to mid adulthood. CVID is clinically defined by reduced serum levels of 
IgG and at least another Ig isotype, impaired antibody response to vaccines, and exclusion of 
defined causes of hypogammaglobulinemia212. Nevertheless, CVID patients present highly 
heterogeneous clinical and immunological profiles. In addition to the high frequency of 
respiratory and gastrointestinal tract infections, a myriad of non-infectious complications have 
been reported in more than two-thirds of CVID patients, ranging from chronic lung disease and 
gastrointestinal inflammatory disease, to autoimmune manifestations, granulomatous disease 
and neoplasias211,213,214. Autoimmunity is being increasingly recognized as a serious medical issue 
in CVID patients, affecting more than 20% of the patients215,216. A recent study has reported the 
immunological parameters, clinical complications and mortality statistics from 473 CVID patients 
followed for over 4 decades214. In this report, it was found that CVID patients had a significantly 
shorter survival rate than age- and gender-matched control populations. In addition, this 
reduced survival was significantly associated with age at diagnosis, lower circulating B cells, and 
lower baseline serum levels of IgG and higher levels of IgM. Patients affected by non-infectious 
complications had a significantly higher mortality risk, which was associated with lymphoma, 
liver or lung disease, and gastrointestinal manifestations, but not with other complications214. 
Moreover, an Italian study has concluded that malignancies are the major cause of death in 
adult-onset CVID217. Another study has analysed and divided 334 CVID patients into distinct 
clinical phenotypes, but failed to identify useful predictors213. 
Even though the vast majority of CVID cases are sporadic, familial patterns of inheritance 
are observed in 10 – 20% of the patients, with a family history of autoimmunity or disorders of 
antibody production218,219. In some families, CVID co-exists with IgA deficiency (IgAD). This 
primary immunodeficiency can be selective for IgA or be associated with deficiency in subclasses 
of IgG, and is the most common primary immunodeficiency. However, the majority of IgAD 
patients are asymptomatic and thus the condition is clinically not very relevant220,221. Some IgAD 
patients progress to CVID, suggesting a degree of common genetic aetiology. In this sense, early 
studies identified certain Human Leukocyte Antigen (HLA) haplotypes to be more common in 
both conditions219,222-226. 
According to the latest update on the classification of Primary Immunodeficiency 
Diseases (PIDs)13, CVID, now standing for Common Variable Immunodeficiency Disorders, groups 
all patients with a severe reduction of at least two Ig isotypes with normal or low B-cell numbers 
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of unknown aetiology. In this recent classification, the molecular defects that give rise to a CVID-
like phenotype are now in separate subgroups, namely mutations in ICOS, CD19, CD81, CD20, 
TACI, and BAFF-R13. 
ICOS deficiency was the first genetic defect to be identified in four patients with adult-
onset CVID, in 200331. Patients failed to express ICOS at the surface of activated T cells, due to a 
partial homozygous deletion in the ICOS gene. Five additional patients have been later described 
to present the same homozygous deletion, indicating that all nine patients probably share a 
common founder227. It is interesting to note that this first description of an autosomal recessive 
disorder underlying CVID was related to a T-cell intrinsic defect that affects the cross-talk 
between T and B cells in GCs. In the original report of the first four patients, ICOS-deficient 
patients were described as lacking major non-infectious complications, such as splenomegaly or 
autoimmunity31. However, the subsequent identification of five additional patients, who 
included patients with early-onset disease, showed that ICOS deficiency can present with the full 
clinical spectrum of CVID123. 
Mutations in CD19 were described in 2006, resulting in a phenotype of 
hypogammaglobulinemia compatible with CVID228. There are currently six cases identified, all of 
which present normal numbers of circulating B cells with minimal or no expression of CD19 at 
their surface199,202,228,229. These include both early- and adult-onset CVID-like phenotypes. Given 
that CD19 is part of a complex that is associated with signal transduction from the BCR230,231, 
mutations in CD19 likely hinder antigenic stimulation and hence result in defective humoral 
responses. Accordingly, B cells from CD19-deficient patients showed defective calcium fluxes 
following BCR stimulation. Vaccination responses were also impaired228. Patients with CD19 
deficiency did not present signs of non-infectious complications, including autoimmunity, 
lymphoid proliferation or neoplasias228. 
CD81 deficiency was reported in 2010 in one patient with severe nephropathy and 
hypogammaglobulinemia232. B cells from the patient did not express CD19, but had normal CD19 
alleles. Instead, a homozygous mutation in CD81 was found, leading to a complete absence of 
CD81 expression. Transduction experiments showed that CD81 expression was crucial for CD19 
membrane expression. So, CD81 deficiency leads to a functional phenotype that is similar to 
CD19 deficiency, with impaired responses through BCR stimulation232. 
Also in 2010, CD20 deficiency was described in a young patient with persistent 
hypogammaglobulinemia233. The patient presented normal peripheral B-cell numbers, but a 
severe decrease in the frequency of memory B cells. SHM was defective and even though the 
patient mounted adequate antibody responses after vaccination with recall antigens, responses 
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to pneumococcal polysaccharides (T-independent) were strongly impaired233, suggesting that 
CD20 may play an important role in the development of T-independent responses. 
TACI mutations were originally reported by two independent studies of two different 
cohorts of CVID and IgAD patients234,235. The pattern of inheritance of these mutations seems to 
be rather complex, since simple heterozygous, compound heterozygous and homozygous 
mutations have all been found, involving both autosomal dominant and recessive mechanisms. 
The most common TACI mutations in CVID are the amino-acid substitutions C104R and A181E236-
238. These, together with the amino-acid substitution S144X, have been identified both in 
heterozygosity and homozygosity. The C104R and S144X mutations, when in a homozygous 
state, abrogate APRIL binding, with loss of TACI function, whereas in heterozygosity APRIL 
binding is retained235. The functional relevance of heterozygous mutations is thus elusive. 
However, work has shown that the assembly of wild-type and mutant receptors together, as it 
would be the case when the mutation is present in a heterozygous state, although not having a 
impact on ligand-binding interferes with the downstream signalling from the receptor239. The 
screening of more than 500 CVID patients from different cohorts has shown that TACI variants 
are found in around 8-10% of CVID patients236. However, the mutations are also found in healthy 
individuals, although at a lower frequency, questioning the relevance of these mutations in CVID 
pathogenesis. Nevertheless, presence of a heterozygous mutation was significantly associated 
with antibody deficiency, particularly relevant in the case of the C104R mutation, indicating that 
this mutation increases the risk for CVID and affects the clinical presentation236. It is worth 
noting though that the C104R homozygous mutation has not been found in healthy controls and 
thus seems to be disease-causing. Accordingly, the murine equivalent to the C104R TACI 
mutation, C76R, significantly disrupts B-cell homeostasis, Ig production, and antigen-stimulated 
humoral responses240. In clinical terms, CVID patients with TACI mutations present a higher 
prevalence of autoimmune manifestations and splenomegaly236, in line with the phenotype of 
TACI-deficient mice241,242. 
Two siblings who present a late-onset CVID-like syndrome have been described to lack 
BAFF-R protein expression with consequent severe B-cell lymphopenia243. The clinical 
manifestations in these patients were however mild in comparison to other antibody-deficient 
settings, with no autoimmune nor lymphoproliferative manifestations reported243. Even though 
both patients presented the same homozygous BAFF-R deletion, their clinical presentation 
differed significantly, demonstrating the variable penetrance of this deficiency243. Nevertheless, 
both patients showed a poor response to T-independent antigens, in correlation with reduced 
numbers of MZ B cells, while maintaining adequate responses against T-dependent antigens243. 
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In addition, polymorphic variants of BAFF-R have been described, affecting both CVID patients 
and healthy individuals244. Such variants do not impact upon BAFF-R expression, neither at the 
mRNA level nor at the protein level244, thus questioning the relevance of such alterations.  
Finally, CD21 deficiency was very recently added to the list of monogenic defects 
resulting in a CVID-like phenotype. One adult patient, who presented with a history of recurrent 
infections, normal B-cell numbers but reduced switched-memory B cells, and 
hypogammaglobulinemia, was found to have undetectable expression of CD21 on B cells. 
Sequence analysis revealed a compound heterozygous deleterious mutation in the CD21 gene245. 
Contrary to was is seen in CD19 and CD81 deficiencies, CD21 deficiency did not impair on the 
expression of other components of the signalling complex, which can explain the fact that CD21-
deficient B cells present normal responses to BCR stimulation. Nevertheless, B cells from the 
patient did not bind or respond adequately to C3d-containing immune complexes. The clinical 
phenotype of the patient was not severe, since he was able to mount specific antibody 
responses upon vaccination, although to a lesser degree in the case of polysaccharide 
antigens245. 
Also quite recently, a genome-wide association and gene copy number variation study 
was performed in 363 CVID patients246. This study confirmed the Major Histocompatibility 
Complex (MHC) locus as being associated with CVID, in line with previous observations that were 
done with different technologies219,222-226. The study also uncovered a region that was associated 
with CVID outside of the MHC locus, encompassing several members of the A Disintegrin and 
Metalloproteinase (ADAM) family246, which are zinc metalloproteases involved in several 
biological processes. Importantly, this study confirmed the view of CVID as being a highly 
heterogeneous disease, even at the genetic level.  
 
The aforementioned genetic defects found to underlie CVID, which together represent 
no more than around 10% of the cases, elegantly illustrate the complexity of CVID 
physiopathology. Deficiencies in receptors that are involved in signal transduction through the 
BCR, molecules expressed by T cells that play an important role in B-cell help, and receptors that 
have a major impact on B-cell survival and function, have all been shown to give rise to a CVID 
phenotype, with defective production of antibodies. However, CVID is not merely a deficiency of 
antibody production. Patients are affected by a myriad of clinical complications that are not 
solely explained by a loss of B-cell function in terms of antibody production.  
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Table 2. Known genetic defects underlying Common Variable Immunodeficiency. 
GENETIC DEFECT ASSOCIATED FEATURES REFERENCES 
CD19 deficiency 
Mild clinical phenotype; 
Normal numbers of circulating B cells 
223, 224 
CD20 deficiency 228 
CD21 deficiency 240 
CD81 deficiency Nephropathy; 
Similar to CD19 deficiency 
227 
ICOS deficiency Variable clinical phenotype; 
Activated T cells fail to express ICOS 
32, 118, 222 
BAFF-R deficiency Late-onset, mild clinical phenotype; 
Severe B-cell lymphopenia 
238 
TACI deficiency 
Complex pattern of inheritance; 
High prevalence of autoimmunity and 
splenomegaly 
229, 230, 231 
 
 
The therapeutic management of CVID patients is mainly focused in reducing the 
morbidity and the mortality that are associated with recurrent infections. IgG replacement 
therapy is the standard treatment for antibody deficiencies ever since the very first case 
reported178, providing patients with the antibodies that they are unable to produce in adequate 
amounts. Even though IgG replacement therapy is highly efficacious in reducing the frequency of 
infections, some patients remain susceptible to recurrent infections and the occurrence of non-
infectious complications is not resolved by the replacement therapy213,247-250. A recent study has 
analyzed the infection outcomes in patients with CVID and XLA in relation to the replacement 
therapy for an extended period of time, showing that XLA patients required significantly higher 
doses to prevent infections251. The same study reported that patients with bronchiectasis 
received higher doses of replacement IgG and that the presence of clinical complications, such as 
enteropathy, cytopenias or lymphoproliferation, resulted in significantly higher levels of IgG 
being administered to CVID patients in order to remain infection-free. They have also shown that 
the infection scores were significantly higher in CVID patients with lymphoproliferation or organ-
specific autoimmunity251. The adequate doses of replacement IgG vary widely from patient to 
patient, a consequence of variable baseline IgG levels and rates of IgG catabolism. It is thus 
necessary to bear in mind that the dose and interval of IgG administration needs to be 
individually tailored to each patient251,252. Interestingly, it has been recently proposed that IgG 
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replacement therapy can induce B-cell proliferation and Ig production in some CVID patients253, 
suggesting that replacement therapy is not a mere passive administration of antibodies but 
rather has an active role in modulating B-cell function. Nevertheless, longitudinal data on the 
impact that IgG replacement therapy has on the immune function of CVID patients is still scarce. 
Even though IgG replacement therapy is highly efficient in decreasing the frequency of 
infectious episodes in antibody-deficient patients, antibiotics are still widely used to eliminate 
on-going infections248,252,254 and also in a prophylactic manner211,252. In addition, IgG replacement 
therapy is not sufficient to treat non-infectious complications that affect CVID patients, namely 
autoimmune and granulomatous disease, for which the use of corticosteroids is often required. 
The treatment of these manifestations remains a challenge, given the potential risk of 
aggravating the underlying immunodeficiency211,252. In this sense, the effectiveness of biological 
therapies with monoclonal antibodies has been documented in several case reports. Infliximab, 
a monoclonal antibody against Tumour Necrosis Factor (TNF)-, has been used in the treatment 
of Inflammatory Bowel Disease (IBD) associated with CVID255,256 and also for caseating 
granulomas, with marked success257. Etanercept, another anti-TNF- monoclonal antibody, has 
also been successfully used in the treatment of refractory cutaneous granulomas258,259. 
Rituximab, a monoclonal antibody directed against CD20 that depletes circulating B cells, has 
been shown to be useful in the treatment of medically refractory autoimmune 
thrombocytopenia purpura260,261 (ITP) and autoimmune haemolytic anemia262,263 (AHA). A recent 
multicentre study has analyzed rituximab treatment for CVID-associated autoimmune 
cytopenias, showing that this can be an extremely effective and relatively safe therapeutic 
strategy262.  
The early observation that IL-2 production by T cells from a subgroup of CVID patients 
was defective and could be corrected by the exogenous provision of IL-2264,265 led to the in vivo 
administration of recombinant IL-2 to CVID patients, which resulted in enhanced T-cell 
proliferative responses to mitogens and antigens, and increased responsiveness of B cells to 
differentiation signals266-270. However, the limited evidence for a beneficial effect of IL-2 on in 
vivo antibody production by B cells from CVID patients made it difficult to ascertain which 
patients would profit from this therapy. It is likely that CVID patients that present with defective 
T-cell function would benefit from IL-2 treatment, but this line of investigation has not been 
pursued252,266. 
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b. B-CELL DISTURBANCES IN COMMON VARIABLE IMMUNODEFICIENCY 
CVID association with intrinsic defects in the B-cell lineage has been recognized early on185 
and extensively documented, including impaired Ig secretion upon several combinations of in 
vitro culture conditions271-274, decreased class-switched B cells and plasma cells in the gut of CVID 
patients275, increased spontaneous B-cell apoptosis276, reduced expression of the co-stimulatory 
molecules CD70, CD86 and CD137277,278, low frequencies of circulating memory CD27+ B 
cells279,280, reduced SHM281, and impaired calcium mobilization following BCR stimulation282,283. 
There has been a long history of attempts to classify CVID patients, a need derived from the 
acknowledgement of the high heterogeneity of the disease. Back in 1982, two classification 
schemes were proposed, one regarding the in vitro induction of IgM responses to sheep 
erythrocytes274, and the other where the distinction was made according to stages of B-cell 
development affected, as assessed by the ability to respond in vitro to Staphylococcus aureus 
Cowan I (SAC) or anti-IgM stimulation273. Later on, another attempt to classify CVID patients was 
made also using a functional assay based on the ability of B cells from CVID patients to produce 
IgM, IgA, and IgG in vitro upon stimulation with SAC plus IL-2 or anti-IgM plus IL-2271. Three 
groups of patients were defined: group A included patients whose lymphocytes fail to produce 
any Ig isotype in vitro; patients in group B produced IgM but no other isotypes; and group C 
patients produced normal amounts of all isotypes in vitro, similarly to healthy individuals, while 
failing to produce adequate amounts of antibodies in vivo271. However, this functional 
classification of CVID patients revealed to be of low prognostic significance and the methodology 
was time-consuming and difficult to standardize, raising the need for more reliable and simple 
procedures. In 2002, the first classification based on flow cytometric phenotypic analysis of 
peripheral blood B-cell subsets from CVID patients was proposed by Warnatz et al., later known 
as the Freiburg classification284. This was also the first work to report a major reduction of 
switched-memory B cells in CVID patients, as it had been previously described in patients with X-
linked HIGM syndrome285. The work also showed that the frequency of switched-memory B cells 
was directly correlated with the ability of B cells to produce IgG in vitro, both in healthy 
individuals and CVID patients284. They thus proposed a classification based on the frequency of 
switched-memory B cells in total peripheral blood lymphocytes (PBLs): group I for patients with < 
0.4% of switched-memory B cells in PBLs; and group II for patients with > 0.4% (and more similar 
to healthy individuals). Group I patients were further subdivided according to the expansion 
(group Ia, > 20% CD21- B cells) or not (group Ib, < 20% CD21- B cells) of what they referred to as 
CD21- “immature” B cells284. Importantly, there was a significant clustering of CVID patients with 
splenomegaly and autoimmune cytopenias in group Ia, supporting the relevance of the 
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classification in defining significant clinical associations284. In 2003, a second scheme of 
classification was proposed by Piqueras et al., later to be known as the Paris classification286. This 
classification was based on memory B-cell defects: patients with normal levels of both switched-
memory and non-switched memory B cells were termed MB2, whereas CVID patients with 
reduced switched-memory B cells but normal frequencies of non-switched memory B cells were 
classified as MB1; patients with defects in both switched and non-switched memory B cells were 
grouped as MB0286. Of note, patients on group MB2 had B- and T-cell phenotypes similar to 
healthy individuals. Patients with complete memory B-cell deficiency (group MB0) had a 
significant higher incidence of granulomatous disease, lymphoproliferation and splenomegaly, 
attesting the usefulness of the proposed classification286. Following studies confirmed this 
association between reduced frequencies of switched-memory B cells and higher incidence of 
clinical manifestations287-289. More recently, a European multicentre trial involving 303 CVID 
patients developed a consensus between the two previously proposed classification schemes290. 
The EUROclass scheme separates patients with virtually absent B cells (< 1% of PBLs), marked 
reduction of switched-memory B cells ( 2%), and expansion of transitional ( 9%) or 
CD21lowCD38low B cells ( 10%) (Figure 6). Significant clinical correlations were found: patients 
with a severe reduction of switched-memory B cells had a higher risk for splenomegaly and 
granulomatous disease; expansion of CD21lowCD38low B cells was associated with splenomegaly; 
and the increase in transitional B cells was connected with adenopathies290.  
 
 
 
Figure 6. The EUROclass classification scheme for Common Variable Immunodeficiency patients, as proposed by 
Wehr et al.
290
. 
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Even though the expansion of CD21low B cells had been previously described to be a 
marker for CVID with autoimmune cytopenias and splenomegaly291, no associations with 
autoimmune phenomena were found in the EUROclass trial290. More recently, distinct 
pathophysiologic backgrounds were identified in CVID through the combined analysis of B-cell 
replication history and SHM status292. In this work, Driessen et al. proposed five different B-cell 
patterns in CVID patients, in addition to those presenting normal peripheral B-cell development: 
(1) impairment in B-cell production, (2) early peripheral B-cell maturation or survival defect, (3) 
defective B-cell activation and proliferation, (4) dysfunctional GC function, and (5) post-GC 
defect (Figure 7)292. With this approach, the authors claim that immunologically homogeneous 
groups of CVID patients can be identified, paving the way for further analysis on the molecular 
defects involved. Defects in the GC reaction and PC development had been previously 
documented in lymph nodes from CVID patients293. Even though PC differentiation was defective 
in all three CVID patients analysed in this report, the developmental stage at which this block 
occurs appears to be variable, once more highlighting the heterogeneity underlying CVID 
physiopathology.  
 
Figure 7. Model of the pathophysiological background of five different B-cell patterns in Common Variable 
Immunodeficiency patients, based on proliferation history and somatic hypermutation levels. Illustration taken 
from Driessen et al.
292
. 
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Additionally, abnormalities in the bone marrow lymphocyte composition have been 
recently described in CVID patients, including absence or very low levels of plasma cells, and a 
partial arrest of early B-cell development in some CVID patients resulting in low peripheral B-cell 
counts294, in line with the observations made by Driessen et al.292. 
In addition to the effort put into finding more appropriate ways of classifying CVID 
patients, several other important observations have been made regarding the B-cell 
compartment of CVID patients. In 2005, Carsetti et al. showed that CVID patients with recurrent 
bacterial pneumonias have very reduced frequencies of IgM+ memory B cells, while patients who 
never had pneumonia present normal frequencies of this population and produced IgM 
antibodies against pneumococcal polysaccharides295. This work illustrated the importance of 
IgM+ memory B cells in the response against encapsulated bacteria and suggests that the 
frequency of this population correlates with different susceptibilities to encapsulated bacterial 
pneumonia in CVID patients. In contrast, the reduction of switched-memory B cells was similar in 
CVID patients who had or not recurrent pneumonias295. IgM+ memory B cells and the ability to 
produce IgM antibodies are very important in CVID patients, since the replacement therapy with 
IgG only provides IgG antibodies and cannot substitute for the function of IgM antibodies. Quite 
recently, it has been shown that the frequency of the population of B cells described as being 
equivalent to the mouse B1 cells, important producers of natural antibodies, is not significantly 
different in CVID patients and healthy individuals, when taking into account the reduction in the 
total memory B-cell pool296. This suggests that CVID patients may be able to maintain, at some 
level, the production of natural antibodies. 
Interestingly, a recent report has shown that the combination of IL-21, IL-4 and anti-
CD40 stimulation in vitro was able to induce CSR in B cells from CVID patients and differentiation 
into PCs. In addition, this combination of stimuli prevented spontaneous B-cell apoptosis, 
suggesting that some defect in IL-21 may be involved in CVID. However, genetic analysis did not 
reveal any mutations in the IL-21 gene of CVID patients, and the expression of both IL-21 and the 
IL-21R was also not impaired297. 
The observation of expanded populations of B cells expressing low levels of CD21 in CVID 
patients284,290,291 has led to intense research regarding the origin and functionality of these cells. 
Rakhmanov et al. made a comprehensive phenotypic and functional analysis of circulating 
CD21low B cells from CVID patients and suggested that these cells show a phenotype that is 
mostly compatible with that of naïve B cells, but they are actually a distinct population of pre-
activated, polyclonal, partially autoreactive cells that are functionally less responsive to BCR 
stimulation and have a preferential enrichment in peripheral tissues298. The fact that CD21low B 
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cells are less responsive to BCR stimulation can be simply explained by the low levels of CD21 
expression, which result in impaired signal transduction from the BCR. The authors 
acknowledged a great similarity of CD21low B cells in CVID and a previously described population 
of tonsillar memory B cells expressing the immunoregulatory molecule FcRH4299, but argued that 
CD21low B cell in CVID are not memory cells in the sense that they lack CSR, SHM, and 
oligoclonality298. Contrary to what was described by Rakhmanov et al., a following study 
reported the existence of two different populations within CD21low B cells according to the 
expression of CD24300. However, the functional relevance of those two different populations has 
not been assessed. Isnardi et al. expanded the knowledge on this B-cell population by 
performing a transcriptome analysis, showing that CD21low B cells up-regulate genes encoding 
molecules likely to inhibit B-cell activation, proliferation, and survival, at the same time that they 
down-regulate genes involved in B-cell activation, supporting the view that these B cells are 
indeed refractory to antigenic stimulation301. Even though CVID patients who present expanded 
populations of CD21low B cells have a higher incidence of autoimmune manifestations, the role of 
these B cells in the development of autoimmunity is still not clear. 
 
CVID patients with known genetic defects sometimes feature distinct impairments on B-
cell phenotype and function. For instance, adult patients with ICOS deficiency present reduced 
frequencies of peripheral B cells, while affected young children do not123. The memory B-cell 
compartment is decreased in all patients, with a severe reduction of switched-memory B cells, 
likely resulting from poor GC formation31,123. Memory IgM+, or MZ, B cells were also found to be 
reduced in the majority of ICOS-deficient patients. However, memory B cells isolated from ICOS-
deficient patients were able to produce all Ig isotypes upon in vitro culture with autologous T 
cells in the presence of SAC and IL-2, demonstrating that these patients do not have a B-cell 
intrinsic defect and that the lack of ICOS:ICOSL interaction can be functionally overcome31. These 
B-cell defects are not exclusive of CVID patients with defective ICOS, but rather typify the 
common CVID phenotype. In the cases where SHM could be analyzed, it was found to be normal 
or slightly reduced123. CD19-deficient patients present normal numbers of circulating B cells, 
with an apparently normal precursor B-cell compartment in the bone marrow228. In addition to 
the lack of CD19 expression, CD21 expression is also reduced. Nevertheless, CD81 and CD225, 
the other members of the signalling complex, were normally expressed at the surface of B 
cells228. The frequencies of both total memory and switched-memory B cells were markedly 
reduced, even though GC formation was normal. In addition, SHM was also comparable to 
normal individuals228. CVID patients with TACI mutations have increased B-cell numbers but 
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decreased immunoglobulin production, contrary to what is observed in the mouse234,235. In 
addition, switched-memory B cells were reduced in these patients236, comparable to other CVID 
phenotypes without TACI mutations. On the contrary, lack of BAFF-R expression in CVID patients 
leads to severe B-cell lymphopenia, with an increase in transitional B cells paralleled by a 
decrease in all mature B-cell populations243. While both IgG and IgM serum levels were severely 
reduced, IgA production was intact in vivo and in vitro, suggesting that BAFF-R signals are 
dispensable for human class-switch to IgA243. All in all, while presenting distinctive alterations at 
the level of the B-cell compartment, CVID patients with known genetic alteration basically show 
the main characteristic defects that are common to all CVID patients. 
 
c. HOW ARE T CELLS AFFECTED BY B-CELL IMMUNODEFICIENCIES 
Given that impaired B-cell function can arise both from B-cell intrinsic defects and lack of 
appropriate B-cell help by T cells, the T-cell compartment has also been extensively studied in 
CVID patients. Early studies reported defects in T-cell activation and proliferation302-306, T-cell 
lymphopenia, particularly of the naïve CD4 T-cell subset307-309, abnormal cytokine 
production265,310-315, impaired expression of CD40L316, of the C-type lectin attractin317, and of the 
adhesion molecule CD62L318, defective TCR signaling315,319-322, perturbed generation of antigen-
specific memory T cells323-325, increased T-cell apoptosis309,326, and oligoclonal expansions of CD8 
T cells327, among others. More recently, it was also described that invariant natural killer T (iNKT) 
cells, a subset of thymically-derived T lymphocytes that have the ability to rapidly produce a 
wide range of cytokines, are markedly decreased in CVID patients, both in terms of frequency 
and absolute numbers in circulation328. In addition, this lost of iNKT cells was more pronounced 
in patients with low switched-memory B cells and no association was found with clinical 
features, arguing that low frequencies of iNKT cells might be contributing to the failure of 
memory B-cell generation328. A different study has however reported that the frequency of 
circulating iNKT cells in CVID patients was similar to healthy subjects, even though iNKT cell 
subsets were skewed and presented an activated phenotype in CVID patients329. Analysis of 
bone marrow biopsies from CVID patients revealed the existence of significantly more diffuse 
and nodular T-cell infiltrates than in healthy subjects, which were correlated with the presence 
of autoimmune cytopenias in CVID patients, but not other clinical manifestations. Nodular T-cell 
infiltrates in the bone marrow were directly correlated with the frequency of circulating memory 
CD45RO+ CD4 T cells294. 
Naïve CD4 T-cell lymphopenia has been linked to defects in thymic function through the 
finding of decreased levels of TCR excision circles (TRECs) on peripheral T cells330,331, an estimate 
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of recent thymic output. In addition, recent thymic emigrants (RTEs), as defined by the 
expression of CD31 on naïve CD4 T cells, were also found to be significantly reduced in CVID 
patients332, in line with the idea of a defective thymic function in these patients. Increased levels 
of circulating IL-7 have been reported in CVID patients333, but these were not related to CD4 T-
cell lymphopenia, contrary to what is found in several clinical settings334-337. Instead, CVID 
patients with high IL-7 levels present increased numbers of CD8 T cells, increased proportion of 
terminally-differentiated T cells and reduced levels of apoptosis333, suggestive of an impairment 
in IL-7-mediated T-cell homeostasis. In 2007, Giovanetti et al. reported an extensive analysis on 
T-cell abnormalities in CVID patients, proposing a new classification scheme based on the 
frequency of naïve CD4 T cells that resulted in a significant association with clinical features, 
such as splenomegaly338. This study showed that naïve CD4 T-cell lymphopenia was accompanied 
by reduced thymic output and contracted CD4 and CD8 TCR repertoires in CVID patients, while 
paralleled by strong T-cell activation, increased T-cell turnover and apoptosis, pointing to a 
perturbed homeostasis of the peripheral T-cell compartment338. Given that the concordance 
between this T-cell based classification scheme and the one based in the frequency of switched-
memory B cells284 was only partial, the authors propose that the function of T cells should also 
be taken into consideration in order to attain a proper classification of CVID patients338. In this 
sense, the DEFI Study Group has made an attempt to develop a classification system based on 
the frequencies of total B cells, switched-memory B cells and naïve CD4 T cells339. With this 
approach, the authors observed that CVID patients with clinical complications such as 
lymphoproliferation and autoimmune cytopenias more frequently present a phenotype with 
major B- and T-cell alterations, while patients presenting with only infections have no significant 
alterations of the B- and T-cell compartments339. Another study has reported that CVID patients 
with expanded CD21low B cells simultaneously present a severe reduction of naïve CD4 T cells 
associated with decreased levels of TRECs, showing a combined defect in B- and T-cell subsets340. 
It had been early on suggested that T cells from CVID patients could exert a suppressive 
effect on B-cell differentiation and antibody production341,342. This idea is however far from the 
current view on regulatory CD4 T cells (Treg). Treg cells are defined by the expression of the 
forkhead box P3 (FOXP3), a transcription factor associated with Treg differentiation
343-345, which is 
considered the best available Treg marker, in addition to high levels of CD25. Treg cells have a 
crucial role in maintaining tolerance to self-antigens and preventing autoimmunity, as 
demonstrated both by the mouse and human models of FOXP3 deficiency346-349, in which 
individuals develop fatal autoimmunity. In recent years, Treg cells have been described to be 
reduced in CVID patients350,351 and this reduction has been proposed to be linked to autoimmune 
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manifestations in the patients350,352,353. In addition, the frequency of Treg cells has been shown to 
negatively associate with the expansion of CD21low B cells352,353, further supporting a link with the 
development of autoimmunity. It has also been reported that Treg cells from CVID patients with 
autoimmune manifestations have a lower suppressive capacity, together with lower expression 
of molecules normally related to Treg function
354. 
In the first four patients described with ICOS deficiency, apart from the lack of ICOS 
expression, T cells were found to be normal with regard to activation, proliferation, cytokine 
production and subset distribution31. However, subsequent studies have reported impaired IL-10 
and IL-17 production by ICOS-deficient T cells123. Furthermore, it has been shown that circulating 
CXCR5+ CD4 T cells are severely reduced in these patients, reflecting the disturbed generation of 
GCs124. CVID patients with TACI mutations present a normal T-cell compartment, with normal T-
cell subsets and maintained proliferative responses235. This is also the case in BAFF-R-deficient 
patients, who have a normal distribution of T-cell populations234. 
Contrary to what is found in CVID patients, little abnormalities have been described at 
the level of the T-cell compartment of patients with Congenital Agammaglobulinemia. Normal 
mitogenic responses were early on described355,356, together with normal T-cell numbers and 
subsets357. Additionally, XLA patients were shown to possess intact T-cell responses305 as well as 
normal CD4 T-cell helper function358. However, other studies have reported a poor helper 
function in XLA359. It had actually been proposed that T cells from XLA patients were 
phenotypically similar to those found in healthy newborns, suggesting immaturity of the T-cell 
compartment360,361, but this is not likely the case since memory T cells are present in XLA in 
normal proportions, contrary to previous observations362, while adequately responding to recall 
antigens, such as tetanus toxoid323,355. In addition, the development of memory T-cell responses 
to viral infections, such as influenza, has been shown to be normal and to not depend on the 
presence of B cells363. On the other hand, it has been recently reported that naturally acquired T-
cell memory responses to meningococcal antigens are reduced in XLA patients as compared to 
healthy individuals, implicating B cells in the induction and maintenance of T-cell memory to 
given pathogens364.  Antigenic and mitogenic responses in XLA patients have been shown to 
present a predominant TH1 phenotype, contrary to what is found in healthy individuals
365. In 
contrast, a different study has shown that both TH1 and TH2 memory-effector and resting T cells 
develop in XLA patients vaccinated against Hepatitis B Virus, suggesting that B cells are not 
absolutely necessary for antigen-specific T-cell memory development, nor do they appear to 
affect the TH1/TH2 balance
366. Quite recently, the importance of B cells in CD4 T-cell 
differentiation has been given further support by the finding that, similar to what is observed in 
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ICOS-deficient patients, XLA patients show decreased frequencies of circulating CXCR5+ CD4 T 
cells, together with a reduction in the total memory T-cell pool, suggesting that B cells are crucial 
for the generation of GCs and the development of TFH cells
367, of which circulating CXCR5+ CD4 T 
cells are believed to be counterparts125. 
 
Along with the observation that IgG replacement therapy can induce B-cell proliferation 
and Ig production in some CVID patients253, several other reports have suggested that it can also 
have an immunomodulatory role on T-cell function. Long-term administration of IgG 
replacement therapy in CVID patients was shown to significantly reduce the numbers of 
circulating T cells368. Also, administration of intravenous IgG (IVIg) leads to an instant increase in 
the production of IL-2 and TNF- by T cells from CVID patients, but not from individuals with 
XLA369, suggesting a disease-specific pattern of action. In addition, IgG replacement therapy 
appears to have an important anti-proliferative effect on T cells from both CVID and Congenital 
Agammaglobulinemia patients370. It has also been shown to significantly increase the in vivo 
expression of both CD25 and Fas within T cells, with a possible impact on T-cell function371. Of 
note, IVIg has also been shown to inhibit the differentiation of TH17 cells from naïve CD4 T cells 
in vitro, but also their amplification and effector function, suggesting that this can be an 
important mechanism in the beneficial therapeutic effect of IVIg in patients with inflammatory 
or autoimmune diseases372.  
 
d. OTHER IMMUNE COMPARTMENTS AFFECTED IN B-CELL IMMUNODEFICIENCIES 
Apart from the impairments found to affect both B- and T-cell compartments in patients 
with antibody deficiencies, other cellular compartments have been shown to be similarly 
compromised. It has long been recognized that macrophages from CVID patients have a lower 
antigen-presenting capacity373,374, together with a defective interaction between macrophages 
and T cells375. Also, DCs from CVID patients were shown to induce abnormal Ig production by 
healthy B cells, suggesting that an impaired accessory function may play an important role in B-
cell differentiation in CVID376. However, normal antigen presentation has also been reported in 
CVID377,378. Monocyte chronic activation has been proposed, relating to raised levels of serum 
neopterin in both CVID and XLA patients379,380, as well as increased production of reactive oxygen 
species, which was only observed in CVID and not in XLA patients381. It has also been reported 
that monocyte production of IL-6 and TNF- in response to Pneumovax-23 (Pneumococcal 
Vaccine Polyvalent) was impaired in CVID patients, possibly underlying the increased 
susceptibility of these patients to Streptococcus pneumoniae infection382.  
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CVID has been associated with defective in vitro maturation of DCs from monocytes, at 
least in a subset of patients383,384, and with disturbances in the monocyte responses upon 
lypopolysaccharide (LPS) stimulation in vitro385. Additionally, CVID patients were shown to have 
reduced numbers of circulating DCs386,387, with perturbed differentiation and function, namely 
reduced expression levels of the co-stimulatory molecules CD80 and CD86, an impaired ability to 
produce IL-12 upon stimulation388-390, as well as lower antigen-presenting capacity in mixed 
lymphocyte reactions389,390. It has also been recently shown that immediately after 
administration of IVIg there is a reduction of pro-inflammatory CD14+CD16+ monocytes in CVID 
patients, and that TNF- production in response to ex vivo LPS stimulation is also reduced, 
implying that IVIg at replacement doses may in this way play an important anti-inflammatory 
role391. It should be noted however that this effect is transient and numbers of CD14+CD16+ 
monocytes return to baseline 20h after IVIg has been administered391. 
Monocyte-related alterations, namely an increased frequency of CD16-positive 
monocytes392 and decreased numbers of mDCs393 have also been reported in XLA patients. A 
previous study reported a lack of major alterations in monocyte function as assessed in vitro in 
patients with XLA385. The same study showed an up-regulation of Human Leukocyte Antigen D-
related (HLA-DR) within the whole monocyte population in CVID patients385. CD86, a marker of 
monocyte differentiation and acquisition of antigen-presentation properties, has been shown to 
be expressed at reduced levels in monocyte-derived DCs generated in vitro from CVID patients, 
supporting an impaired function as APCs in CVID383,394.  
It has also been shown that TLR7 and TLR9 function is defective in CVID patients395,396. 
pDCs from CVID patients produced markedly less IFN- upon TLR9 stimulation, even though 
TLR9 expression was normal395. Stimulation through these endosomal TLRs resulted in defective 
B-cell proliferation, lack of IL-6 and IL-10 production, defective up-regulation of AID mRNA, low 
isotype switch, and impaired IgG and IgA production in both CD27− naïve and CD27+ memory 
CVID B cells. 
Given that Btk is not only crucial for B-cell development, but is also expressed in cells of 
the myeloid lineage202, including DCs and monocytes, it could be anticipated that these cellular 
compartments would be affected in XLA patients. Btk has been found to interact with TLR8, and 
to TLRs 4, 6 and 9 to a lesser degree. In addition, Btk also interacts with proteins of the TLR 
signalling pathway, suggesting that Btk may be part of the protein complex recruited upon 
signaling397. However, it has been shown that DCs from XLA patients can be fully differentiated 
from monocyte precursors, as well as matured in response to LPS398. In addition, these DCs were 
entirely capable of priming naïve CD4 T cells, arguing against a role for Btk in DC differentiation, 
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maturation and function398. Another study has nevertheless reported that differentiation and 
maturation of DCs from monocytes of XLA patients in the presence of autologous plasma is 
impaired, but it could be restored upon stimulation with CD40L or supplementation with IVIg399. 
It has also been reported that peripheral blood mononuclear cells (PBMCs) from XLA patients 
produce reduced amounts of TNF- when stimulated with LPS in vitro400. A subsequent study has 
contradicted this observation by showing that the early events of LPS signalling in monocytes 
from XLA patients, including TNF- and IL-6 production, are similar to those in healthy 
subjects401. It was later shown that both mDCs and pDCs are present in normal numbers in the 
peripheral blood of XLA patients402. Nevertheless, the same study reported impaired TLR8-
mediated IL-6 and TNF- production in DCs from XLA patients, while phenotypic maturation, 
APC function and responses to TLRs 1/2, 2/6, 3, 4, and 5 were normal, suggesting that defective 
TLR8 signalling can underlie the increased susceptibility of XLA patients to enteroviral 
infections402. Another study has shown that PBMCs from XLA patients produce significantly less 
TNF- and IL-1 than healthy controls when stimulated through TLR2 or TLR4, while IL-6 and IL-
10 production were unaffected403. This was also observed in another report, where it was shown 
that the expression of TLRs is not defective in monocytes and DCs from XLA patients, but 
stimulation through TLRs 2, 4, or 8 elicited significantly less maturation of DCs404. Importantly, 
DC responses to influenza virus were found to be normal in XLA patients, with normal ability to 
produce IFN-363. 
Neutropenia has been reported as a frequent finding at diagnosis in XLA patients, 
although with an unclear etiology405,406. Episodes of neutropenia are usually resolved upon 
starting IgG replacement therapy406. Nevertheless, it has been recently shown that Btk is 
necessary for neutrophil development and function in a mouse model of XLA407. In this work, the 
authors have shown that, despite an increased granulopoiesis, Btk-deficient neutrophils have 
defective maturation and function in an acute inflammatory response407. However, it has been 
shown that Btk-deficiency in XLA patients does not impair essential functional responses of 
neutrophils to TLR stimulation408, suggesting a fundamental difference between the human and 
the mouse model of Btk-deficiency in what regards the myeloid compartment. 
 
Natural Killer (NK) cells, an important arm of the innate immune system, have been 
reported to be severely reduced in both CVID and XLA patients, although with no clear clinical 
relevance409,410. Although decreased, NK cells seem to be fully functional and may thus 
functionally compensate for the low numbers present410. It has been very recently described 
that Btk expression is up-regulated during maturation of murine NK cells, while being involved in 
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TLR3-mediated NK activation411. In this study, XLA patients were reported to have normal NK cell 
numbers, while TLR3-mediated NK activation was decreased, with reduced expression of IFN- 
and killing capacity, implying that Btk is important for NK function411. 
 
 
This overview illustrates how primary B-cell defects can impact in all compartments of 
the immune system. It seems unlikely that these impairments can be solely attributed to a lack 
of B cells, as in the case of XLA patients. Immunological alterations most likely result from the 
interplay of defective B cells and other cells of the immune system, an area of research that 
remains largely unexplored.  
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B lymphocytes are central players of the immune system, mainly recognized by the 
production of antibodies. Moreover, the interaction between B and T cells has a crucial role in 
the generation of adaptive immune responses. B cells are also important in linking innate and 
adaptive immune responses, given the fact that they express receptors that recognize both 
specific antigens and microbial patterns. The integration of signals coming from these pathways 
thus determines the fine-tuning of the overall B-cell response.  
 
The general aim of this work was to study the interplay between B cells and other 
elements of the immune system, for which we have taken advantage of two clinical models of 
primary B-cell immunodeficiencies, CVID and Congenital Agammaglobulinemia. We reason that 
studying these human clinical models will not only extend our knowledge on the function of the 
immune system, but will also provide new tools regarding the treatment and follow-up of these 
patients.  
 
CVID is a primary immunodeficiency defined by impaired antibody production. CVID 
patients have heterogeneous immunological and clinical profiles, and although some cases have 
been associated with monogenic defects affecting CD19, ICOS, and the B-cell-associated 
receptors TACI and BAFF-R, the immunodeficiency is fundamentally considered to be of 
polygenic aetiology. The defects in mature B-cell development that characterize CVID are 
thought to mainly result from impairments in GC organization. Although being a B-cell 
immunodeficiency, CVID is associated with perturbations of the T-cell compartment, namely 
naïve/memory disturbances and increased levels of cellular activation, among others, which are 
reported even in patients under replacement therapy with IgG. Indeed, non-infectious 
complications, such as lymphoproliferation, granulomatous disease and autoimmune 
manifestations, are currently main causes of morbidity and mortality in CVID. The mechanisms 
underlying the chronic immune activation associated with CVID remain largely unclear. 
 
Congenital Agammaglobulinemia is associated with a disruption of early B-cell 
development in the bone marrow that results, in the majority of cases, from mutations in the 
Btk gene, frequently leading to a complete lack of circulating B cells. As expected, these patients 
have a high frequency of respiratory infections. However, they do not have major non-infectious 
complications. We found that despite the absence of B cells, patients with Congenital 
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Agammaglobulinemia do not normally present with major T-cell imbalances, thus providing us 
with an excellent model to study the interaction between the different compartments of the 
immune system, in contrast to CVID patients. 
 
The specific aims of this work were the following: 1) to study the modulation of BAFF-R 
and TACI expression in CVID, in what regards its role in B-cell homeostasis; 2) to investigate a 
putative relationship between B- and T-cell imbalances in CVID and Congenital 
Agammaglobulinemia, namely regarding the autoimmunity-associated CD4 T-cell population 
that produces IL-17, TH17, and the differentiation of mature B cells; and 3) to assess monocyte 
imbalances and their possible relationship with increased microbial translocation in CVID 
patients and with chronic immune activation. Additionally, the CVID patients enrolled in this 
study, which are followed at the Serviço de Imunoalergologia from the Hospital de Santa Maria, 
Lisbon, were characterized and classified according to their B-cell phenotypes, in line with the 
most recent classification of CVID, as proposed by Wehr et al.. 
 
 
I. Modulation of BAFF-R and TACI expression in CVID 
 
Peripheral B-cell survival and differentiation mainly rely on two major factors, BAFF and 
APRIL, and on their interaction with the receptors BAFF-R, TACI, and BCMA. BAFF serum levels 
have been shown to be elevated in numerous clinical settings, such as in autoimmune diseases 
or lymphoid cancers. Both BAFF and APRIL circulating levels have also been shown to be highly 
increased in CVID patients. However, no relationship has been found between high BAFF and 
APRIL levels and clinical manifestations in CVID patients, such as autoimmunity or splenomegaly. 
In addition, mutations in TNFRSF13B and TNFRSF13C, encoding TACI and BAFF-R, respectively, 
have been associated with CVID. 
The first aim of this work was to investigate BAFF-R and TACI expression in CVID. For this 
purpose, the levels of protein expression of BAFF-R and TACI at the surface of B cells were 
compared in cohorts of CVID patients and healthy controls. The in vitro modulation of BAFF-R 
expression by recombinant BAFF, recombinant APRIL, and autologous serum was also assessed. 
Additionally, the levels of mRNA transcripts of TNFRSF13C, encoding BAFF-R, were quantified in 
these conditions, in order to evaluate a possible transcriptional regulation. Finally, longitudinal 
data on BAFF-R expression and serum levels of BAFF were collected, with the purpose of 
determining the impact of the introduction of IgG replacement therapy on these parameters.  
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The results obtained are shown in the chapter 1 of the Results. 
 
II. Relationship between B- and T-cell imbalances in primary B-cell immunodeficiencies 
 
The interaction between T cells and B cells is fundamental to generate adaptive immune 
responses. The establishment of long-term humoral immunity implies that B cells receive 
appropriate help from CD4 T cells in the context of a GC reaction, with the generation of 
memory B cells and antibody-producing plasma cells. T-cell help is known to be essential to the 
induction and subsequent organization of GCs. This help has mainly been attributed to a 
particular subset of T cells termed follicular helper T cells, TFH, which are identified by the 
expression of the chemokine receptor CXCR5, necessary for their specific homing within GCs. 
The lack of adequate T-cell help during the priming of B cells results in apoptosis, rather than 
their differentiation into GC B cells or plasma cells. The functional interaction between T cells 
and B cells rely both on the expression of co-stimulatory molecules, such as CD40-CD40L and 
ICOS molecule, as well as in cytokine production, with the best example being IL-21. These 
pathways have also been implicated in the induction and/or survival of TH17 cells. 
IL-17 is a pro-inflammatory cytokine implicated in autoimmune and inflammatory 
conditions. The development/survival of TH17 cells share critical cues with B-cell differentiation 
and the circulating TFH subset has been shown to be enriched in TH17 cells able to help B-cell 
differentiation, so potentially the homeostasis of the circulating TH17 compartment may be 
related to B-cell differentiation. CVID is frequently associated with autoimmune and 
inflammatory manifestations, and thus it is plausible that IL-17 may play a role in these 
processes. 
As a strategy to understand the contribution of TH17 cells to the mechanisms underlying 
inflammatory manifestations, the frequency of TH17 cells was compared in CVID patients, 
Congenital Agammaglobulinemia patients and healthy individuals. The relationship between 
TH17 cells and parameters of naïve T-cell depletion and T-cell activation was determined, in 
comparison to the populations of CD4 T cells producing other pro-inflammatory cytokines, such 
as IFN- and TNF-. In addition, it was also studied the association of TH17 cells with populations 
of B cells that are commonly impaired in CVID. In Congenital Agammaglobulinemia patients, who 
are expected to have severely impaired GC formation, circulating TFH cells were additionally 
studied. With the aim of better understanding the relationship between cues involved in B-cell 
differentiation and the homeostasis of T-cell populations, serum levels of BAFF, a crucial 
cytokine for B-cell survival and maturation, were quantified in CVID and Congenital 
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Agammaglobulinemia, and their relationship with TH17 cells was investigated. In addition, in 
order to understand if the relationship between TH17 cells and B cells relies on cues involved in 
class-switch to IgA, TH17 cells were measured in patients with selective IgA deficiency, a primary 
B-cell immunodeficiency that is characterized by a strict deficiency in IgA production, with all 
other Ig subclasses normal. To test the possibility of an intrinsic impairment in the ability of CD4 
T cells from Congenital Agammaglobulinemia patients to differentiate into TH17 cells, in vitro 
TH17 differentiation assays were performed and compared to healthy individuals. 
Treg and TH17 cells are believed to possess reciprocal pathways of differentiation. In order to 
determine the relationship between Treg cells and TH17 cells in primary B-cell 
immunodeficiencies, Treg cells were quantified in terms of FOXP3 and CD25 expression in CVID 
patients, and their association with TH17 cells and the abovementioned B- and T-cell subsets was 
analysed. 
The results generated are presented in the chapter 2 of the Results. 
 
III. Monocyte imbalances in primary B-cell immunodeficiencies and their possible 
relationship with increased microbial translocation and chronic immune activation in 
CVID patients. 
T-cell activation and granulomatous manifestations represent main causes of CVID 
morbidity, even in patients under IgG replacement therapy. The mechanisms underlying the 
chronic immune activation associated with CVID remain largely unclear. Another main cause of 
CVID morbidity is gastrointestinal pathology, with or without mal-absorption. The impairment in 
IgA production and other CVID-associated mucosal alterations have been shown to be often 
associated with increased intestinal permeability. Thus, it is plausible that increased levels of 
microbial translocation, particularly of bacterial products such as LPS, with consequent 
monocyte stimulation, may contribute to the chronic immune activation observed in CVID 
patients, as reported for HIV-1 infected individuals. 
To assess this premise, the monocyte compartment was characterized in patients with CVID 
and Congenital Agammaglobulinemia, and compared to healthy controls. The possible 
relationship with increased microbial translocation in CVID patients was evaluated by the 
quantification of plasma LPS, and serum levels of soluble CD14 (sCD14), LPS-binding protein 
(LBP), and anti-LPS antibodies in samples from CVID patients. In addition, to assess the impact of 
IgG replacement therapy on these parameters, monocyte and T-cell subsets were analyzed 
longitudinally in a group of CVID patients, before and after starting IgG replacement therapy. 
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These results are presented in the chapter 3 of the Results. 
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Abstract 
 
Peripheral B-cell survival and differentiation critically depend on the interaction of B-cell 
activating factor receptor (BAFF-R) and transmembrane activator and calcium modulator and 
cyclophilin ligand interactor (TACI) with their ligands, BAFF and a proliferation-inducing ligand 
(APRIL). We hypothesize that disruption of these pathways plays a role in Common Variable 
Immunodeficiency Disorders (CVID), which are defined by defects in mature B-cell function with 
impaired antibody production. We found that BAFF-R expression was significantly reduced in all 
B-cell subsets in CVID, both at the protein and the mRNA levels, particularly in patients with very 
low memory B-cell frequencies. Conversely, TACI expression was increased in CVID patients, 
especially in the memory B-cell compartment. Relevant polymorphisms in the genes encoding 
these receptors were excluded in the studied CVID patients, given that monogenic defects have 
been described in rare cases. Reduced BAFF-R and increased TACI expression were both directly 
associated with high BAFF serum levels, but not APRIL, even though being a ligand for TACI. 
Using an in vitro culture approach, we observed that recombinant BAFF, as well as autologous 
serum, induced down-modulation of BAFF-R protein expression, both in healthy individuals and 
CVID patients. However, the degree of modulation seemed to be impaired in CVID patients, 
suggesting that these dynamics are affected. In addition, BAFF did not seem to regulate BAFF-R 
expression at the transcriptional level in this in vitro model. Understanding the mechanisms 
involved in the modulation of BAFF-R expression by its ligand BAFF will be crucial to clarify the 
role of BAFF-R dysregulation in CVID pathogenesis, in particular, and in B-cell biology, in general. 
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Introduction 
 
Peripheral B-cell survival and differentiation mainly rely on two major factors, BAFF (B-
cell activating factor of the TNF family; BLyS/TALL-1/THANK/zTNF4) and APRIL (a proliferation 
ligand), and on their interaction with the receptors BAFF-R (BAFF receptor; BR3), TACI 
(Transmembrane Activator and CAML Interactor), and BCMA (B-cell maturation antigen)1. BAFF-
R is expressed by all peripheral B cells and is critical for their survival and maturation. TACI is 
mainly expressed on memory peripheral B cells and it is suggested to act as a negative regulator 
of B-cell development. BCMA is expressed on memory B cells in secondary lymphoid organs but 
its highest levels are found in plasma cells1. BAFF-R only binds BAFF, whereas TACI and BCMA 
can bind both BAFF and APRIL, and BCMA binds APRIL with a 10-fold higher affinity than BAFF1. 
BAFF and APRIL are primarily produced by neutrophils, monocytes, macrophages and 
dendritic cells. They are also produced by non-hematopoietic cells at local niches to promote 
survival and function of B cells and plasma cells1. T cells may also produce BAFF2,3. In addition, 
BAFF and APRIL can be produced by lymphoid tumour cells to promote survival in an autocrine 
fashion1,4-6. It has been shown in the mouse that two distinct pools of BAFF actually exist: a 
constitutive pool that is produced by radiation-resistant cells and controls the size of the 
peripheral B cell pool; and a cytokine-induced pool that acts at sites of inflammation7,8. 
BAFF transgenic mice present B-cell hyperplasia and autoimmune manifestations that 
resemble systemic lupus erythematosus (SLE) and Sjögren’s syndrome9-11, pointing out the 
immunoregulatory potential of the BAFF system on B cells. BAFF serum levels have been shown 
to be elevated in numerous clinical settings, such as in autoimmune diseases, or lymphoid 
cancers. BAFF can also be increased during inflammation and infection, possibly modulated by 
type I interferons1. BAFF-deficient animals have a similar phenotype to A/WySnJ mice, which 
have a mutant BAFF-R gene, and to BAFF-R-null mice, all of which present severe mature B-cell 
lymphopenia12-15. In agreement, both BAFF-deficient and BAFF-R-deficient mice show abnormal 
germinal centre (GC) development and progression16. TACI-deficient mice, on the contrary, show 
a marked expansion of B cells that includes almost all mature peripheral B cell populations, 
splenomegaly and over-production of immunoglobulins17,18, suggesting a negative regulatory 
role for TACI in B-cell homeostasis. Nevertheless, TACI-deficient mice also present defective T-
independent type 2 responses in vivo, indicating a positive outcome of TACI stimulation18,19. 
APRIL-deficient mice have normal B and T-cell development, but impaired class-switching to 
IgA20. APRIL-transgenic mice, on the other hand, develop B-cell neoplasias as they age21 and 
present increased T-cell survival22. 
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Common Variable Immunodeficiency (CVID) is the most prevalent symptomatic primary 
immunodeficiency. Patients present a heterogeneous immunological and clinical profile, and 
although some cases have been associated with monogenic defects, the disease is largely 
considered to be of polygenic etiology23. Importantly, some of the referred monogenic defects 
include polymorphisms in the coding genes for BAFF-R and TACI24-27. Humans lacking TACI 
expression have a CVID clinical phenotype, with increased B-cell numbers but decreased 
immunoglobulin production, contrary to what is observed in the mouse24,27. Nevertheless, the 
murine equivalent to the C104R TACI mutation, C76R, significantly disrupts B-cell homeostasis, 
immunoglobulin production, and antigen-stimulated humoral responses28. Two siblings who 
present an adult-onset CVID-like syndrome have been described to lack BAFF-R protein 
expression with consequent severe B-cell lymphopenia26. The clinical manifestations in these 
patients were however mild in comparison to other antibody-deficient settings26. In addition, 
polymorphic variants of BAFF-R have been described, affecting both CVID patients and healthy 
individuals. Such variants do not impact in BAFF-R expression, neither at the mRNA level nor at 
the protein level25. However, ligand-binding capacity has not been evaluated in these subjects25. 
  Little is known about the expression of these receptors in CVID patients and how it is 
related to disease pathogenesis. Both BAFF and APRIL circulating levels have been shown to be 
highly increased in CVID patients29-32. However, no relationship has been found between high 
BAFF and APRIL levels and clinical manifestations in CVID patients, such as autoimmunity or 
splenomegaly30,31. 
The aim of this work was to study BAFF-R and TACI expression in CVID patients, and its 
relationship to BAFF and APRIL serum levels. In this study, we show that BAFF-R and TACI 
expression is altered in CVID patients, likely contributing to disease pathogenesis. 
  
76 B cells at the crossroad of immune responses: 
insights from primary B-cell immunodeficiencies 
 
Materials and Methods 
 
Cohorts 
The study involved 33 patients with CVID and 19 healthy individuals. All subjects gave written 
informed consent for blood sampling and processing. The study was approved by the Ethical 
Board of the Faculty of Medicine of Lisbon. CVID patients were diagnosed according to the 
European Society for Immunodeficiency criteria (www.esid.org), namely IgG levels at least 2 
standard deviations below the mean for age and a decrease of at least one of the IgM or IgA 
isotypes, impaired Ab response to vaccines, absent/low isohemagglutinins, and exclusion of 
defined causes of hypogammaglobulinemia. 27 out of 29 CVID patients were under long-term 
IgG replacement therapy, adjusted to guarantee pre-infusion Ig levels above 650mg/dL. The two 
other CVID patients not receiving IgG had levels of total serum IgG of 227 and 473 mg/dL. 4 CVID 
patients were enrolled in a longitudinal study prior to and after starting IgG replacement 
therapy. The collection of the blood samples was always performed immediately before the 
immunoglobulin infusions in the patients under intravenous administration. 5 CVID patients 
were under subcutaneous IgG administration. 
 
Cell culture 
Fresh peripheral blood mononuclear cells (PBMCs) were isolated through Ficoll-Hypaque density 
gradient (Amersham Pharmacia Biotech), and cultured in RPMI1640 medium (Gibco-Invitrogen) 
supplemented with 10% (vol/vol) human AB serum (Sigma-Aldrich), 100 U/ml penicillin/100 
g/ml streptomycin and 2 mM glutamine (Gibco-Invitrogen). 
 
Cell stimulation and treatment 
Recombinant human BAFF and recombinant human APRIL (PeproTech) were used at 
concentrations of 100ng/mL, unless otherwise indicated. Serum from healthy donors or CVID 
patients was added at a final concentration of 10% (vol/vol) for medium supplementation, 
where indicated. 
 
B cell purification 
B lymphocytes were purified from PBMCs by negative selection (STEMCELL Technologies). The 
purity of isolated CD19+ B cells was routinely over 95%. 
 
 
Chapter 3 – Results 
3.1. Modulation of BAFF-R and TACI expression in CVID 
77 
 
Cell staining, flow cytometric analysis and monoclonal Ab (mAb) used in flow cytometry 
Phenotypic analysis was performed in whole blood samples, after staining with mAb for 20 
minutes and red blood cells lysis using BD FACS Lysing Solution (BD Biosciences). Cultured 
PBMCs were stained for surface markers, followed by fixation with 2% formaldehyde. Samples 
were acquired on a FACSCalibur flow cytometer (BD Biosciences) and data analysed using 
CellQuest (BD Biosciences) and FlowJo (Tree Star Inc.) softwares. Results are presented as a 
proportion of total lymphocytes or of a given cell population. The following anti-human mAb 
were used, with clone and the directly conjugated fluorochrome specified in brackets: CD3 
(UCHT1; V500), CD11c (B-ly6; APC), CD38 (HB7; PE), IgD (IA6-2; PE), IgM (G20-127; APC), HLA-DR 
(L243; PerCP-Cy5-5), from BD Biosciences; CD3 (OKT3; PerCP-Cy5.5), CD8 (RPA-T8; FITC, PE and 
APC), CD14 (61D3; Efluor 450), CD16 (eBioCB16; FITC), CD19 (HIB19; PerCP-Cy5.5, PE-Cy7 and 
APC efluor 780), CD123 (6H6; PE-Cy7), CD23 (EBVCS2; APC), CD27 (O323; FITC, PE, and APC), 
CD38 (HB7; PE), CD56 (MEM188; FITC), BAFFR (8A7; FITC and PE), TACI (11H3; PE) from 
eBiosciences; CD4 (S3.5; PE) from Caltag; CD21 (BL13; FITC) from IO Test, Beckman Coulter; 
BAFFR (11C1; Alexa Fluor 647) from Biolegend. 
 
Quantification of serum levels of BAFF and APRIL 
Serum concentrations of BAFF and APRIL were quantified by Enzyme Linked Immunosorbent 
Assay (ELISA) using the BAFF Immunoassay Kit (R&D Systems) and the human APRIL ELISA (IBL 
International), respectively, according to the manufacturer's instructions. Samples were assayed 
in duplicate. 
 
Isolation of mRNA and quantitative RT-PCR 
mRNA was extracted using either the AllPrep DNA/RNA Micro Kit or the RNeasy Kit (both from 
Qiagen), according to cell numbers, following the manufacturer’s instructions. Single-stranded 
cDNA was produced by reverse transcription of 50ng of mRNA with the Superscript III First-
Strand Synthesis System and oligo (dT) (Invitrogen). The concentration of mRNA was measured 
for normalization of all amounts used for reverse transcription. Power SYBR Green PCR Master 
Mix (Applied Biosystems) and Applied Biosystems 7500 Fast (Applied Biosystem) were used for 
quantitative RT-PCR. Samples were amplified in duplicate for 40 cycles and target gene 
expression was normalized to the expression of GAPDH (encoding Glyceraldehyde 3-phosphate 
dehydrogenase). Primer pairs for quantitative RT-PCR were as follows: 5’-
GGTGGTCTCCTCTGACTTCAACA-3’ and 5’-GTTGCTGTAGCCAAATTCGTTGT-3’ for GAPDH and 
QuantiTect Primer Assay for TNFRSF13C (Qiagen). 
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Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Software Inc.). 
Two group comparisons were performed using Mann-Whitney test. Analysis of dependent 
samples was performed using Wilcoxon matched-pairs signed rank test. Spearman’s coefficient 
was used to determine the significance of the correlation between two variables. Results are 
expressed as meanSEM, and P-values <0.05 were considered to be significant. 
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Results 
 
Reduced ex vivo BAFF-R expression and increased TACI expression were associated with high 
serum levels of BAFF in CVID patients 
The first aim of this work was to evaluate the expression of BAFF-R and TACI on B cells 
from CVID patients, and to study its relationship with BAFF and APRIL serum levels.  
BAFF-R expression was uniformly reduced on B cells from CVID patients as compared to 
healthy individuals, and this was observed for both naïve and memory B cells (Figure 1A).  
In order to evaluate if decreased BAFF-R protein expression on B cells from CVID patients 
was a result of decreased gene expression, we assessed the mRNA levels of the TNFRSF13C 
gene, which encodes for BAFF-R, in purified B cells from CVID patients. Given the fact that we 
observed differential BAFF-R expression on memory and naïve B cells, and in order to be better 
able to overcome the possible impact of the imbalances of memory B-cell development in CVID 
patients, we selected to include in this study 3 CVID patients with frequencies of memory B cells 
within the normal range (“mem+”) and 3 CVID patients with very low memory B-cell frequencies 
(“mem-“), as well as 6 healthy controls. As expected, these selected CVID patients had lower 
BAFF-R protein expression than healthy individuals (Figure 1B). In addition, “mem-“ CVID 
patients clearly expressed less BAFF-R on their B cells as compared to “mem+” CVID patients, 
who presented BAFF-R protein levels similar to healthy controls (Figure 1B). The same trend was 
observed in relation to TNFRSF13C mRNA levels, although not as striking (Figure 1C). 
Nevertheless, BAFF-R protein levels were directly associated with the levels of TNFRSF13C mRNA 
(Figure 1D), suggesting that the events of gene and protein expression are not uncoupled in CVID 
patients. 
Importantly, when CVID were stratified according to clinical manifestations, such as 
autoimmunity, splenomegaly, adenopathies, lymphoid proliferation, or chronic diarrhoea, we 
observed that BAFF-R protein expression was uniformly decreased in all subgroups of patients, 
irrespective of clinical complications. 
On the other hand TACI expression was significantly increased on B cells from CVID 
patients, both in the naïve and memory subsets (Figure 2A). In addition, TACI levels were 
significantly increased in CVID patients with splenomegaly, as compared to those that do not 
present this clinical manifestation, when CVID patients were stratified according to clinical 
complications (Figure 2B). 
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Figure 1. B-cell expression of BAFF-R was decreased in CVID patients, irrespective of clinical phenotype. Mean 
fluorescence intensity (MFI) of BAFF-R (A) in CVID patients and healthy individuals, within total B cells and within naïve 
and memory B-cell subsets. Analysis of healthy subjects and of CVID patients further divided into two subgroups, 
namely “mem+” for patients presenting more than 25% memory B cells and “mem-“ for patients having less than 7% 
memory B cells, in relation to: (B) the mean fluorescence intensity (MFI) of BAFF-R expression within total B cells, and 
(C) mRNA transcripts for TNFRSF13C, encoding BAFF-R, assessed in purified B cells. (D) Correlation between BAFF-R 
protein expression and TNFRSF13C mRNA levels. (E) Stratification by clinical complications in CVID patients of B-cell 
expression of BAFF-R. Each dot represents one individual. Bars indicate mean. P values are shown. 
 
A negative association between BAFF-R expression and BAFF serum levels was observed 
in both CVID patients and healthy individuals (Figure 3A, left panel), that was not observed for 
APRIL (Figure 3A, right panel). On the other hand, TACI expression on memory B cells was 
directly associated with BAFF serum levels in CVID patients, but not in healthy individuals (Figure 
3B, left panel). No relationship was found with the serum levels of APRIL, which is the other 
described ligand for TACI (Figure 3B, right panel).  
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Figure 2. TACI expression was increased in CVID, particularly in patients with splenomegaly. Mean fluorescence 
intensity (MFI) of TACI (A) in CVID patients and healthy individuals, within total B cells and within naïve and memory B-
cell subsets. (B) Stratification by clinical complications in CVID patients of B-cell expression of TACI. Each dot 
represents one individual. Bars indicate mean. P values are shown. 
 
 
Figure 3. High serum levels of BAFF were associated with reduced BAFF-R expression and increased TACI in CVID. 
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Our data showing BAFF-R down-regulation in the presence of high levels of BAFF may be 
particularly relevant in CVID patients, given the increased serum levels of these cytokines that 
we and others have reported in CVID 29,30,32. Of note, high serum levels of both BAFF and APRIL 
were observed in CVID patients, irrespective of clinical manifestations, such as autoimmunity, 
splenomegaly, lymphoproliferation, adenopathies, or chronic diarrhoea (Figure 3C and 3D). 
Furthermore, our results raise the possibility that the increased serum BAFF levels may play a 
role in TACI up-regulation in CVID patients. 
 
BAFF-R protein expression was modulated upon culture in the presence of BAFF 
In order to further investigate how BAFF modulates the expression of its receptor BAFF-
R, we cultured PBMCs from the selected CVID patients and healthy controls mentioned above in 
the presence of BAFF or in medium alone, as well as in the presence of APRIL as a negative 
control, for different time points. In terms of BAFF-R protein expression, we observed that B cells 
cultured in the presence of BAFF strongly down-regulate its receptor relative to ex vivo 
expression levels, in contrast to B cells cultured in medium alone or APRIL, which gain some 
BAFF-R expression. Of note, BAFF also induces down-regulation of BAFF-R expression in CVID 
patients (Figure 4A). However, BAFF-R down-regulation by BAFF on B cells from CVID patients 
was not as striking as in healthy individuals, which could be related to the fact that B cells from 
CVID patients already express lower levels of BAFF-R ex vivo (Figure 4A). It is also possible that 
these dynamics of modulation of BAFF-R expression by BAFF are impaired in CVID patients. In 
line with this view was the fact even though B cells from CVID patients recovered some BAFF-R 
expression when they are cultured for 24h in the absence of BAFF, the levels attained were 
always lower than those observed in healthy individuals (Figure 4B). 
Next, we asked whether the down-regulation of BAFF-R expression could have an impact 
in TNFRSF13C transcription and in order to do this we quantified its mRNA levels in the different 
culture conditions previously described. TNFRSF13C transcripts did not change significantly upon 
culture, in either of the time-points assessed (Figure 4C), suggesting that BAFF is not modulating 
the expression of BAFF-R at the transcriptional level. 
 
 
 
Figure 3. (cont.) (A) Correlation between BAFF serum levels and the mean fluorescence intensity (MFI) of BAFF-R or 
TACI (left and right panels, respectively). (B) Correlation between APRIL serum levels and the MFI of BAFF-R or TACI 
(left and right panels, respectively). Stratification by clinical complications in CVID patients of BAFF (C) and APRIL (D) 
serum levels. Each dot represents one individual. Bars indicate mean. P values and Spearman’s correlation coefficients 
are shown. 
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Figure 4. BAFF-R protein expression was modulated upon culture in the presence of BAFF. (A) Fold change in the 
mean fluorescence intensity (MFI) of BAFF-R expression on B cells upon culture in the presence of either medium 
alone, BAFF or APRIL, for 4h and 24h relative to ex vivo levels, in a group of 6 CVID patients and 6 healthy individuals. 
(B) Comparison between the MFI of BAFF-R expression on B cells from healthy individuals and CVID patients, either ex 
vivo or after 24h of culture in medium alone. (C) mRNA transcripts of TNFRSF13C in cells cultured as described in A. 
Levels of TNFRSF13C expression were normalized to the relative proportion of CD19
+
 B cells present in culture. (D) 
Fold change in the MFI of BAFF-R expression on B cells upon culture in the presence of either medium alone, BAFF or 
APRIL, for 4h, 24h, 48h, 72h, and 96h, relative to ex vivo levels. Shown are the results of 3 independent experiments of 
healthy subjects. (E) Fold change in the MFI of BAFF-R expression on B cells upon short-term stimulation with either 
BAFF or APRIL. Cells were cultured for 5, 15, 30 minutes, 1 hour or 24h. After 24h of culture, cells were washed and re-
plated in medium alone for the indicated period of time. Shown are the results of 2 independent experiments of 
healthy subjects. Bars indicate mean±SEM. Each dot represents one individual. * indicates P value <0.05 relative to 
healthy individuals. 
 
Further in vitro studies in healthy individuals showed that recombinant BAFF induced 
down-regulation of BAFF-R as early as after 4h of culture, and that this effect was sustained up 
to 96h of culture, but not increased, suggesting that the maximal response to BAFF in terms of 
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BAFF-R modulation is attained very early (Figure 4D). In order to assess the possibility of BAFF 
inducing BAFF-R internalization, we performed short-term cultures with BAFF, from 5 minutes 
up to 1h. Our results showed that BAFF-R expression is down-modulated as early as after 5 
minutes of culture with BAFF (Figure 4E), suggesting that internalization might be occurring. 
Additionally, removal of BAFF from cultures resulted in BAFF-R time-dependent up-regulation. 
Next, we asked whether serum from CVID patients with high BAFF levels would be able 
to recapitulate the results obtained with recombinant BAFF, i.e., if cultures in the presence of 
autologous serum would induce per se down-regulation of BAFF-R protein expression. B cells 
from CVID patients cultured with autologous serum expressed lower levels of BAFF-R than those 
of healthy controls, consistent with the increased amount of BAFF found in the serum (Figure 
5A). In addition, this down-regulation was greater in “mem-“ than in “mem+” CVID patients, who 
behaved similarly to healthy individuals (Figure 5A). BAFF-R protein down-regulation was 
proportional to the level of BAFF found in the serum, as shown in Figure 5B. High concentrations 
of BAFF in the serum from CVID patients are thus able to recapitulate the modulation of BAFF-R 
expression driven by the addition of recombinant BAFF to the culture. 
 
 
Figure 5. Autologous serum from CVID patients was able to recapitulate the effects of recombinant BAFF in culture. 
(A) Fold change in BAFF-R MFI expression on B cells cultured in the presence of autologous serum relative to levels 
expressed on B cells cultured in medium alone.  CVID patients were divided into two subgroups: “mem+” for patients 
presenting more than 25% memory B cells; and “mem-“ for patients having less than 7% memory B cells. BAFF serum 
levels (mean±SEM) for each group of individuals is indicated below the bars. (B) Correlation between BAFF-R MFI 
expression within total B cells cultured in the presence of autologous serum and the amount of BAFF found in the 
serum, in CVID patients and healthy controls. Bars indicate mean±SEM. Each dot represents one individual. 
Spearman’s correlation coefficients are shown. 
 
Overall, we show that BAFF directly modulates BAFF-R expression both in healthy 
subjects and CVID patients. 
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BAFF-R expression and BAFF serum levels did not change significantly upon starting IgG 
replacement therapy in CVID patients 
CVID patients receive IgG replacement therapy, aiming to restore antibody levels that 
the patients are not able to produce. BAFF serum levels can change in a variety of settings29,33, 
and we hypothesized they may be modulated by the IgG treatment and the control of infections. 
We thus asked whether the introduction of IgG replacement therapy is able to correct the 
disturbances in BAFF-R and TACI expression in CVID patients. For this purpose, we performed a 
longitudinal assessment of serum BAFF levels and BAFF-R protein expression in a group of 4 CVID 
patients, prior to starting IgG replacement therapy and up to 12 months after commencing it. 
Even though inter-individual variability was high, we found that BAFF serum levels were 
remarkably stable over the time-period analyzed (Figure 6A) and that BAFF-R protein levels did 
not change significantly over time with IgG replacement therapy (Figure 6B). It is important to 
note that the major B-cell subsets that are considered in CVID, such as the frequency of memory 
B cells, switched-memory B cells, CD21lowCD38low B cells, transitional B cells and plasmablasts, 
remain virtually unchanged over the time-period analyzed following the introduction of IgG 
replacement therapy (Supplemental Figure 2A-F).  
 
Figure 6. BAFF-R expression and BAFF serum levels did not significantly change upon starting IgG replacement 
therapy. Time-course analysis of BAFF serum levels (A) and of the mean fluorescence intensity (MFI) of BAFF-R 
expression on B cells (B) in 4 CVID patients prior to and after starting IgG replacement therapy. (C) Correlation 
between MFI of BAFF-R expression within total B cells and BAFF serum levels found in the different time-points of the 
4 CVID patients. Each dot represents one individual. Spearman’s correlation coefficients are shown. 
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In addition, and in agreement with our previous observations, BAFF-R protein expression 
was inversely associated with the serum levels of BAFF when all time-points and all individuals 
were considered (Figure 6C). Thus, the relationship between BAFF serum levels and BAFF-R 
protein expression also seems to be independent of therapy and of the associated control of 
infectious events in CVID patients. 
Altogether, our data suggest that increased serum BAFF and reduced BAFF-R expression 
levels are features of CVID that are not modulated by IgG replacement therapy. 
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Discussion 
 
In this study, we showed that BAFF-R and TACI expression were altered in CVID patients, 
likely contributing to disease pathogenesis. We found that BAFF-R expression was significantly 
reduced in all B-cell subsets from CVID patients, both at the protein and the mRNA levels, 
particularly in patients with very low frequencies of memory B cells. In contrast, TACI expression 
was increased in CVID patients, especially in the memory B-cell compartment. Relevant 
polymorphisms in the genes encoding these BAFF-R and TACI were excluded in the studied CVID 
patients, given that monogenic defects have been described in rare cases (Supplemental Tables 
1 and 2). Reduced BAFF-R and increased TACI expression were both directly associated with high 
BAFF serum levels, but not APRIL. Using an in vitro culture approach, we observed that 
recombinant BAFF, as well as autologous serum, induced down-modulation of BAFF-R protein 
expression, both in healthy individuals and CVID patients. However, the degree of modulation 
seemed to be impaired in CVID patients, suggesting that these dynamics are affected. In 
addition, BAFF did not seem to regulate BAFF-R expression at the transcriptional level in this in 
vitro model. We also observed that BAFF-R expression and BAFF serum levels were rather stable 
over time in CVID patients starting IgG replacement therapy. 
Since the identification of APRIL34 and BAFF35,36 as members of the TNF family with B-cell 
stimulating capacities, and the subsequent discovery of their three receptors, BCMA, TACI37,38, 
and BAFF-R13,14, much knowledge has been gained regarding the specificities of receptor-ligand 
interactions, signalling pathways involved and biological functions1. It has been shown that BCR 
signals39,40 and TLR stimulation41,42 can increase the expression of BAFF receptors, BAFF-R and 
TACI. However, little is known about the modulation of receptor expression in response to the 
ligands themselves, particularly in humans. The negative correlation that we observed between 
BAFF serum levels and BAFF-R expression on B cells, not only in CVID patients, but also in healthy 
individuals, support the view that BAFF can actually modulate the levels of BAFF-R in a 
physiological context. It has been previously reported that high BAFF levels are associated with 
low BAFF-R expression on B cells from SLE and Sjögren’s syndrome patients, and that low BAFF-R 
expression is linked to disease activity43. The same study has also shown that the low levels of 
BAFF-R expression in Sjögren’s syndrome patients were not due to transcriptional modulation, 
since BAFF-R mRNA levels were not reduced in those patients43, in agreement with the data we 
obtained in CVID patients. Our in vitro studies showed that recombinant BAFF induced down-
regulation of BAFF-R as early as 4h of culture. This effect was sustained at later time-points, but 
not increased, suggesting that the maximal response to BAFF in terms of BAFF-R modulation is 
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achieved early on. It is possible that BAFF-R may be internalized upon BAFF binding, a process 
that was demonstrated to occur in other settings, such as in the response of T cells to IL-7, 
where the IL-7R is internalized upon binding of IL-744. This is particularly interesting as BAFF 
effects on B cells share great similarities to those of IL-7 on T cells. The possible internalization of 
BAFF-R has been discussed in the past in the contexts of SLE and Sjögren’s syndrome, even 
though hypothesis has not been formally assessed43,45. We observed BAFF-R down-regulation as 
early as after 5 minutes of stimulation with BAFF. Moreover, removal of BAFF from cultures 
resulted in BAFF-R time-dependent up-regulation. These observations suggest a dynamic 
mechanism by which BAFF is modulating BAFF-R expression, and not simply a matter of receptor 
occupancy, as it has been proposed to be underlying the low levels of BAFF-R detection on the 
surface of B cells from patients with SLE45. A component of receptor occupancy does seem to 
exist in the modulation of BAFF-R expression by BAFF, but only at high concentrations 
(>10ng/mL) and not at the levels of BAFF found in circulation in either CVID patients or healthy 
individuals (Supplemental Figure 3). However, receptor occupancy does not explain by itself the 
modulation of BAFF-R expression that we reported, even with higher concentrations of BAFF 
(Supplemental Figure 3). 
Another possibility that can be responsible for the down-regulation of BAFF-R upon BAFF 
binding is that BAFF-R is being cleaved and shed into the extracellular space. This is a rather 
interesting possibility, since it would prevent BAFF from acting on its target B cells. BAFF-R 
shedding could then act as a buffer in situations where excess BAFF is present. This mechanism 
has been described to occur for TNF receptors and to be critical for the regulation of TNF activity 
in vivo46. Although BAFF-R shedding has also been discussed in the past43,45, it has not been 
formally evaluated. TACI has been detected in a soluble form, particularly in the serum of CVID 
patients24,30, indicating that some cleavage from the cell surface can occur. Nevertheless, the 
biological relevance of this phenomenon remains elusive.  
It will be important to determine if lower BAFF-R expression on B cells from CVID 
patients render them less responsive to BAFF signals, as proposed in the case of SLE45. A 
previous study has shown that BAFF induces proliferative and antibody-secreting responses in B 
cells from some CVID patients47. However, the same study claimed that the expression of 
receptors for BAFF was not altered in those CVID patients47. 
The basis of elevated serum levels of BAFF in CVID patients is a question that remains 
unclear. It has been recently proposed that steady-state soluble BAFF levels are determined by 
the size of the B-cell pool and the availability of BAFF receptors, although the actual expression 
of these BAFF receptors has not been formally addressed31. It had already been shown in the 
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mouse that two distinct pools of BAFF actually exist: a constitutive pool that is produced by 
radiation-resistant cells and controls the size of the peripheral B cell pool; and a cytokine-
induced pool that will act at sites of inflammation7,8. We and others have shown that the highest 
serum BAFF levels are found in individuals lacking B cells, as exemplified by Congenital 
Agammaglobulinemia patients29,31,32, supporting a relevance of target availability in the 
regulation of serum BAFF levels. We could also confirm that BAFF serum levels were inversely 
correlated with both the percentage and total circulating numbers of B cells (data not shown), as 
reported by Kreuzaler and coleagues31. Several studies have investigated whether high BAFF or 
APRIL levels could be related to polymorphisms in the coding genes for these cytokines48,49. BAFF 
polymorphisms have been studied in CVID patients, but no mutations were found49. One 
polymorphism in the human APRIL gene has been found to be associated with SLE, even though 
it is also found in the healthy population and no functional assessment of this polymorphism has 
been made48. Thus, it seems unlikely that the high levels of BAFF and APRIL observed in 
autoimmune diseases and in CVID are a consequence of genetic alterations in the coding genes 
for these factors. 
The description of BAFF-transgenic mice as presenting with autoimmune manifestations 
that include autoantibody production, proteinuria and Ig deposition in the kidneys10,11 led to 
intense research about the role of BAFF in human autoimmune diseases, such as SLE, Sjögren’s 
syndrome or rheumatoid arthritis. Several reports have shown that BAFF levels are increased in 
these conditions43,50-56, but its association with disease activity is controversial. Some works 
found a direct association between high levels of BAFF and autoantibody production and disease 
stage50-53, while others did not43,55. APRIL levels have also been described to be increased in SLE 
and to be associated with autoimmune features57. Our CVID cohort has a high prevalence of 
autoimmune manifestations, as previously reported32,58. Nevertheless, despite the increased 
circulating levels of BAFF and APRIL observed in CVID patients, as previously reported29-32, we did 
not find any relationship between serum BAFF or APRIL levels and the clinical manifestations 
that CVID patients presented, namely autoimmunity, lymphoid proliferation or splenomegaly. 
Our work showed that B-cell homeostasis is likely impaired in CVID, given that 
expression of BAFF-R is significantly reduced, while TACI expression is increased in CVID patients, 
both of which in direct correlation with high serum levels of BAFF. These data raise the 
possibility of BAFF-depleting therapies being envisaged in the treatment of CVID. Understanding 
the mechanisms involved in the modulation of BAFF-R expression by its ligand BAFF will be 
crucial to clarify the role of BAFF-R dysregulation in CVID pathogenesis, in particular, and in B-
cell biology, in general. 
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Supplemental Data 
 
 
 
Supplemental Figure 1. BAFF-R expression within peripheral blood populations. Given that cultures with BAFF were 
performed using total PBMCs and not purified B cells, the expression of BAFF-R by other cell populations was 
assessed, at the protein level. BAFF-R expression assessed by flow cytometry in B cells, monocytes, T cells, NK cells, 
plasmacytoid dendritic cells (pDCs) and basophils. Gating strategy for each population is shown, within a manually set 
lymphocyte+monocyte gate. One of two representative experiments is shown.  
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Supplemental Figure 2. B-cell populations in CVID patients before and up to 12 months after starting IgG 
replacement therapy. Frequencies of total B cells within lymphocytes (A), memory B cells (CD27
+
, B), switched-
memory B cells (CD27
+
IgD
-
, C), CD21
low
CD38
low
 B cells (D), transitional B cells (CD38
hi
IgM
hi
, E), and plasmablasts 
(CD38
hi
IgM
-
, F), in four CVID patients before (time 0) and after starting IgG replacement therapy. 
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Supplemental Figure 3. Down-regulation of BAFF-R expression upon BAFF binding appeared to occur independently 
of receptor occupancy. To analyze receptor occupancy by BAFF on BAFF-R expression, peripheral blood mononuclear 
cells were incubated for 30 minutes with increasing amounts of BAFF, either at 4ºC or 37ºC, and BAFF-R expression 
was subsequently determined and compared. Receptor occupancy is observed at 4ºC, while the observations at 37ºC 
reflect both receptor occupancy and modulation of BAFF-R expression. The grey bar represents the range of BAFF 
serum levels found in healthy individuals, while the dashed lines indicate the range of BAFF serum levels in CVID 
patients. 
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Supplemental Table 1. Analysis of sequence variants in the BAFF-R gene in the cohort of CVID patients studied. 
Work done in collaboration with Professor Lennart Hammarström (Department of Laboratory Medicine, Karolinska 
Institut, Stockholm, Sweden). 
 EXON 1 EXON 2 INTRON 1 INTRON 2 EXON 3 
CVID #001* none none none none none 
CVID #002 none none none none none 
CVID #003 none none none none none 
CVID #004 none G64V(191G/T;192C/T)het none none none 
CVID #005 none G64V(191G/T;192C/T)het none none none 
CVID #006 P21R(het) none IVS2+72G/C(het) IVS2-33T/C(het) none 
CVID #007 P21R(het) none IVS2+72G/C(het) IVS2-33T/C(hom) none 
CVID #008* none none none none none 
CVID #009 P21R(het) none none IVS2-33T/C(het) none 
CVID #010 none G64V(191G/T;192C/T)het none none none 
CVID #011 none none none none none 
CVID #012 none none none none none 
CVID #013 none none none none none 
CVID #014 none none none none none 
CVID #015 none none none none none 
CVID #016* none none none none none 
CVID #017 none none none none none 
CVID #018 P21R(het) none IVS2+72G/C(het) IVS2-33T/C(het) none 
CVID #019 none G64V(191G/T;192C/T)hom none none none 
CVID #020* none none none none none 
CVID #021 none none none none none 
CVID #022 none none none none none 
CVID #023 none none none none none 
CVID #024 P21R(het) none IVS2+72G/C(hom) IVS2-33T/C(hom) none 
CVID #025* none none none none none 
CVID #026* none none none none none 
CVID #027 none none none none none 
CVID #028 P21R(het) none none IVS2-33T/C(het) none 
CVID #029 P21R(het) none none IVS2-33T/C(het) none 
* patients selected for the study of TNFRSF13C quantification and cultures with BAFF                                                 het= 
heterozygous; hom= homozygous 
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Supplemental Table 2. Analysis of sequence variants in the TACI gene in the cohort of CVID patients studied. Work 
done in collaboration with Professor Lennart Hammarström (Department of Laboratory Medicine, Karolinska Institut, 
Stockholm, Sweden). 
 
EXON 
1 
EXON 2 EXON 3 INTRON 3 EXON 4 INTRON 4 EXON 5 3’ UTR 
CVID 
#001 
none T27T(hom) none none none none none none 
CVID 
#002 
none T27T(hom) none none none none none none 
CVID 
#003 
none T27T(hom) none none none none none none 
CVID 
#004 
none T27T(het) none IVS3+25A>C(het) none IVS4+60T>C(het) S277S(het) 
G or A 
(hom) 
CVID 
#005 
none T27T(het) none IVS3+25A>C(het) none IVS4+60T>C(het) S277S(het) 
G or A 
(het) 
CVID 
#006 
none T27T(hom) none none none none 
c.980-
982del 
none 
CVID 
#007 
none T27T(hom) none none none none none none 
CVID 
#008 
none T27T(hom) none none none none none none 
CVID 
#009 
none T27T(hom) none IVS3+25A>C(het) A181E(het) IVS4-84G>C(het) S277S(het) 
G or A 
(het) 
CVID 
#010 
none T27T(het) none IVS3+25A>C(hom) none IVS4+60T>C(het) 
S277S(hom) 
P251L(het) 
G or A 
(hom) 
CVID 
#011 
none T27T(hom) none none none none none none 
CVID 
#012 
none T27T(het) none IVS3+25A>C(het) none IVS4+60T>C(het) S277S(het) 
G or A 
(hom) 
CVID 
#013 
none T27T(het) none IVS3+25A>C(het) none IVS4+60T>C(het) S277S(het) 
G or A 
(het) 
CVID 
#014 
none T27T(hom) none none none none S277S(het) 
G or A 
(het) 
CVID 
#015 
none T27T(hom) none none none none none none 
CVID 
#016 
none T27T(hom) none none none none none none 
CVID 
#017 
none none none IVS3+25A>C(het) none IVS4+60T>C(het) S277S(het) 
G or A 
(het) 
CVID 
#018 
none T27T(hom) none IVS3+25A>C(het) none none S277S(het) 
G or A 
(het) 
CVID 
#019 
none T27T(hom) none none none none none none 
CVID 
#020 
none T27T(het) none IVS3+25A>C(het) none none S277S(het) 
G or A 
(hom) 
CVID 
#021 
none T27T(hom) none none none none none none 
CVID 
#022 
none T27T(het) P97P(het) IVS3+25A>C(hom) none IVS4+60T>C(het) S277S(hom) 
G or A 
(het) 
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CVID 
#023 
none T27T(het) none IVS3+25A>C(het) none IVS4+60T>C(het) S277S(het) 
G or A 
(het) 
CVID 
#024 
none T27T(het) none IVS3+25A>C(het) none IVS4+60T>C(het) S277S(het) 
G or A 
(het) 
CVID 
#025 
none T27T(het) none IVS3+25A>C(hom) none IVS4+60T>C(het) 
S277S(hom) 
P251L(het) 
G or A 
(hom) 
CVID 
#026 
none T27T(het) none IVS3+25A>C(het) none IVS4+60T>C(het) S277S(het) 
G or A 
(het) 
CVID 
#027 
none T27T(hom) none none none none none none 
CVID 
#028 
none T27T(het) none none none none none none 
CVID 
#029 
none T27T(het) none none none none none none 
het= heterozygous; hom= homozygous 
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Abstract 
 
IL-17 is a pro-inflammatory cytokine implicated in autoimmune and inflammatory 
conditions. The development/survival of IL-17-producing CD4 T cells (TH17) share critical cues 
with B-cell differentiation and the circulating follicular T helper subset was recently shown to be 
enriched in TH17 cells able to help B-cell differentiation. We investigated a putative link between 
TH17-cell homeostasis and B cells by studying the TH17-cell compartment in primary B-cell 
immunodeficiencies. Common Variable Immunodeficiency Disorders (CVID), defined by defects 
in B-cell differentiation into plasma and memory B cells, are frequently associated with 
autoimmune and inflammatory manifestations but we found no relationship between these and 
TH17-cell frequency. In fact, CVID patients showed a decrease in TH17-cell frequency in parallel 
with the expansion of activated non-differentiated B cells (CD21lowCD38low). Moreover, 
Congenital Agammaglobulinemia patients, lacking B cells due to impaired early B-cell 
development, had a severe reduction of circulating TH17 cells. Finally, we found a direct 
correlation in healthy individuals between circulating TH17-cell frequency and both switched-
memory B cells and serum BAFF levels, a crucial cytokine for B-cell survival. Overall, our data 
support a relationship between TH17-cell homeostasis and B-cell maturation, with implications 
for the understanding of the pathogenesis of inflammatory/autoimmune diseases and the 
physiology of B-cell depleting therapies. 
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Introduction 
 
CD4 T cells with the ability to produce the pro-inflammatory cytokine interleukin (IL)-17, 
designated TH17
1-3, act as co-ordinators of the innate and adaptive immune responses to 
bacteria and fungi, in particular Candida albicans4, and have been implicated in several 
autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, systemic lupus 
erythematosus, psoriasis and Crohn’s disease5. Common Variable Immunodeficiency Disorders 
(CVID) are defined by impaired antibody production and frequently associate with autoimmune 
and inflammatory manifestations6-9. It is thus plausible that IL-17 may play a role in these 
processes.  
The defects in mature B-cell development that characterize CVID mainly result in 
impaired organization of germinal centres (GC)10, specialized structures within follicles where 
antigen-driven somatic hypermutation and class switch recombination occur, and thus the main 
source of switched-memory B cells and plasma cells11. Several molecular cues that are essential 
for B-cell differentiation in GCs are also required or may contribute to the induction and/or 
survival of TH17 cells. IL-6, a major factor for the differentiation of naive CD4 T cells into TH17 
cells3, also plays a key role in B-cell proliferation and antibody secretion12. IL-21 was first 
described as having a critical role in the regulation of antibody production by B cells13,14, and was 
later shown to be involved in TH17-cell differentiation
15,16. Furthermore, IL-21 is abundantly 
produced by TH17 cells and plays an important autocrine role in their differentiation and 
maintenance4. Several co-stimulatory molecules have also been shown to play roles in both Th17 
induction and/or survival as well as in B-cell differentiation into plasma and memory B cells, 
namely ICOS and CD40L17-22. T-cell help is known to be fundamental to the induction and 
subsequent organization of GCs, enabling an adequate generation of plasma and memory B 
cells. This help is a characteristic of a particular subset of T cells, follicular helper T cells (TFH), 
identifiable by the expression of the chemokine receptor CXCR5, which is essential for their 
specific homing to follicles in lymphoid tissues, and by the production of IL-2123. Although TFH 
cells reside mainly within follicles and GCs, a population of circulating TFH cells has been 
consistently observed in humans24,25. This circulating TFH subset has been recently demonstrated 
to be a counterpart for TFH cells found in GCs
26, and to be enriched not only in TH2 but also in 
TH17 cells that are able to help B-cell differentiation
26. 
We hypothesized that the homeostasis of the circulating TH17 compartment may be 
related to B-cell differentiation. Confirming such a relationship would have major clinical 
implications, given the increasing use of B-cell depleting therapies in many autoimmune and 
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lymphoproliferative diseases. As a strategy to investigate the contribution of B cells to the TH17 
subset, we studied this population in CVID patients as well as in patients lacking B cells due to 
Congenital Agammaglobulinemia. This latter condition is associated with impaired early B-cell 
development in the bone marrow as a result, in the majority of cases, of mutations in the 
Bruton’s tyrosine kinase gene, usually leading to a complete lack of circulating B cells27. The 
evaluation of these primary B-cell deficiencies combined with the study of healthy individuals 
supports a link between the homeostasis of the circulating TH17-cell pool and B-cell 
differentiation. 
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Materials and Methods 
 
Ethics Statement 
All subjects gave written informed consent for blood sampling and processing. The study was 
approved by the Ethical Board of the Faculty of Medicine of Lisbon. 
 
Participants 
The study involved 30 healthy individuals, 31 patients with CVID, and 6 patients with Congenital 
Agammaglobulinemia. The clinical-epidemiological data of the three groups are summarized in 
Table 1. CVID patients were diagnosed according to the European Society for Immunodeficiency 
criteria (www.esid.org), namely decreased serum IgG as well as IgM and/or IgA levels at least 2 
SD below the mean for age, impaired antibody response to vaccines, absent/low 
isohemagglutinins, and exclusion of defined causes of hypogammaglobulinemia. The 31 CVID 
patients were not related, with the exception of two homozygous twins. All the patients with 
Congenital Agammaglobulinemia had less than 1% B cells within total peripheral lymphocytes.  
29 CVID and all Congenital Agammaglobulinemia patients were under IgG replacement therapy, 
adjusted to guarantee pre-infusion Ig levels above 650mg/dL. The two CVID patients not 
receiving IgG had levels of total serum IgG of 227 and 473 mg/dL.  
 
Monoclonal antibodies used in flow cytometry 
The following anti-human monoclonal antibodies were used, with clone and the directly 
conjugated fluorochrome specified in brackets: CD3 (SK7; peridinin chlorophyll protein (PerCP)),  
CD4 (SK3; PerCP), CD8 (SK1; PerCP and allophycocyanin (APC)-Cy7; RPA-T8; APC), CCR6 (11A9; 
phycoerythrin (PE)), CD38 (HB7; PE), CD45RA (L48; PE-Cy7), IgD (IA6-2; PE), IgM (G20-127; APC), 
HLA-DR (L243; fluorescein isothiocyanate (FITC)), IFN- (4S.B3; FITC), IL-2 (MQ1-17H12; PE), IL-4 
(MP4-25D2; PE), from BD Biosciences, San Jose, CA; CD3 (UCHT1; APC-eFluor780), CD4 (RPA-T4, 
FITC, PerCP-Cy5.5 and PE-Cy7), CD8 (RPA-T8; FITC and PE), CD19 (HIB19; PerCP-Cy5.5 and PE-
Cy7), CD27 (O323; FITC, PE, APC and PE-Cy7), CD45RO (UCHL1; PE), CD69 (FN50; FITC), CD45RA 
(HI100; FITC and APC), IL-17A (eBio64DEC17; PerCP-Cy5.5 and Alexa Fluor 647), TNF- (MAb11; 
PE), from eBiosciences, San Diego, CA; CD4 (S3.5; PE) from Caltag, Buckingham, UK; CCR7 
(150503; FITC), CXCR5 (51505.111; PE), from R&D Systems, Minneapolis, MN; CD21 (BL13; FITC) 
from IO Test, Beckman Coulter, Brea, CA.  
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Table 1. Clinical and epidemiological data of the cohorts studied 
 
Healthy CVID 
Congenital 
Agammaglobulinemiaa
 
Number (male/female) 30 (9/21)d 31 (11/20) 6 (6/0) 
Age (yrs.) 4115d 4013 245 
Clinical manifestationsb,c
  
Autoimmune disease n.a. 17/31 (55%) 0 
Adenopathies n.a. 10/31 (32%) 0 
Lymphoid proliferation n.a. 18/20e (86%) 0 
Granulomas  n.a. 3/20e (15%) 0 
Chronic diarrhoea n.a. 15/31 (48%) 0 
Splenomegaly n.a. 16/31 (52%) 0 
IgG replacement therapyc  
intravenous n.a. 24/31 (77%) 6 (100%) 
subcutaneous n.a. 5/31 (16%) 0 
Length of IgG therapy (yrs.) n.a. 76 159 
n.a. not applicable, CVID: Common Variable Immunodeficiency Disorders 
a
 Genetic defects in the Btk gene were 
identified in 4 of the congenital agammaglobulinemia patients, namely IVS17-1GC, R288Q, IVS8-2AG,  and Y375X 
mutations; in the other 2 patients, Btk mutations have been excluded and other genes are currently being evaluated.
 b
 
Diagnostic criteria: Autoimmune disease - clinical data, given the impairment in Ab production; Adenopathies - lymph 
node larger than 1cm diameter in 2 or more lymphatic chains in clinical and/or imaging exams; Lymphoid proliferation 
and Granulomas - diffuse lymphocytic infiltrates or granulomas on gastrointestinal, lymph node or pulmonary 
biopsies; Splenomegaly - longitudinal spleen diameter superior to 15cm (computed tomography or ultrasonography). 
c
 
Percentage within total cohort evaluated in brackets. 
d
 15/30 healthy subjects were included in detailed 
immunological studies (10 female; age 39±11 years). 
e
 Total number of individuals with biopsies. 
 
 
Cell staining and flow cytometric analysis 
Phenotypic analysis was performed in whole blood samples collected immediately before IgG 
administration, after staining with monoclonal antibodies and red blood cells lysis using BD FACS 
Lysing Solution (BD Biosciences). Samples were acquired on a FACSCalibur or on a FACSCanto 
flow cytometer (BD Biosciences). A minimum of 100,000 lymphocytes were acquired per sample. 
Data were analysed using CellQuest Software (BD Biosciences) and FlowJo Software (Tree Star 
Inc., Ashland, OR). Total cell numbers were calculated by multiplying the percentage of each 
population within total lymphocytes by the peripheral blood lymphocyte count obtained at the 
clinical laboratory on the day of sampling. 
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Analysis of cytokine production 
Freshly isolated peripheral blood mononuclear cells (PBMC) by Ficoll-Hypaque density gradient 
(Amersham Pharmacia Biotech, Uppsala, Sweden) were assessed for cytokine production at the 
single-cell level, as previously described28. Briefly, after a 4-hour culture with phorbol myristate 
acetate (PMA) (50ng/mL, Sigma-Aldrich) plus ionomycin (500ng/mL; Calbiochem, Merck 
Biosciences, Nottingham, U.K.), in the presence of brefeldin A (10g/mL; Sigma-Aldrich), PBMC 
were surface stained and then fixed (2% formaldehyde; Sigma-Aldrich, St Louis, MO), 
permeabilized (phosphate buffered saline/1% bovine serum albumin/0.5% saponin) (Sigma-
Aldrich)  and stained intracellularly with monoclonal antibodies against IL-2, IL-4, IFN-, TNF- 
and IL-17. Flow cytometric analysis was subsequently performed as described above.  
 
Quantification of serum levels of BAFF 
Serum concentrations of BAFF (BlyS/TNFSF13B; B-cell activating factor) were quantified by 
Enzyme Linked Immunosorbent Assay (ELISA) using the BAFF Immunoassay Kit (R&D Systems), 
according to the manufacturer's instructions. 
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Software Inc, 
SD). Two group comparisons were performed using Mann-Whitney test. Spearman’s coefficient 
was used to determine the significance of the correlation between two variables. Results are 
expressed as meanSEM, and P-values <0.05 were considered to be significant. 
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Results 
 
TH17 cells in patients with CVID  
We evaluated, for the first time, the frequency of circulating TH17 cells in CVID. Our CVID 
cohort (Table 1) featured the characteristic impairment of GC organization and generation of B-
cell memory, demonstrated by the striking decrease in the frequency of switched-memory B 
cells, accumulation of CD38hiIgMhi transitional B cells, and expansion of CD21lowCD38low B cells, a 
population believed to be related to continuous B-cell activation in the presence of impaired GC 
function29,30 (Supplemental Figure S1A and S1B). No association was observed between the 
frequency of TH17 cells and transitional B cells, a pre-GC B-cell population (Figure 1A).  In 
contrast, we found a statistically significant negative correlation between TH17 cells and 
CD21lowCD38low B cells, in CVID patients (Figure 1A), 
 
Figure 1. TH17 cells in patients with CVID. (A) Correlation between TH17 frequency and frequency of switched-
memory B cells (left), transitional B cells (middle) or CD21
low
 B cells (right), in CVID patients. Switched-memory B cells 
were defined as CD27
+
 IgD
-
 cells,  transitional B cells as CD38
high
 IgM
high
 cells and CD21
low
 B cells were defined as 
CD21
low
 CD38
low
 cells within gated B cells (CD19
+
) after surface staining of whole blood samples. IL-17 expression was 
assessed at the single-cell level by intracellular staining following short-term stimulation of PBMC with PMA and 
ionomycin.  (B) TH17 frequency in CVID individuals stratified according to their clinical manifestations, namely 
autoimmunity, lymphoid proliferation, splenomegaly, and adenopathies.  (C)  TH17 frequency in healthy controls and 
CVID patients grouped according to EUROclass. (D) Correlations between frequencies of activated CD4 T cells, defined 
by concurrent expression of HLA-DR and CD38, and of TH17 cells in CVID and healthy individuals. Each symbol 
represents one individual. Bars represent mean. Data were compared using Mann-Whitney test, and P values are 
shown. Correlation significance was assessed using Spearman coefficient test, and r and P values are shown. 
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suggesting a decline in the frequency of circulating TH17 cells that matched the B-cell 
disturbances indicative of GC disruption. The fact that we did not observe a relationship with the 
frequency of switched-memory B cells is likely related to the heterogeneity of blocks in GC 
differentiation that CVID patients present10. Our CVID cohort presented an unusually high 
proportion of autoimmune and lymphoproliferative manifestations (Table 1), possibly related to 
a reference bias associated with an immunology department in a central hospital. We next 
assessed whether these inflammatory and autoimmune manifestations could be related to an 
expansion of TH17 cells, as reported in other autoimmune settings
5. We found no increase in the 
frequency of TH17 cells in CVID patients with autoimmunity (Figure 1B), even when CVID patients 
were split according to the type of autoimmune manifestation, namely autoimmune cytopenias 
and organ specific autoimmunity (data not shown). In contrast, the CD21lowCD38low B-cell subset 
was significantly expanded in the subgroup of CVID patients with autoimmunity (Supporting 
Information, Figure S1C).  
CVID patients have been classified according to the previously mentioned B-cell sub-
populations9. The stratification of our CVID cohort according to the EUROclass classification9 
revealed that a statistically significant decrease in TH17 frequency was restricted to the group 
with less than 2% switched-memory B cells and more than 10% CD21lowCD38low B cells (Figure 
1C), in agreement with the above results.  
Several T-cell imbalances were also observed in the CVID cohort, as previously 
reported31, namely an expansion of effector-memory T cells, increased production of the pro-
inflammatory cytokines interferon (IFN)- and tumour necrosis factor (TNF)-, and up-regulation 
of activation markers within both CD4 and CD8 T cells (Supplemental Figure S2). Of note, the 
frequency of TH17 cells was found to negatively correlate with CD4 T-cell activation in CVID 
patients (Figure 1D), with no relationship with naïve/memory T-cell imbalances (correlation with 
the frequency of naïve cells within CD4 T cells, r=0.3065, P=.1058). In contrast, the frequency of 
IFN--producing cells was found to negatively correlate with naïve CD4 T cells (r=-0.8199, 
P<.0001) and positively with the levels of CD4 T-cell activation in CVID patients (r=0.6098, 
P=.0003). Similar relationships were observed with the expression levels of activation markers 
within the CD8 T-cell subset (data not shown). We also investigated whether the increased 
production of IFN- observed in CVID patients had an impact on the concomitant production of 
this cytokine by TH17 cells. We found no significant differences in the proportion of IFN-
+ cells 
within the IL-17-producing CD4 subset as compared to healthy subjects (22.55%±2.34% in CVID 
and 14.45%±1.70% in healthy, P=.0567) and no relationship between the frequencies of IFN-- 
and IL-17-producing CD4 T cells (r=-0.2504, P=.1821). Moreover, in contrast to IFN--producing 
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CD4 T cells, no association was found between the frequency of IL-17+IFN-+ CD4 T cells and the 
naïve/memory imbalances (P>.1500).  
In conclusion, no association between TH17 cells and autoimmune manifestations or 
production of other pro-inflammatory cytokines was observed in CVID patients. The levels of 
TH17 cells were apparently more directly related to B-cell differentiation than to T-cell 
disturbances, showing a negative correlation with the pathological expansion of a B-cell 
population associated with impaired GC function (CD21lowCD38low B cells) in CVID. 
 
Decreased frequency of TH17 cells in individuals without B cells 
In order to further investigate the relationship between B cells and the IL-17-producing 
CD4 subset, we evaluated this population in individuals with Congenital Agammaglobulinemia, 
who lack mature B cells due to genetic defects impairing early B-cell development27 (Table 1).  A 
marked reduction in the frequency of TH17 cells was found in these patients (Figure 2A and 2B). 
 
 
Figure 2. Decreased frequency of TH17 cells in individuals lacking B cells. (A) Representative dot-plots of the analysis 
of IFN- and IL-17 production by CD4 T cells, determined by intracellular staining, for a healthy individual (left), a CVID 
patient (middle) and a Congenital Agammaglobulinemia (Agamma) patient (right). Numbers inside dot-plots represent 
the proportion of cells expressing the markers. (B) Frequency of TH17 cells (left) and CXCR5
+
 CD4 T cells (right) in 
healthy individuals and Congenital Agammaglobulinemia patients (Agamma). Each symbol represents one individual. 
Bars represent mean. Data were compared using Mann-Whitney test, and P values are shown. 
In spite of the reduced TH17 frequency, these patients do not exhibit a major increase in 
the frequency of infections with Candida albicans, which may be related to the preservation of 
innate sources of IL-17, such as  T cells, natural killer T cells or myeloid cells.  
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Of note, these individuals featured neither significant naïve T-cell imbalances, nor major 
alterations in the levels of T-cell activation nor frequencies of IFN--, TNF--, IL-2- or IL-4-
producing cells, as compared to healthy subjects (Supplemental Figure S2).  
Importantly, a significant reduction of circulating TFH cells was found in these patients 
(Figure 2B), likely related to decreased GC generation in the context of Congenital 
Agammaglobulinemia, as recently reported32. A decrease in this circulating CD4 T-cell population 
has also been described in the context of human ICOS-deficiency, a situation in which the 
generation of GCs is known to be severely perturbed33. 
In conclusion, we report here a major reduction in the TH17-cell pool in patients lacking B 
cells. 
 
Direct correlation between the frequency of circulating TH17 cells and switched-memory B cells in 
healthy individuals 
Our findings suggesting a relationship between the homeostasis of the circulating TH17 
compartment and B-cell disturbances led us to investigate this putative relationship in healthy 
individuals. We found a direct correlation between the frequency of CD4 T cells able to produce 
IL-17 and the frequency of B cells exhibiting a switched-memory phenotype in these individuals 
(Figure 3). This relationship was also observed when absolute numbers of the circulating 
populations were considered (r=0.4565, P=.0249). 
 
 
Figure 3. Direct correlation between the frequencies of circulating TH17 cells and switched-memory B cells in 
healthy individuals. Correlation between the frequencies of switched-memory (CD27
+
IgD
-
) B cells and TH17 cells in 
healthy individuals. Each symbol represents one healthy individual. Correlation significance was assessed using 
Spearman coefficient test, and r and P values are shown. 
In addition, healthy individuals exhibited a negative correlation between the frequency 
of TH17 cells and the serum levels of B-cell activating factor (BAFF) (Figure 4A), a critical cytokine 
for B-cell differentiation and survival34. In contrast, we did not observe any relationship between 
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BAFF serum levels and the production of other pro-inflammatory cytokines, such as IFN- and 
TNF-, or IL-4 (data not shown), thus highlighting the specificity of the link to TH17 cells. These 
results are in conformity with our previous observation of a relationship between IL-17 
production by CD4 T cells and B-cell maturation in the context of primary B-cell deficiencies. 
 
 
Figure 4. Negative correlation between the frequency of TH17 cells and serum BAFF levels in healthy subjects. (A) 
Correlation between the frequency of TH17 cells and serum levels of the cytokine BAFF, as determined by ELISA, in 
healthy individuals. (B) Analyses of the serum levels of BAFF in healthy individuals, CVID and Congenital 
Agammaglobulinemia patients. Each symbol represents one individual. Data were compared using Mann-Whitney 
test, and P values are shown. (C) The same correlation described in (A) for CVID patients and Congenital 
Agammaglobulinemia patients. Each symbol represents one individual. Correlation significance was determined using 
Spearman coefficient test, and r and P values are shown. 
 
It has recently been demonstrated in mice that local BAFF-gene targeting in dendritic 
cells suppressed both the generation of plasma cells and TH17 cells
35, suggesting that BAFF 
promotes TH17-cell proliferation and expansion, possibly through the modulation of the cytokine 
milieu. However, providing our finding of a negative association between BAFF and IL-17 we 
hypothesize that BAFF effects may be indirectly mediated by the B-cell subset. In order to 
further investigate this possibility we quantified serum BAFF levels in the CVID and Congenital 
Agammaglobulinemia cohorts. In agreement with recent reports36,37, serum BAFF levels were 
significantly increased in CVID patients, and were even higher in Congenital 
Agammaglobulinemia, reaching statistical significance in comparison to both healthy individuals 
and to CVID patients (Figure 4B). However, no correlation was found between BAFF serum levels 
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and the frequency of TH17 cells in CVID and Congenital Agammaglobulinemia patients (Figure 
4C). Notably, in the absence of B cells as illustrated by Congenital Agammaglobulinemia patients, 
very high levels of BAFF may be associated with very low frequencies of TH17 cells (Figure 4C), 
not supporting a direct role of BAFF in the induction/survival of TH17 cells. Overall, our data 
suggest that the association between IL-17-producing CD4 T cells and BAFF is likely related to its 
effects on B cells. 
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Discussion 
 
We report here an association between the frequencies of TH17 cells and switched-
memory B cells in healthy individuals, and a marked reduction of this CD4 subset in patients with 
congenital absence of peripheral B cells. Additionally, in patients with primary defects in mature 
B-cell differentiation, the frequency of TH17 cells was inversely correlated with markers of GC 
impairment, further supporting the link between B cells and the differentiation or maintenance 
of TH17 cells.  
Our data generated in human B-cell deficiencies suggest, for the first time, that B cells 
play a role in the homeostasis of the TH17 subset. On the other hand, several previous reports 
have implicated IL-17 in B-cell differentiation and function. A recent report38 suggested that IL-
17 and possibly TH17 cells can contribute to GC function in general. This work using BXD2 mice, 
which develop spontaneous erosive arthritis associated with auto-antibody production, showed 
that the enhanced somatic hypermutation and class-switch recombination found in these 
animals resulted from the direct action of IL-17 on B cells, leading to increased frequency and 
duration of GCs38. Recent data from human studies also suggest that TH17 cells may contribute 
to the generation of ectopic GCs within kidney allografts through the production of IL-2139, 
further establishing a link between IL-17 and B-cell function. Importantly, IL-17 alone has been 
described to promote human B-cell survival and to synergize with BAFF to induce B-cell 
proliferation and differentiation into antibody-secreting plasma cells40. Recent reports have, in 
this sense, established a direct impact of IL-17 on B cells38,40, with respect to proliferation, 
survival and antibody production, and have shown that TH17 cells can act as B-cell helpers
41. Our 
observation of markedly reduced levels of TH17 cells in the absence of other major T-cell 
imbalances in patients with congenital absence of B cells suggests an important contribution of B 
cells to the homeostasis of TH17 cells. Although the number of patients with this rare 
immunodeficiency under follow-up is small, the remarkable consistency of the results generated 
in these patients strengthens our finding of a reduced TH17 compartment in Congenital 
Agammaglobulinemia. Such a relationship was further supported by the negative correlation 
between TH17 frequency and the expansion of the CD21
lowCD38low B-cell subset in CVID patients, 
a pathological B-cell population resulting from altered B-cell activation associated with defects in 
GC function29,30.  
Our results raise the possibility of a follicular contribution to the maintenance of the 
TH17-cell subset, a notion further supported by a recent report
26. We were able to reveal a 
fraction of TH17 cells expressing both CXCR5 and CCR7, in addition to CCR6, likely having the 
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potential to home to follicles (data not shown). This is particularly relevant given the fact that 
circulating TFH cells were reported to be enriched in TH17 cells that are able to help B-cell 
differentiation26. We have studied this population in patients without peripheral B cells due to 
early defects in B-cell development, which, as described in ICOS-deficient patients33,42, are 
expected to have reduced generation of GCs. We found the circulating CXCR5+ CD4 T-cell 
population to be significantly diminished in these patients, as compared to healthy subjects, in 
agreement with a recent report32, further supporting the notion of circulating TFH cells being 
counterparts of the follicular helper T cells found in GCs. Our results suggest that the impairment 
in GC generation may underlie the reduced frequencies of both TFH and TH17 cells. 
Contrary to what we observed in Congenital Agammaglobulinemia, CVID patients presented with 
several T-cell imbalances31, namely an increase in the production of the pro-inflammatory 
cytokines IFN- and TNF-, in direct correlation with the up-regulation of activation markers. We 
found that the TH17-cell population decreased concurrently with the hyper-activated state, 
suggesting that a different mechanism is involved in its regulation in CVID patients. Furthermore, 
a significant proportion of our CVID cohort featured autoimmune manifestations and some 
patients exhibited inflammatory processes that shared similarities with the pathology of Crohn’s 
disease, a condition in which TH17 cells have been implicated
5,43. However, in contrast to Crohn’s 
disease, it has been shown that CVID patients with symptomatic gut inflammation exhibit a 
reduced ability to produce IL-17 and IL-23 by the lamina propria mononuclear cells, in spite of 
increased IL-12 and IFN- secretion43. Importantly, we found no increase in the frequency of CD4 
T cells able to produce IL-17 in CVID patients presenting with autoimmune disease, either with 
autoimmune cytopenia or other autoimmune disorders. In fact, an inverse correlation was found 
with the expansion of the CD21lowCD38low B-cell subset that has been implicated in 
autoimmunity. These findings are particularly relevant given that our cohort presents an 
exceptionally high prevalence of autoimmune manifestations. 
A recent report suggested that the commercial immunoglobulin (Ig) used in intravenous 
therapy has the ability to inhibit the differentiation, amplification and function of human TH17 
cells in vitro44. However, such an effect is unlikely to account for the observations described 
here, since both Congenital Agammaglobulinemia and CVID patients undergo replacement 
therapy with Ig (Table 1). 
The development and homeostasis of TH17 cells and memory B cells share several 
determinants. Tumour growth factor (TGF)- has a unique role in driving IgA isotype switching, 
which is the major Ig type produced at mucosal sites45, and is also critical for TH17-cell 
differentiation15,16.  Both IgA and IL-17-producing CD4 T cells have an important function in the 
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modulation of gut flora and mucosal immunity45. It is thus plausible that the link between IL-17 
production and B-cell function could mainly lie in the isotype switch to IgA, a notion further 
supported by the fact that patients with Congenital Agammaglobulinemia or CVID have impaired 
IgA production. This possibility led us to investigate the frequency of circulating TH17 cells in 
patients with selective IgA deficiency. However, no imbalances in this CD4 subset were found in 
patients with undetectable serum levels of IgA as compared to healthy individuals (data not 
shown), suggesting that the link between B cells and IL-17 production is not dependent of the 
development of IgA-producing cells. It is unlikely that a unique molecule or pathway determine 
the impact of B cells in the homeostasis of the TH17 subset, being more plausible that several 
mechanisms are involved, either through direct interactions or through the influence of factors 
modulated by B cells. 
BAFF is a crucial survival factor for peripheral B cells. As expected from previous reports, 
both CVID and Congenital Agammaglobulinemia patients presented highly increased serum 
levels of this cytokine36,37. Although increased BAFF production by cells of the innate immune 
system, such as neutrophils, macrophages, monocytes and dendritic cells, could be enhanced in 
these patients, contributing to these increased levels, it is more likely that they resulted from 
reduced consumption of BAFF due to the decreased number of target cells in both conditions. 
This latter hypothesis is supported by the fact that B-cell depletion upon rituximab treatment, a 
monoclonal antibody targeting CD20, results in significantly increased levels of BAFF that return 
to baseline levels upon B-cell re-population46. Thus, high BAFF levels may be considered a 
measure of B-cell dysfunction and, in this sense, the negative correlation we report in healthy 
individuals between the frequency of TH17 cells and the serum levels of BAFF further 
strengthens the link between IL-17 production and B-cell maturation. 
B cell-depleting therapies have been increasingly used in various clinical settings, 
including pathologies where IL-17 has been implicated46-48. Additionally, BAFF-targeting 
therapies offer a promising approach for autoimmune/inflammatory disorders46,48. Our data 
raise the possibility that these treatments may have an impact on TH17 cells and, in this way, 
influence the clinical outcome mediated by these therapeutic strategies. In line with these 
observations, a very recent report has shown that rituximab treatment selectively reduces the 
TH17-cell response in rheumatoid arthritis patients
49. Nevertheless, such an inhibition does not 
seem to lead to an increased frequency of mucocutaneous candidiasis in rituximab-treated 
patients49, an infection associated with TH17 deficiency. 
In conclusion, our data show, for the first time, that the induction/proliferation/survival 
of TH17 cells is related to B-cell function. These results provide support for a link between TH17 
118 B cells at the crossroad of immune responses: 
insights from primary B-cell immunodeficiencies 
 
and B cells that is relevant for the understanding of the pathogenesis of 
inflammatory/autoimmune diseases as well as the mechanisms underlying the effects of 
therapeutic strategies targeting B cells. 
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Supplemental Data 
 
 
 
Supplemental Figure 1. B-cell disturbances in CVID patients. (A) Representative plots of the flow cytometry analysis 
of switched-memory B cells (top), CD21
low
CD38
low
 B cells (middle) and transitional B cells (bottom), in healthy 
individuals (left panels) and CVID patients (right panels). Numbers represent the percentage of the given population 
within CD19
+
 cells. (B) Comparison of the frequencies of these B-cell subsets in CVID and in healthy individuals. (C) 
Frequency of CD21
low
CD38
low
 within B cells in healthy controls and CVID individuals stratified according to their clinical 
manifestations, namely autoimmunity, lymphoid proliferation, splenomegaly, and adenopathies.  Each symbol 
represents one individual. Bars represent mean. Data were compared using Mann-Whitney test, and P values are 
shown. 
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Supplemental Figure 2. T-cell disturbances in CVID and Congenital Agammaglobulinemia patients. Analysis of: (A) 
frequency and absolute numbers of naïve (CD45RA
+
CD27
+
) within CD4 T cells; (B) frequency and absolute numbers of 
naïve (CD45RA
+
CD27
+
) and terminally-differentiated (CD45RA
+
CD27
-
) within CD8 T cells; (C) frequency of activated 
(HLA-DR
+
CD38
+
) within CD4 T cells and CD8 T cells; and (D) frequencies of IFN--, TNF--, IL-4-, and IL-2-producing CD4 
T cells assessed at the single-cell level by intracellular staining following short-term PBMC stimulation with PMA and 
ionomycin. Bars represent meanSEM. Data were compared using Mann-Whitney test, and P values are shown. 
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3.2 – SUPPLEMENT A 
EVALUATION OF THE FREQUENCY OF TH17 CELLS IN PATIENTS WITH 
SELECTIVE IgA DEFICIENCY 
 
 
As mentioned previously, the development and homeostasis of TH17 cells and B-
differentiation share several molecular factors. Both patients with Congenital 
Agammaglobulinemia or CVID have impaired IgA production. TGF- has a crucial role in B-cell 
function by driving IgA isotype switching, which is the major Ig type produced at mucosal sites1. 
TGF- is also critical for TH17-cell differentiation
2,3. Given that both IgA and TH17 cells have an 
important function in the modulation of gut flora and mucosal immunity1, it is thus reasonable 
to speculate that the link between IL-17 production and B-cell function that we described could 
primarily lie in the isotype switch to IgA. This reasoning led us to investigate the frequency of 
circulating TH17 cells in patients with selective IgA deficiency (sIgAD). We have used strict criteria 
to define selective IgA deficiency, including undetectable serum levels of IgA, and we evaluated 
the frequency of circulating CD4 T cells able to produce IL-17, using the protocols described in 
Chapter 3.2.  
 
 
Figure 1. Frequency of TH17 cells in patients with selective IgA deficiency (sIgAD). Comparison of the frequency of IL-
17-producing CD4 T cells between healthy individuals (filled circles) and sIgAD patients (grey triangles), as determined 
by intracellular staining at the single-cell level. Each symbol represents one individual. Bars represent the mean value. 
Data were compared using the Mann-Whitney test, and p values are shown. 
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We found no difference between patients with sIgAD and healthy individuals in what 
concerns the frequency of IL-17-producing CD4 T cells (Figure 1). Our data thus suggest that the 
relation between B cells and IL-17 production is not dependent on the isotype switch to IgA.  
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3.2 – SUPPLEMENT B 
DIFFERENTIATION OF TH17 CELLS FROM NAÏVE CD4 T CELLS FROM 
CONGENITAL AGAMMAGLOBULINEMIA PATIENTS 
 
 
Our observation of markedly reduced frequencies of IL-17-producing CD4 T cells in 
patients with Congenital Agammaglobulinemia (see Chapter 3.2), who lack circulating B cells, has 
led us to question whether TH17 differentiation was affected in these patients. 
In order to assess this possibility, we have optimized an in vitro TH17 differentiation 
protocol using isolated naive CD4 T cells from Congenital Agammaglobulinemia patients with 
defined mutations in the Btk gene (X-Linked Agammaglobulinemia patients).  
Human TH17 differentiation was first described to depend on IL-23 and IL-1
1 or IL-1 
and IL-62. In these reports, both TGF- and IL-12 were shown to inhibit TH17 differentiation
2. 
However, later on it has been shown that TGF- is actually required for TH17 differentiation, 
although at very low levels, while it can have an inhibitory effect when present at higher 
concentrations3. We have chosen to employ a protocol4 that combines the use of special culture 
medium (IMDM - Iscove’s modified Dulbecco’s medium), in the presence or absence of low 
concentrations of TGF- (0.5ng/mL), and a cytokine mix composed of IL-6, IL-1 and IL-23, in the 
presence of blocking antibodies against IFN- and IL-4, to help prevent potential TH1 and TH2 
polarization, respectively. Naive CD45RA+CD45RO- CD4 T cells were isolated using an EasySep 
magnetic kit and cultured for 5 days with -CD3 and -CD28 antibodies to provide TCR and co-
stimulation, and IL-2, in the described conditions. Five healthy controls and four XLA patients 
were studied in parallel. 
Figure 1A illustrates the variability of TH17 polarization between individuals and different 
experiments after five days of culture. Nevertheless, TH17 polarization was always more effective 
in the condition where TGF- was not added to the culture medium (“cytokine mix”).  
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Figure 1. TH17 differentiation in naïve CD4 T cells from Congenital Agammaglobulinemia patients. (A) Flow 
cytometry plots representing IL-17 and IFN- expression in naïve CD4 T cells cultured for five days in different 
conditions: medium alone (“medium”), -CD3/CD28 plus IL-2 (“IL-2”), -CD3/CD28 plus IL-2 and cytokine cocktail for 
TH17 differentiation in the presence (“cytokine mix+TGF-”) or not (“cytokine mix”) of TGF-. Shown are the different 
pairs of healthy (Healthy) and Congenital Agammaglobulinemia (Agamma) individuals studied in parallel. (B and C) 
Frequency of IFN-
+
 (B) and IL-17
+
 (C) cells recovered from each culture condition, as described in (A). Healthy 
individuals are shown as filled circles and Congenital Agammaglobulinemia patients as grey squares. Each symbol 
represents one individual. Bars represent mean value. Data were compared using the Mann-Whitney test, and p 
values are shown. (D) Comparison between healthy individuals and Congenital Agammaglobulinemia patients studied 
in parallel, in what concerns IFN- (left panel) and IL-17 (right panel) expression. 
 
TH17 polarization appeared to be defective in XLA patients, while TH1 polarization was 
normal (Figure 1A-D).  
Even though our results are highly preliminary and need to be further confirmed, they 
suggest that the reduced ex vivo frequency of TH17 cells found in Congenital 
Agammaglobulinemia patients can be directly related to a lower cell-specific ability to 
differentiate into the TH17 pathway.  
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Methods 
 
In vitro differentiation of TH17 cells 
Naive (CD45RA+CD45RO-) CD4 T cells were isolated through magnetic negative selection using a 
kit from EasySep (StemCell Technologies). Cells were cultured in IMDM (Iscove’s modified 
Dulbecco’s medium) (Gibco, Invitrogen) supplemented with 5% fetal bovine serum (Gibco, 
Invitrogen), 1% Pen/Strep (Gibco, Invitrogen), and 1% non-essential aminoacids (Gibco, 
Invitrogen). Different culture conditions were assessed: medium alone; immobilized -CD3 
(1ug/mL; Ebioscience) and -CD28 (2.5ug/mL; Ebioscience) plus IL-2 (10U/mL; obtained through 
the National Institutes of Health (NIH)/AIDS Research and Reference Program, Division of AIDS, 
National Institute of Allergy and Infectious Diseases, NIH [IL-2] from Hoffman-La Roche); -
CD3/CD28 plus IL-2 in the presence of a Th17 cytokine differentiation cocktail [IL-6 (30ng/mL), IL-
1 (10ng/mL), IL-23 (10ng/mL); -IFN- (5ug/mL), -IL-4 (5ug/mL); all from Ebioscience], in the 
presence or not of TGF- (0.5ng/mL; Peprotech). Cells were cultured for five days at a 
concentration of 5x105/mL. Following the culture period, cells were assessed for cytokine 
production at the single-cell level, as previously described5. Briefly, after a 4-hour culture with 
phorbol myristate acetate (PMA) (50ng/mL, Sigma-Aldrich) plus ionomycin (500ng/mL; 
Calbiochem, Merck Biosciences), in the presence of brefeldin A (10g/mL; Sigma-Aldrich), cells 
were surface stained and then fixed (2% formaldehyde; Sigma-Aldrich), permeabilized 
(phosphate buffered saline/1% bovine serum albumin/0.5% saponin) (Sigma-Aldrich)  and 
stained intracellularly with monoclonal antibodies against IL-4, IFN-, and IL-17. Flow cytometric 
analysis was subsequently performed. Samples were acquired on a FACSCalibur (BD Biosciences) 
and data were analysed using FlowJo Software (Tree Star Inc.). 
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3.2 – SUPPLEMENT C 
REGULATORY T CELLS IN COMMON VARIABLE IMMUNODEFICIENCY 
 
 
Treg and TH17 cells are believed to possess reciprocal pathways of differentiation
1. 
Several reports have described a decrease in the frequency of Treg cells in of CVID patients
2,3 and 
a link to autoimmunity has been proposed4,5. However, important questions prevail, namely 
concerning how these alterations are related to the TH17 compartment. It was thus our aim to 
determine the relationship between Treg cells and TH17 cells in CVID patients, for which purpose 
Treg cells were quantified in terms of FOXP3 and CD25 expression and characterized for the 
expression of naïve/memory markers and markers of Treg-associated function.  
 
Regulatory T cells in Common Variable Immunodeficiency 
We analysed the population of Treg cells in our cohort of CVID patients, using both FOXP3 
and CD25 expression to identify these cells. CD25, the alpha-chain of the IL-2 receptor, is up-
regulated upon TCR stimulation and is constitutively expressed at high levels by Treg cells
6-10. It 
can also be up-regulated upon stimulation with c cytokines11-13. Expression of the FOXP3, a 
transcription factor associated with Treg differentiation
14-16, is currently considered the best 
available Treg marker. However, it has also been shown that it may be up-regulated upon T-cell 
activation17,18.  
We observed that the frequency of FOXP3+ cells within CD4 T cells shows a trend to be 
increased in CVID patients as compared to healthy individuals (Figure 1B and 1C). However, 
CD25 expression was significantly decreased in CVID patients, both in terms of total CD25+ within 
CD4 T cells as well as CD25bright CD4 T cells (Figure 1A, 1D and 1E, respectively). Of note, this 
reduction of CD25 expression does not seem to have an impact on the frequency of 
FOXP3+CD25+ CD4 T cells, since it was similar between CVID patients and healthy individuals 
(Figure 1F). This decrease in CD25 expression was not apparently related to a decrease in the 
ability to produce IL-2 since the proportion of IL-2-producing cells was relatively preserved (see 
Chapter 3.2, Supplemental Figure 2).  
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Importantly, we observed an expansion of FOXP3+CD25- CD4 T cells in CVID patients 
(Figure 1G). This population has been shown to be also expanded in the context of SLE19,20. 
However, its function remains elusive21, with reports showing that FOXP3+CD25- CD4 T cells are 
phenotypically and functionally similar to Treg cells and thus would represent dysfunctional Treg
22, 
while others concluded that this population most likely represents previously activated 
conventional T cells, since they are able to produce considerable amounts of cytokines, contrary 
to true Treg cells
23.  
 
 
Figure 1. CVID was associated with decreased CD25 expression, while FOXP3 expression was maintained. (A and B) 
Representative flow cytometric plots of CD25 and FOXP3 expression in a healthy individual and a CVID patient. (C to 
G) Frequency of different regulatory T-cell populations, as defined by FOXP3 and/or CD25 expression, in healthy 
controls (filled circles) and CVID patients (open squares). Frequency of FOXP3
+
 (C), CD25
+
 (D), CD25
bright
 (E), 
FOXP3
+
CD25
+
 (F) and FOXP3
+
CD25
-
 (G) within CD4 T cells. Each symbol represents one individual. Bars represent the 
mean value. Data were compared using the Mann-Whitney test, and p values are shown. 
 
Nevertheless, the expansion of FOXP3+CD25- CD4 T cells has been associated with disease 
activity and severity and also with the titres of autoantibodies in SLE patients20,22, suggesting that 
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this population can actually have a role in disease pathogenesis. It is still unknown where these 
cells originate from. Studies have shown that CD25- cells can give rise to CD25+ cells that are 
similar to recently isolated Treg cells, upon homeostatic proliferation
24, and it has been further 
suggested that FOXP3+CD25- cells constitute a peripheral reservoir of differentiated Treg cells that 
can be recruited to the CD25+ pool upon homeostatic expansion25. In addition, studies in mice 
have described an accumulation of a FOXP3+ population within CD4+CD25- T cells with 
suppressive capacity in aged mice, but not in young animals26. In this sense, it has been 
proposed that the increased FOXP3+CD25- CD4 T-cell population in SLE patients constitutes a 
pool of cells that, under the conditions where autoimmune responses are reactivated, can be 
recruited to expand the Treg population by gaining CD25 expression
27. 
 
Given the apparent dissociation between FOXP3 and CD25 expression in CVID patients, 
we chose to analyse separately the expression of the two Treg markers. We then analysed the 
expression of FOXP3 and CD25 in naïve (CD45RA+) and memory (CD45RA-) CD4 T cells (Figure 2).  
 
Figure 2. Regulatory T cells in relation to naïve and memory T-cell subsets. Distribution of Treg cells as defined by 
either CD25
bright
 (A) or FOXP3
+
 (B) expression within naïve (CD45RA
+
) and memory (CD45RA
-
) CD4 T-cell populations. 
Healthy individuals are represented in black and CVID patients in white bars. Bars represent meanSEM. Analysis of 
dependent samples was performed using Wilcoxon matched-pairs signed rank test. (C and D) Quality of Treg cells in 
terms of the expression of naive cell markers (CD45RA
+
). Healthy individuals are shown as filled circles and CVID 
patients as open squares. Each symbol represents one individual. Bars represent the mean value. Data were compared 
using the Mann-Whitney test, and p values are shown. 
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We found that the frequency of CD25bright cells within naïve CD4 T cells is very small and 
similar in both healthy individuals and CVID patients (Figure 2A). In the memory CD4 T-cell 
population, we observed that the frequency of CD25bright cells is significantly decreased in CVID 
patients as compared to healthy individuals, reflecting the overall loss of CD25 expression we 
observed in CVID patients (Figure 1A, 1D and 1E). We also found that the frequency of FOXP3+ 
cells within naïve CD4 T cells is significantly increased in CVID patients, while the frequency in 
memory CD4 T cells was similar in CVID patients and healthy individuals (Figure 2B). 
Interestingly, when comparing the two subpopulations within the same cohort, we found that 
memory CD4 T cells have a higher frequency of FOXP3+ cells than naïve CD4 T cells in healthy 
individuals, but in CVID patients the frequencies are similar. Again, there seems to be a 
dissociation between FOXP3 and CD25 expression even within the naïve and memory CD4 T-cell 
compartments. Conversely, we analysed the frequency of naïve cells within the Treg populations. 
The CD4+CD25bright population includes less than 20% of naïve cells, and this percentage is similar 
in healthy individuals and CVID patients (Figure 2C). Of note, the CD4+FOXP3+ population 
includes a significantly lower percentage of naïve cells in CVID patients as compared to healthy 
individuals (Figure 2D). It should be noted that CVID patients have significantly lower frequencies 
of naïve CD4 T cells (as shown in Chapter 3.2). 
 
CD39 is an ectoenzyme that degrades adenosine triphosphate (ATP) to adenosine 
monophosphate (AMP) and has been suggested as an important mechanism of Treg-mediated 
suppression of inflammatory responses28. The frequency of CD25+CD39+ within CD4 T cells was 
significantly reduced in CVID patients (Figure 3A), probably reflecting the fact that CD25 
expression, as a whole, is prominently diminished in these patients. Supporting this view is the 
fact that the frequency of FOXP3+CD39+ within CD4 T cells was similar in healthy individuals and 
CVID patients (Figure 3B). To overcome the issue of total CD25 or FOXP3 expression, we 
analysed the expression of CD39 within the differently defined Treg populations. 
We observed that CD39 expression in CVID patients and healthy individuals was not 
significantly different, both in the FOXP3+ CD4 T-cell population as well as in the CD25bright subset 
(Figure 3C and 3D, respectively). It is worth mentioning that the CD25bright CD4 T-cell population 
comprised a higher amount of CD39+ cells, which may suggest that high levels of CD25 
expression may be a more suitable marker to define Treg cells than FOXP3 expression, as it has 
actually been proposed in the context of SLE29. 
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Figure 3. Expression of the ectoenzyme CD39 in regulatory T cells. Frequency of CD25
+
CD39
+
 (A) and FOXP3
+
CD39
+
 
(B) cells within CD4 T cells. Expression of CD39 within CD25
bright
 (C) and FOXP3
+
 (D) populations. Healthy individuals 
are shown as filled circles and CVID patients as open squares. Each symbol represents one individual. Bars represent 
the mean value. Data were compared using the Mann-Whitney test, and p values are shown. 
 
Relationship between regulatory T cells and T-cell imbalances  
Increased levels of T-cell immune activation are a hallmark of the immunodeficient state 
observed in HIV-infected patients and are considered to be a good surrogate marker of disease 
progression30. It has been reported that the frequency of Treg cells positively associates with the 
levels of T-cell activation in HIV infection31,32, possibly reflecting a self-regulatory mechanism to 
counterbalance the immune activation. Since our CVID cohort also presents increased levels of 
T-cell immune activation, we sought to determine if this was associated with the frequency of 
different subsets of Treg cells and their functional potential. We found no association between 
the levels of CD4 T-cell activation and the frequency of either CD25bright or FOXP3+ CD4 T cells in 
CVID patients (Figure 4A and 4B, respectively). However, CD4 T-cell activation was inversely 
correlated with the total frequency of CD25-expressing CD4 T cells (Figure 4C). In order to better 
understand whether FOXP3+CD25- CD4 T cells can be related to T-cell activation, we analysed the 
relationship between the frequency of either FOXP3+CD25+ or FOXP3+CD25- CD4 T-cell 
populations and the levels of T-cell activation. We observed that the frequency of the 
FOXP3+CD25+ population was negatively associated with CD4 T-cell activation, in CVID patients 
(Figure 4D), while the frequency of FOXP3+CD25- CD4 T cells was directly associated with T-cell 
activation (Figure 4E), further suggesting that the expression of FOXP3 in the CD25- population 
may be directly related to events of immune activation. As previously mentioned, CVID patients 
also have naïve/memory T cell imbalances, namely a loss of naïve CD45RA+ T cells with a 
consequent accumulation of memory CD45RA-CD45RO+ T cells and increased levels of T-cell 
activation (see Chapter 3.2)33.  
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Figure 4. Relationship between regulatory T-cell subsets and T-cell activation in CVID. Correlations between the 
frequencies of activated CD4 T cells as defined as HLA-DR
+
CD38
+
 and CD25 and/or FOXP3-expressing regulatory T-cell 
subsets, in healthy individuals (filled circles) and CVID patients (open squares). Correlation between activated CD4 T 
cells and CD25
bright
 (A), FOXP3
+
 (B), total CD25
+
 (C), FOXP3
+
CD25
+
 (D) and FOXP3
+
CD25
-
 (E) within CD4 T cells. Each 
symbol represents one individual. Correlation significance was determined using the Spearman coefficient test, and r 
and p values are shown. 
 
In order to bypass the impact of such imbalances in the frequency of Treg cells, we 
analysed the frequencies of these cells within the CD45RA+ and the CD45RA- CD4 T cell subsets 
and then studied their relationships with the levels of CD4 T cell activation. We observed that, 
within the naïve CD45RA+ subset, there were no relationship between the frequency of either 
CD25bright or FOXP3+ within CD4 T cells and the levels of CD4 T cell activation (Figure 5A, left and 
right panel, respectively). However, within the memory CD45RA- subset, the frequency of 
FOXP3+ CD4 T cells was negatively associated with the levels of CD4 T-cell activation in CVID 
patients (Figure 5B).  
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Figure 5. Relationship between naïve and memory regulatory T-cell subsets and T-cell activation in CVID. 
Correlations between the frequencies of activated CD4 T cells as defined as HLA-DR
+
CD38
+
 and the distribution of 
regulatory T cells as defined by either CD25
bright
 (left panels) or FOXP3
+
 (right panels) expression within naive 
(CD45RA
+
) (A) and memory (CD45RA
-
) (B) CD4 T-cell populations. Each symbol represents one individual. Correlation 
significance was determined using the Spearman coefficient test, and r and p values are shown. 
 
Interestingly, we observed that the frequency of CD25bright cells within CD4 T cells was 
directly associated with the frequency of naïve CD4 T cells, in CVID patients (Figure 6A).  
 
Figure 6. The frequency of regulatory T cells was directly associated with the frequency of naïve T cells in CVID. 
Correlations between the frequencies of naive CD4 T cells as defined as CD45RA
+
CD27
+
 and CD25bright (A), 
FOXP3
+
CD25
+
 (B), and FOXP3
+
CD25
-
 (C) CD4 T-cell populations, in healthy individuals (filled circles) and CVID patients 
(open squares). Each symbol represents one individual. Correlation significance was determined using the Spearman 
coefficient test, and r and p values are shown. 
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No relationship was found between the frequency of naïve CD4 T cells and that of FOXP3+ cells 
within CD4 T cells. However, the frequency of FOXP3+CD25+ CD4 T cells was also directly 
associated with the frequency of naïve CD4 T cells, in CVID patients (Figure 6B), while no 
relationship was found for the frequency of Foxp3+CD25- CD4 T cells (Figure 6C). 
 
Regulatory T cells and their relationship to IL-17-producing CD4 T cells 
As previously mentioned, Treg and TH17 cells are thought to have reciprocal pathways of 
differentiation1, and although human peripheral blood and lymphoid tissue have been shown to 
contain CD4+FOXP3+ T cells that express CCR6 and have the capacity to produce IL-17 upon 
activation34, we observed very low frequencies of FOXP3+IL-17+ cells within circulating CD4 T cells 
(Figure 7A). We found that the frequency of FOXP3+ cells within CD4 T cells was directly 
associated with TH17 cells in CVID patients (Figure 7B).  
 
 
Figure 7. Direct association between the frequency of IL-17-producing CD4 T cells and regulatory T cells in CVID. (A) 
Representative plots of the analysis of FOXP3 and CCR6, and FOXP3 and IL-17 expression on CD4 T cells, for a healthy 
individual. In order to analyse concomitant expression of FOXP3 and IL-17, PBMC were intracellular stained after 
short-term stimulation with PMA and ionomycin, using the FOXP3 Staining Set. The right panel shows the expression 
of FOXP3 and CCR6 within IL-17
+
 CD4 T cells. The frequency of FOXP3
+
IL-17
+
 cells within CD4 T cells (0.06%0.04%, 
n=6) represented around 8% of the total IL-17
+
 CD4 T-cell population (7.89%2.50%, n=6) in a subgroup of healthy 
subjects assessed. Correlations between the frequencies of IL-17-producing CD4 T cells and FOXP3
+
 (B) and CD25
+
 (C) 
CD4 T cells, in healthy individuals (filled circles) and CVID patients (open squares). Each symbol represents one 
individual. Correlation significance was determined using the Spearman coefficient test, and r and p values are shown.   
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We also documented a direct correlation with CD25 expression in CVID (Figure 7C), in clear 
contrast with the negative correlation found between IL-17 production and markers classically 
up-regulated in clinical settings associated with T-cell activation (see Chapter 3.2). 
 
Regulatory T cells and their relationship to pro-inflammatory cytokine production by CD4 T cells 
Given the results obtained for IL-17 production, we sought to analyse the association 
between the different Treg subsets and the CD4 T-cell populations that produce other pro-
inflammatory cytokines, such as IFN- or TNF-. 
We found that both the frequencies of IFN--producing CD4 T cells (Figure 8A) and TNF-
-producing CD4 T cells (Figure 8B) were inversely correlated with the frequency of Treg cells in 
CVID patients, defined either as FOXP3+CD25+ CD4 T cells or as CD25bright CD4 T cells. The loss of 
Treg cells was directly associated to expansions of CD4 T-cell populations that produce the pro-
inflammatory cytokines IFN- and TNF-, in contrast to what was found for the production of IL-
17. 
 
 
Figure 8. Expansion of T-cell populations producing pro-inflammatory cytokines was directly associated with loss of 
regulatory T cells in CVID. Correlations between the frequencies of regulatory T (Treg) cells and CD4 T-cell populations 
producing the pro-inflammatory cytokines IFN- and TNF-, in healthy individuals (filled circles) and CVID patients 
(open squares). (A) Association between FOXP3
+
CD25
+
 and IFN--producing CD4 T cells. (B) Correlation between the 
frequency of CD25
bright
 and TNF--producing CD4 T cells. Each symbol represents one individual. Correlation 
significance was determined using the Spearman coefficient test, and r and p values are shown. 
 
Regulatory T cells and clinical manifestations in CVID patients 
We have found that the frequency of FOXP3+ cells within CD4+ T cells was increased in 
CVID patients as compared to healthy controls. Subsequently, we sought to investigate whether 
this increase was associated with particular clinical manifestations, namely autoimmune 
disorders, chronic diarrhea, splenomegaly, lymphoid proliferation and adenopathies. When we 
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stratified the CVID patients according to these manifestations, no particular pattern was found in 
what concerns the frequency of FOXP3+ cells within CD4+ T cells (Figure 9A).  
 
Figure 9. Association of regulatory T-cell imbalances with clinical manifestations in CVID patients. Stratification of 
different regulatory T (Treg) cell populations in CVID patients, according to the occurrence or not of the following 
clinical manifestations: autoimmunity, splenomegaly, adenopathies, lymphoid proliferation, and chronic diarrhea. 
Frequencies of FOXP3
+
 (A), CD25
bright
 (B), FOXP3
+
CD25
+
 (C), and FOXP3
+
CD25
-
 (D) CD4 T-cell populations are shown. (E) 
Mean fluorescence intensity (MFI) of FOXP3 expression within CD4
+
FOXP3
+
 cells. Healthy individuals are shown as 
filled circles and CVID patients as squares with two different shades of grey. Each symbol represents one individual. 
Bars represent the mean value. Data were compared using the Mann-Whitney test, and p values are shown. 
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While we had observed that the frequency of CD25bright within CD4+ T cells was decreased in total 
CVID patients when compared to healthy individuals, the stratification upon clinical 
manifestations showed that CVID patients with autoimmune disorders, splenomegaly, 
adenopathies, or lymphoid proliferation, exhibited the same decrease in the frequencies of 
CD25bright CD4 T cells when compared to healthy individuals, at the levels observed in CVID 
patients without these clinical complications (Figure 9B). No differences have been found in the 
frequency of FOXP3+CD25+ cells within CD4 T cells between total CVID patients and healthy 
controls. However, when we stratified the patients according to clinical manifestations we 
verified that patients with splenomegaly showed significantly decreased frequencies of this 
population as compared to patients without splenomegaly, as well as to healthy individuals 
(Figure 9C). On the other hand, while total CVID patients showed an increased frequency of 
FOXP3+CD25- cells within CD4+ T cells, the stratification of these patients demonstrated that all 
patients that presented with the clinical manifestations mentioned above had significantly 
higher frequencies of FOXP3+CD25- CD4 T cells as compared to healthy individuals (Figure 9D). It 
is worth mentioning that the expansion of this population was not significant when compared to 
CVID patients that did not present the clinical manifestations, showing that the increased 
frequency of FOXP3+CD25- CD4 T cells was common to the majority of CVID patients. Even 
though we found no difference between healthy subjects and CVID patients in what concerns 
the levels of FOXP3 expression within CD4+FOXP3+ cells, when CVID patients were stratified 
according to clinical complications the picture was quite different. In agreement with the data 
reported by Yu et al.35, CVID patients with autoimmunity have significantly lower levels of FOXP3 
expression than healthy controls (Figure 9E). In addition, CVID patients with lymphoid 
proliferation and chronic diarrhea also present a reduction in FOXP3 expression on FOXP3+ cells 
(Figure 9E). This suggests that in a particular subset of CVID patients Treg function may actually be 
decreased and associated with phenomena of loss of T-cell balance. 
 
Relationship between regulatory T cells and B-cell imbalances in CVID patients 
The CD21lowCD38low B-cell population is thought to be an activated B-cell population that 
fails to further differentiate. This population frequently accumulates in CVID patients. Of note, 
Treg frequency, particularly the FOXP3
+CD25+ CD4 T cell population, inversely correlated with the 
frequency of CD21lowCD38low B cells in CVID patients (Figure 10), in agreement with a previous 
report4. This suggests a possible link between the size of the Treg subset and GC disturbances. 
The expansion of CD21lowCD38low B cells, which has been shown to be associated with 
autoimmunity36,37, is associated with a lower frequency of Treg cells, suggesting that a loss of Treg 
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cells may actually be underlying autoimmune phenomena in CVID patients. It has been described 
that the frequency of Treg is significantly decreased in CVID patients with autoimmune 
manifestations as compared with patients without autoimmunity4,5, but we did not find such 
clinical correlation in our cohort (Figure 9).  
 
 
Figure 10. Expansion of the CD21
low
CD38
low
 B-cell population correlated with loss of regulatory T cells in CVID. 
Correlation between the frequencies of FOXP3
+
CD25
+
 CD4 T cells and CD21
low
CD38
low
 B cells, in healthy individuals 
(filled circles) and CVID patients (open squares). Each symbol represents one individual. Correlation significance was 
determined using the Spearman coefficient test, and r and p values are shown. 
 
 
Concluding Remarks 
 
 We found that CVID patients present a reduction in the frequency of Treg cells in what 
regards the expression of CD25, while FOXP3 expression appeared to be maintained. We also 
showed that in CVID patients the frequencies of Treg cells and TH17 cells were directly associated. 
In addition, Treg frequency was also inversely associated with the frequency of CD21
lowCD38low B 
cells. These data support the view that the impairment of the GCs found in CVID may have an 
impact in both Treg and TH17 populations.  
It will be important to study the basis of this apparent dissociation between C25 and 
FOXP3 expression and to clarify whether there is a true loss of regulatory function in these CVID 
patients, with a possible association with autoimmunity, as previously suggested35. This would 
imply that the maintenance of FOXP3 expression might be related to T-cell activation.  
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Methods 
 
Cell staining and flow cytometric analysis 
PBMCs isolated from heparinized blood, immediately after venipuncture, by Ficoll-Hypaque 
density gradient (Amersham Pharmacia Biotech), were stained for surface markers, followed by 
intracellular staining for FOXP3 using the FOXP3 Staining Set (eBiosciences) according to the 
manufacturer’s instructions. A mean of 150.000 PBMCs was analysed. Samples were acquired on 
a FACSCalibur (BD Biosciences) and data analysed using FlowJo Software (Tree Star Inc.). Results 
are presented as a proportion of a given cell population. 
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Abstract 
 
Common Variable Immunodeficiency Disorders (CVID), the most frequent cause of 
symptomatic primary immunodeficiency, are defined by impaired antibody production. 
Notwithstanding, T-cell activation and granulomatous manifestations represent main causes of 
CVID morbidity even in patients under immunoglobulin G (IgG) replacement therapy. 
Additionally, gut pathology is a frequent feature of CVID. Here, we investigated monocyte 
imbalances and their possible relationship with increased microbial translocation in CVID 
patients. 
Monocyte subsets were defined according to CD14 and CD16 expression levels and 
evaluated in terms of HLA-DR, CD86 and PD-L1 expression by flow cytometry, in parallel with the 
quantification of plasma Lipopolysaccharide (LPS), and serum levels of soluble CD14 (sCD14), 
LPS-binding protein (LBP), and anti-LPS antibodies. 
CVID patients (n=31) featured significantly increased levels of serum sCD14 and an 
expansion of CD14brightCD16+ monocytes in direct correlation with T-cell and B-cell activation, the 
latter illustrated by the frequency of CD21lowCD38low subset. Such alterations were not observed 
in patients lacking B cells due to Congenital Agammaglobulinemia (n=4). Moreover, we found no 
significant increase in circulating LPS or LBP levels in CVID patients, together with a relative 
preservation of serum anti-LPS antibodies, in agreement with their presence in commercial IgG 
preparations.  
In conclusion, CVID was associated with monocyte imbalances that directly correlated 
with T-cell activation markers and with B-cell imbalances, without an association with plasma 
LPS levels. The heightened monocyte activated state observed in CVID may represent an 
important target for complementary therapeutic strategies. 
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Introduction  
 
Common Variable Immunodeficiency Disorders (CVID) represent the most frequent 
cause of symptomatic primary immunodeficiency1. CVID are defined by quantitative and 
qualitative reduction in antibody production due to heterogeneous defects in mature B cells1,2. 
Besides imbalances in B-cell subsets, CVID are frequently associated with persistent T-cell 
activation and loss of naive T cells, which are reported even in patients under replacement 
therapy with immunoglobulin G (IgG)1-4. Indeed, non-infectious complications, such as 
lymphoproliferation and granulomatous disease, are currently main causes of morbidity and 
mortality in CVID1,2. The mechanisms underlying the chronic immune activation associated with 
CVID remain largely unclear. Another main cause of CVID morbidity is gastrointestinal pathology, 
with or without mal-absorption1,2. The impairment in IgA production and other CVID-associated 
mucosal alterations have been shown to be often associated with increased intestinal 
permeability5. Thus, it is plausible that increased levels of microbial translocation, particularly of 
bacterial products such as Lipopolysaccharide (LPS), with consequent monocyte stimulation, may 
contribute to the chronic immune activation observed in CVID patients, as reported for HIV-1 
infected individuals6.  
Monocytes are important orchestrators of the immune system, linking innate and 
adaptive immune responses. Blood monocytes have the ability to migrate into tissues, where 
they can differentiate and give rise to distinct functional cell types, such as macrophages and 
dendritic cells (DCs)7. They have long been recognized as the main promoters of inflammatory 
responses to pathogens and to be involved in many inflammatory diseases7.  Recent studies 
have called attention to their suppressive and regulatory functions, suggesting that monocytes 
play a central role in the modulation of immune responses, particularly in the context of chronic 
immune activation8. These data point to the heterogeneity of monocyte subsets, with distinct 
functions and phenotypes9-11. Recently, an effort was made in putting forward a consensus 
nomenclature that proposed three main monocyte subsets defined according to the expression 
levels of CD14 and CD16, as follows: classical CD14brightCD16- monocytes, the most abundant 
monocyte population found in peripheral blood; intermediate CD14brightCD16+, and non-classical 
CD14dimCD16+ subsets12. The intermediate CD14brightCD16+ monocyte subset has been 
consistently shown to expand in many pro-inflammatory clinical settings12,13, and particularly in 
association with HIV infection14,15.   
CVID has been associated with defective in vitro maturation of DCs from monocytes, at 
least in a subset of patients16,17, and with disturbances in the monocyte responses upon LPS 
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stimulation in vitro18. Additionally, CVID patients were shown to have  reduced numbers of 
circulating DCs19,20, with perturbed differentiation and function, namely reduced expression 
levels of the co-stimulatory molecules CD86 and CD80, an impaired ability to produce IL-12 upon 
stimulation21-23, as well as lower antigen presenting capacity in mixed lymphocyte reactions22,23.  
Monocyte-related alterations, namely an increased frequency of CD16-positive 
monocytes24 and decreased numbers of myeloid DCs25 have also been reported in patients 
lacking B cells due to blockade in early B-cell development in the bone marrow due to genetic 
defects in Bruton’s tyrosine kinase (Btk) leading to Congenital Agammaglobulinemia26. 
Nevertheless, we and others have shown that, in contrast to CVID, Congenital 
Agammaglobulinemia is not associated with a significant increase in T-cell activation 
markers3,18,27. 
Here, we investigated the monocyte compartment in patients with CVID and provide 
evidence that CVID was associated with increased markers of monocyte activation in direct 
correlation with the expansion of activated T-cell subsets, irrespectively of plasma LPS levels. 
Monocytes may thus be important contributors to the inflammatory milieu that leads to T-cell 
activation, lymphoproliferative manifestations, and granuloma formation associated with 
CVID1,28. 
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Material and Methods 
 
Cohort characterization 
The study involved 31 patients with CVID, diagnosed according to the European Society for 
Immunodeficiencies criteria (www.esid.org), namely IgG and IgA and/or IgM levels at least two 
standard deviations below the mean for age, impaired antibody response to vaccines, 
absent/low isohemagglutinins, and exclusion of defined causes of hypogammaglobulinemia. 
Patients with Congenital Agammaglobulinemia, presenting less than 1% B cells within total 
peripheral lymphocytes (n=4), were also included. These cohorts have been previously 
described3. The clinical and epidemiological characterization of these cohorts is summarized in 
Table 1. 29 CVID and all Congenital Agammaglobulinemia patients were under IgG replacement 
therapy, adjusted to maintain pre-infusion Ig levels above 650 mg/dL. The two CVID patients not 
receiving IgG featured levels of total serum IgG of 227 and 473 mg/dL. All patients were free 
from symptomatic infections at the time of sample collection, and the collection of the blood 
samples was always performed immediately before the immunoglobulin infusions in the patients 
under intravenous administration. 4 CVID patients were under steroid therapy at the time of the 
study. 15 healthy individuals were studied in parallel. All subjects gave written informed consent 
for blood sampling and processing. The study was approved by the Ethical Boards of the 
Faculdade de Medicina da Universidade de Lisboa and of the Hospital de Santa Maria, and 
performed in accordance with the 1964 Declaration of Helsinki and its later amendments. 
 
Cell staining and flow cytometric analysis 
Phenotypic analysis was performed using whole blood samples collected immediately before IgG 
administration. After staining with monoclonal antibodies and red blood cells lysis using BD FACS 
Lysing Solution (BD Biosciences), samples were acquired on a FACSCalibur flow cytometer (BD 
Biosciences). The following anti-human monoclonal antibodies were used, with the clone and 
the respective directly-conjugated fluorochrome specified in brackets: CD16 (3G8; FITC), CD3 
(SK7; PerCP), CD4 (SK3; PerCP), CD8 (SK1; PerCP), CD8 (RPA-T8; APC), CD38 (HB7; PE), CD45RA 
(L48; PE-Cy7), CD86 (FUN-1; PE), IgD (IA6-2; PE), IgM (G20-127; APC), HLA-DR (L243; FITC and 
PerCP), IFN- (4S.B3; FITC), from BD Biosciences; CD4 (RPA-T4, FITC, and PerCP-Cy5.5), CD8 (RPA-
T8; FITC and PE), CD14 (61D3; PE-Cy7 and APC), CD19 (HIB19; PerCP-Cy5.5 and PE-Cy7), CD27 
(O323; FITC, PE, and APC), CD45RA (HI100; FITC and APC), PD-L1 (MIH1; APC), TNF- (MAb11; 
PE), from eBiosciences; CD21 (BL13; FITC) from IO Test, Beckman Coulter.   
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Table 1. Clinical and epidemiological data of the studied cohorts 
  
Healthy CVID 
Congenital 
Agammaglobulinemiaa 
Number (male/female) 15 (5/10) 31 (11/20) 4 (4/0) 
Age (yrs.) 3911 4013 265 
Clinical manifestationsb,c    
Autoimmune disease n.a. 17/31 (55%) 0 
Adenopathies n.a. 10/31 (32%) 0 
Lymphoid proliferation n.a. 18/20d (86%) 0 
Granulomas  n.a. 3/20d (15%) 0 
Chronic diarrhoea n.a. 15/31 (48%) 0 
Splenomegaly n.a. 16/31 (52%) 0 
EUROclass classification     
smB+21norm  n.a. 5/29 (17%) n.a. 
smB+21lo  n.a. 9/29  (31%) n.a. 
smB-21norm  n.a. 6/29 (21%) n.a. 
smB-21lo  n.a. 9/29 (31%) n.a. 
smB-Trnorm  n.a. 9/29 (31%) n.a. 
smB-Trhi  n.a. 6/29 (21%) n.a. 
IgG replacement therapyc    
intravenous n.a. 24/31 (77%) 4 (100%) 
subcutaneous n.a. 5/31 (16%) 0 
Length of IgG therapy 
(yrs.) 
n.a. 76 1611 
n.a. not applicable, CVID: Common Variable Immunodeficiency 
a
 Two of the congenital 
agammaglobulinemia patients had a known genetic defect in the Btk gene, namely one had the 
IVS17-1GC mutation and the other presented with the R288Q mutation; in the other two 
patients, mutations in the Btk gene have been excluded and evaluation of autosomal recessive 
forms is ongoing.
 b
 Diagnostic criteria: Autoimmune disease - clinical data, given the impairment in 
Ab production; Bronchiectasis - computed tomography; Splenomegaly - longitudinal spleen 
diameter superior to 15cm (computed tomography or ultrasonography); Adenopathies - lymph 
node larger than 1cm diameter in 2 or more lymphatic chains in clinical and/or imaging exams; 
Lymphoid proliferation and Granulomas - diffuse lymphocytic infiltrates or granulomas on 
gastrointestinal, lymph node or pulmonary biopsies. 
c
 Percentage within total cohort evaluated in 
brackets. 
d
 Total number of individuals with biopsies.
  
 
Data were analysed using CellQuest (BD Biosciences) and FlowJo (Tree Star Inc.) softwares. 
Lymphocyte and monocyte subsets were defined within manually set lymphogate/monogate. 
Results were expressed as percentage of cells that stained positive for a given marker, or as its 
mean fluorescence intensity (MFI) within the defined population. Total cell numbers were 
calculated by multiplying the percentage of each population within total 
lymphocytes/monocytes by the peripheral blood lymphocyte/monocyte count obtained at the 
clinical laboratory on the day of sampling. 
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Analysis of cytokine production 
Cytokine production was assessed at the single-cell level, as previously described3. Briefly, 
freshly isolated peripheral blood mononuclear cells cultured in the presence of Brefeldin A 
(10µg/mL; Sigma-Aldrich), for 4h at 37 ºC with 5% CO2, were stimulated with Lipopolysaccharide 
(LPS; 100 ng/ml; Sigma-Aldrich) for assessing TNF-α production by monocytes or with Phorbol 
Myristate Acetate (50ng/mL, Sigma-Aldrich) and Ionomycin (500ng/mL; Calbiochem, Merck 
Biosciences) for assessing the lymphocyte production of IFN-γ.  
  
Quantification of soluble CD14 (sCD14), LBP, LPS and IgG EndoCAb 
The human EndoCAb® Assay Kit and the ELISA Kit for Endoblock Lipopolysaccharide Binding 
Protein (LBP, HyCult Biotechnology) were used to quantify the serum concentrations of IgG 
EndoCAb and LBP, respectively. Serum sCD14 levels were quantified by ELISA using the human 
sCD14 Quantikine (R&D Systems). Plasma LPS levels were quantified using the Limulus 
Amebocyte Assay (Cambrex); plasma samples were diluted and pre-treated as previously 
described6. All samples were assayed in duplicate, according to the manufacturer’s instructions.  
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software). Two group 
comparisons were performed using Mann-Whitney test. Spearman’s coefficient was used to 
determine the significance of the correlation between two variables. Results are expressed as 
meanSEM, and P-values <0.05 were considered to be significant. 
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Results 
 
CVID was associated with monocyte activation  
The monocyte compartment was investigated in a previously described cohort of 31 
patients with CVID (Table 1)3.  
CVID patients showed significantly higher levels of sCD14 than healthy subjects (Figure 
1a), suggesting significant levels of monocyte activation6,29. 
 
 
Figure 1. Monocyte activation markers in CVID and Congenital Agammaglobulinemia. (A) Serum levels of soluble 
CD14 (sCD14). Each dot represents one individual, with bars indicating mean values. Open circles refer to healthy 
individuals, solid circles to CVID patients, and grey squares to Congenital Agammaglobulinemia (Agamma) patients. (B) 
Illustrative flow cytometric analysis of monocyte subsets according to CD14 and CD16 expression levels in 
representative CVID (right panel) and healthy (left panel) individuals. (C) Frequency and absolute counts of monocyte 
subsets as defined in (B). (D) Mean fluorescence intensity (MFI) of HLA-DR, CD86 and PD-L1 within total monocytes. 
Healthy individuals are represented in open, CVID patients in solid, and Congenital Agammaglobulinemia patients in 
grey bars. Bars indicate mean±SEM. P values of statistically significant differences are shown. 
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Monocyte subsets were defined by flow cytometric whole blood analysis through the 
differential expression of CD14 and CD16, as illustrated in Figure 1b. Although the number of 
total circulating monocytes in CVID patients was similar to age-matched healthy individuals 
(493.335.81 cells/uL in controls vs. 504.740.25 cells/uL in CVID patients; p=0.9810), we found 
a significant increase in both the frequency and absolute numbers of CD14brightCD16+ monocytes 
in CVID patients, in comparison with controls (Figure 1c), a subset associated with inflammatory 
settings11-15,30.  
In agreement with a state of monocyte activation in CVID patients, the levels of 
expression of HLA-DR within total monocytes were significantly higher than in controls (Figure 
1d), mainly due to increased levels of HLA-DR within the expanded CD14brightCD16+ monocyte 
subset (MFI in healthy individuals 133.011.34 vs. 187.213.28 in CVID patients; p=0.0052). 
Conversely, no significant alterations in the expression levels of the co-stimulatory molecule 
CD86 were found in CVID patients (Figure 1d).  
We found no increase in the expression levels of PD-L1 on monocytes in CVID patients, 
as compared to healthy subjects (Figure 1d), suggesting that this inhibitory pathway was 
probably not significantly induced in CVID, despite the evidence for immune activation.  
We also investigated the monocyte compartment in a group of patients with Congenital 
Agammaglobulinemia (Table 1), that we have previously described3, who lack circulating B cells 
due to defects in early B-cell development, and found no significant increase in serum sCD14 or 
in the frequency of CD14brightCD16+ monocytes in these patients (Figure 1a and 1c).  
Btk deficiency, a main cause of Congenital Agammaglobulinemia, has been shown to be 
associated with an increased frequency of CD16-expressing monocytes24, but no distinction was 
made, at that time, between CD14brigthCD16+ and CD14dimCD16+ subsets, which are believed to 
possess distinct functional properties30. We found that the increase in CD16 was restricted to 
CD14dimCD16+ monocytes (Figure 1c). This subset was significantly expanded in patients with 
Congenital Agammaglobulinemia, both in terms of frequency and absolute counts, in relation to 
both healthy individuals and CVID patients (Figure 1c).  
Although the results should be cautiously interpreted given the small number of patients 
with Congenital Agammaglobulinemia evaluated, our data showed that, in contrast to CVID, 
there was no expansion of the CD14brightCD16+ subset and no increase in sCD14 levels.  
Overall, we provided evidence for significant levels of monocyte activation being a 
feature of CVID. 
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Monocyte activation was unrelated to plasma LPS levels in CVID 
Our findings of no up-regulation of markers of monocyte activation in patients lacking B 
cells raise the possibility that factors other than defective mucosal IgA production, and the 
possible related increase in microbial translocation, are contributing to the CVID-associated 
monocyte activation.  
CVID patients showed low to undetectable levels of plasma LPS, a bacterial product that 
increases in the peripheral blood as a result of microbial translocation in the gut (Figure 2a). 
Moreover, CVID patients with gastrointestinal manifestations, such as chronic diarrhea or 
evidence of mal-absorption, did not feature higher levels of plasma LPS than healthy controls 
(Figure 2a). 
 
 
Figure 2. Plasma LPS levels and related molecules in CVID. (A) Plasma LPS levels. (B) Serum LBP levels. (C) Anti-LPS 
antibodies (left) and its ratio relative to total IgG (right). Each dot represents one individual: healthy individuals are 
represented in open circles, CVID patients in solid circles. Bars indicate mean. P values of statistically significant 
differences are shown. 
We also confirmed that monocytes from CVID patients were not impaired in their ability 
to produce TNF-α upon in vitro LPS stimulation (percentage of monocytes expressing TNF-α: 
55.75±3.56 in 26 CVID patients and 65.96±4.24 in 8 healthy controls; p=0.2820), as previously 
reported18.  These data showing that monocytes from CVID patients were not refractory to 
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additional LPS stimulation in vitro further suggest a lack of previous exposure to increased 
plasma LPS. 
We measured the levels of LPS-binding protein (LBP), a molecule that binds circulating 
LPS29, and found them to be similar in healthy individuals and CVID patients (Figure 2b), further 
suggesting that the degree of microbial translocation was not substantial.  
Another important pathway contributing to LPS clearance from circulation involves 
antibodies against the LPS core oligosaccharide (endotoxin core antibodies - EndoCAb)6. It is 
possible that IgG replacement therapy provides adequate amounts of EndoCAb levels, restoring 
the humoral response to LPS that patients are likely unable to mount.  
We measured EndoCAb IgG levels in 5 IgG lots administered to the patients (2 lots of 
intravenous Octagam 5%, 2 lots of subcutaneous Vivaglobin 16%, and 1 lot of subcutaneous 
Gammanorm 16,5%) and found these antibodies to be present in significant amounts (values 
between 120 GMU (IgG median units)/mL and 250 GMU/mL). Additionally, the amount of 
EndoCAb IgG within total IgG was similar in the serum of CVID patients and healthy individuals, 
even though total serum IgG was significantly lower in CVID patients than in controls (Figure 2c). 
All patients assessed were under IgG replacement therapy, with the exception of one, who still 
presented detectable amounts of EndoCAb IgG (29,78 GMU/mL; total IgG 473 mg/dL and 
EndoCAb IgG within total IgG 6,13 GMU/mg). 
Thus, given the reduced plasma LPS and the unaltered serum LBP levels that we 
documented in CVID patients, IgG replacement therapy might be sufficient to limit the levels of 
LPS in peripheral blood. These results are against a major role of the gut-associated microbial 
translocation to the documented monocyte activation. 
In summary, the alterations observed in the monocyte populations from CVID patients 
seemed to be unrelated to plasma LPS levels. 
 
Monocyte activation was directly associated with T-cell disturbances in CVID patients 
We reported above that, in contrast to CVID, patients with Congenital 
Agammaglobulinemia had no increase in markers associated with monocyte activation.  Our 
results are particularly interesting since we had previously reported the lack of T-cell activation 
and significant T-cell imbalances in these patients with Congenital Agammaglobulinemia3. 
Accordingly, in CVID patients the expansion of CD14brightCD16+ monocytes was directly 
associated with T-cell activation, and inversely correlated with the frequency of naive CD4 T cells 
(Figure 3).  The expansion of this population in CVID patients was also associated with the 
frequency of IFN--producing CD4 T cells (Figure 3), another measure of T-cell activation that we 
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have previously shown to be significantly increased in this CVID cohort in comparison to healthy 
individuals3. 
 
 
Figure 3. Relationship between markers of monocyte and T-cell activation in CVID. Correlation between the 
frequency of CD14
bright
CD16
+
 monocytes and the frequency of naive (CD45RA
+
CD27
+
, left panel), activated (HLA-
DR
+
CD38
+
, middle panel), or IFN--producing cells (right panel) within CD4 T cells in CVID patients (solid circles) and in 
healthy individuals (open circles). Each dot represents one individual. Spearman’s correlation coefficients are shown. 
Importantly, as described above, we found no significant up-regulation of the inhibitory 
molecule PD-L1 in CVID patients as compared to healthy subjects, both within whole monocytes 
(Figure 1d) and in the three monocyte subsets (data not shown). We further investigated a 
possible association between PD-L1 levels in monocytes and T-cell imbalances and found that 
PD-L1 levels within the expanded CD14brightCD16+ monocyte subset increased in direct 
correlation with CD4 T-cell activation (r=0.6056, p=0.0003), and the loss of naive CD4 T cells (r=-
0.5202, p=0.0038) in CVID patients. Nevertheless, PD-L1 up-regulation in the CD14brightCD16+ 
monocyte subset of CVID patients was apparently not as marked as that observed in other 
persistent inflammatory settings, like HIV-1 infection31-33, suggesting an impairment of the PD-L1 
pathway in CVID, possibly translating into a reduced ability to control immune activation. This is 
particularly relevant given the fact that the PD-1/PD-L1 pathway is involved in peripheral 
tolerance and autoimmunity34 and that the expansion of CD14brigthCD16+ monocytes was 
significantly higher in CVID patients with autoimmune disease (p=0.0328). Of note, this 
expansion was not more marked in CVID patients with granuloma or lymphoproliferation 
(p>0.05). Additionally, significant correlations were also observed between the expression levels 
of the co-stimulatory molecule CD86 within CD14brightCD16+ monocytes and T-cell imbalances 
(r=0.3706, p=0.0402 with CD4 T-cell activation; r=-0.4300, p=0.0199 with the frequency of naive 
CD4 T cells) in CVID patients, reinforcing the relevance of addressing the regulation of co-
stimulatory and inhibitory pathways in future CVID studies. 
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Altogether, our data showed that monocyte activation in CVID was directly associated 
with markers of T-cell activation. 
 
CVID patients grouped according to the EuroClass classification featured distinct monocyte 
imbalances 
B-cell imbalances have been used as an attempt to classify CVID patients into more 
homogeneous subgroups. The EuroClass classification has thus been proposed based in three 
main B-cell abnormalities observed in CVID: the reduction in switched-memory B cells, and the 
expansions of either transitional or CD21lowCD38low B cells35. When our cohort was stratified 
according to the EuroClass, we found no differences regarding CD86 expression within 
CD14brightCD16+ monocytes among the different subgroups (p>0.1900). However, PD-L1 
expression within this subset was significantly higher in patients with reduced switched-memory 
B cells and expansion of transitional B cells (smB-Trhi) as compared to those that did not present 
that expansion (smB-Trnorm) (Figure 4a). 
 
 
Figure 4. Markers of monocyte activation in CVID grouped according to the EuroClass classification. (A) Mean 
fluorescence intensity (MFI) of PD-L1 within CD14
bright
CD16
+
 monocytes. Healthy individuals are represented in open 
and CVID patients in solid bars. (B) Frequency of CD14
bright
CD16
+
 monocytes. Bars indicate mean±SEM. P values of 
statistically significant differences are shown. (C) Correlation between the frequency of CD14
bright
CD16
+
 monocytes 
and the frequency of CD21
low
CD38
low
 B cells in CVID patients (solid circles) and in healthy individuals (open circles). 
Each dot represents one individual. Spearman’s correlation coefficients are shown. 
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In addition, we also found that the expansion of CD14brightCD16+ monocytes was 
particularly relevant in patients that did not have reduced switched-memory B cells but had 
expanded CD21lowCD38low B cells (smB+21lo) as compared to patients that did not (smB+21norm) 
(Figure 4b). In agreement, the frequency of CD14brightCD16+ monocytes was directly associated 
with the frequency of CD21lowCD38low B cells in CVID patients (Figure 4c). 
In conclusion, we showed that monocyte imbalances were particularly marked in CVID 
patients lacking switched-memory B cells and/or having an abnormal expansion of the 
CD21lowCD38low B cells. 
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Discussion  
 
We showed here that CVID is associated with increased serum levels of sCD14 and an 
expansion of CD14brightCD16+ monocytes, in direct correlation with T-cell and B-cell imbalances. 
Moreover, monocyte hyper-activation occurred irrespective of plasma LPS levels, suggesting that 
monocytes may represent important targets for therapies complementary to IgG replacement 
aiming to control the granulomatous and lymphoproliferative manifestations in CVID.  
Such monocyte activation markers were not observed in patients lacking peripheral B 
cells due to Congenital Agammaglobulinemia who, notably, also did not present major T-cell 
imbalances. Although the number of patients with Congenital Agammaglobulinemia was small, 
our results are in agreement with a previous study that also reported a lack of major alterations 
in monocyte function as assessed in vitro in patients with X-linked Agammaglobulinemia18. 
CD14 shedding from the membrane of monocytes is generally accepted as a marker of 
monocyte activation, with levels of sCD14 being increased in inflammatory and autoimmune 
diseases, in the context of acute inflammation and sepsis, as well as in HIV-infected patients6,29. 
CD14brightCD16+ monocytes have been shown to have a high inflammatory potential, based on 
transcriptome analysis11,30, and to be expanded in inflammatory conditions12,13, being associated 
with disease progression in chronic HIV-1 infection14,15.  
We showed that the expression of HLA-DR within total monocytes was significantly 
higher in CVID than in controls, compatible with a state of monocyte activation. This is in 
agreement with the study of Cambronero et al, which showed an up-regulation of HLA-DR within 
the whole monocyte population in CVID patients18. It is worth to note that this increase was 
mainly due to the expression of HLA-DR within the expanded CD14brightCD16+ monocyte subset, 
supporting its enhanced inflammatory capacity. On the other hand, expression levels of the co-
stimulatory molecule CD86 were similar in CVID patients and in healthy individuals. CD86, a 
marker of monocyte differentiation and acquisition of antigen-presentation properties, has been 
shown to be expressed at reduced levels in monocyte-derived DCs generated in vitro, supporting 
an impaired function as antigen-presenting cells in CVID16,36.  
Monocytes may also up-regulate inhibitory molecules, which are thought to play an 
important role in the regulation of immune responses and in limiting immunopathology. PD-L1 
(B7-H1) binds programmed death-1 molecule (PD-1), an inhibitory receptor expressed on many 
cells, particularly activated T and B lymphocytes, establishing a pathway of central relevance in 
inflammatory states31,32. Both PD-L1 and PD-1 can be up-regulated upon activation, with PD-1 
expression on T cells having been associated with functional exhaustion in the context of chronic 
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viral infection, due to persistent antigen exposure37-39. Of note, PD-L1 expression has been 
shown to be up-regulated on monocytes from HIV-infected patients31,32. We found that 
monocyte activation in CVID was not accompanied by significant up-regulation of the inhibitory 
molecule PD-L1, which may favor the deleterious impact of activated monocytes.  
In addition, we showed that monocyte imbalances were unrelated to plasma LPS levels 
in CVID patients, who appear to have a relatively good preservation of the pathways involved in 
LPS clearance, including anti-LPS antibodies provided by the IgG replacement therapy, and 
normal levels of LBP. Serum LBP quickly binds LPS molecules in circulation29. LBP levels have 
been shown to increase in sepsis associated with LPS-containing microorganisms (Gram-negative 
bacteria) and in HIV infection6,29, in which case a direct correlation with the degree of microbial 
translocation, estimated by plasma LPS levels, has been reported14. Furthermore, both LPS and 
LBP levels are increased in inflammatory bowel disease, in correlation with disease activity, and 
recover to normal levels following treatment40. The fact that LBP levels were similar in healthy 
individuals and CVID patients, and that there was no increase in plasma LPS, further suggests 
that the degree of microbial translocation was not significant. Thus, our data raise the possibility 
that IgG replacement therapy may provide sufficient antibodies against LPS to control the 
putative increase in microbial translocation. Longitudinal studies assessing patients prior to and 
after commencing replacement therapy with IgG will be of great relevance to understand its 
potential role in regulating microbial translocation, which may have implications in other clinical 
settings, such as HIV/AIDS. 
Additionally, we show that the expansion of CD14brightCD16+ monocytes was particularly 
relevant in CVID patients with autoimmunity and that the frequency of this monocyte population 
was directly correlated with the frequency of CD21lowCD38low B cells. The expansion of this B-cell 
subset has also been associated with autoimmunity in CVID35, supporting a role for 
CD14brightCD16+ monocytes in the course of the disease. We should point out that our CVID 
cohort presents an unusually high frequency of autoimmune manifestations, probably related to 
a reference bias associated with an immunology department in a central hospital. 
Although several studies have acknowledged the relevance of immune activation in CVID 
pathophysiology, little is known about what drives and sustains it, whether it is related to the 
increased frequency of infections, or to altered response to pathogens. Our data are in 
agreement with a possible multi-factorial event impacting on several compartments of the 
immune system. Irrespective of the monocyte alterations that we describe contributing to the 
inflammatory process itself or being a marker of underlying inflammation, our finding of major 
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monocyte imbalances in particular subgroups of CVID patients may help in defining new lines of 
investigation.  
In conclusion, our data show that CVID was associated with monocyte alterations that 
directly correlated with T-cell activation markers and with B-cell imbalances, without a 
relationship to plasma LPS levels, supporting a potential clinical relevance of therapeutic 
strategies targeting monocytes to control the inflammatory manifestations in CVID patients. 
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3.3 – SUPPLEMENT A 
LONGITUDINAL STUDY OF COMMON VARIABLE IMMUNODEFICIENCY 
PATIENTS PRIOT TO AND AFTER STARTING IgG REPLACEMENT 
THERAPY 
 
 
Our results concerning monocyte activation in CVID patients suggested that IgG 
replacement therapy could actually play a role in modulating microbial translocation and 
consequently influence the obtained results. In addition, virtually all published data on CVID 
immune imbalances relates to patients that are under IgG replacement therapy1-4. Therefore, it 
is very important to perform longitudinal studies in order to assess the possible modulation of 
different immunological parameters in CVID patients upon starting IgG replacement therapy. 
With this aim, four CVID patients were followed for a period of 12 months after starting IgG 
replacement therapy. 
 
We found that the inter-subject variability was high at day 0 in all subjects studied. In 
relation to the monocyte imbalances that we reported in this chapter 3.3, we observed that the 
frequency of CD14brightCD16+ monocytes, which we found to be increased in treated CVID 
patients, tended to decrease with the introduction of IgG replacement therapy (Figure 1B). 
Scattered variations were also noted in CD14brightCD16- and CD14dimCD16+ monocyte populations 
(Figure 1A and 1C). However, it does not seem to have an impact on the expression of HLA-DR by 
total monocytes (Figure 1D), suggesting that IgG replacement therapy may have an overall 
limited effect on monocyte activation as measured by these parameters. 
 
In addition to being used as replacement therapy for B-cell immunodeficient patients, 
intravenous IgG therapy is also used for the treatment of inflammatory and autoimmune 
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diseases, where it has been shown to play an anti-inflammatory role by decreasing immune 
activation, among others5. Even though this effect has been shown to occur with much higher 
doses of intravenous IgG therapy than the ones that are given as replacement therapy to CVID 
patients, we aimed to understand if IgG replacement therapy could have an effect on overall T-
cell activation and the naive/memory T-cell imbalances that are usually associated with CVID6,7. 
 
 
 
Figure 1. Monocyte populations and HLA-DR expression on monocytes in CVID patients, before and up to 12 months 
after starting IgG replacement therapy. (A to C) Frequencies of CD14
bright
CD16
-
 (A), CD14
bright
CD16
+
 (B), and 
CD14
dim
CD16
+
 monocytes (C) and (D) HLA-DR mean fluorescence intensity (MFI) of expression within total monocytes, 
in four CVID patients before (time 0) and after starting IgG replacement therapy. 
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We observed that the levels of T-cell activation were unchanged over time, both in CD4 
and CD8 T cells (Figure 2A and 2B, respectively). In addition, the frequency of naive T cells, both 
within CD4 and CD8 T cells, was remarkably stable, regardless of the inter-subject variability 
(Figure 2C and 2D, respectively). Also, the frequency of terminally-differentiated CD8 T cells 
(CD45RA+CD27-), which is significantly increased in CVID patients6,7 (see Chapter 3.2 of results), is 
very regular over time in the different CVID patients (Figure 2E). Importantly, the frequency of 
circulating CXCR5+ CD4 T cells, which we have found to be severely reduced in patients with 
Congenital Agammaglobulinemia6, was remarkably constant (Figure 2F) and significantly 
increased in CVID patients, as compared to healthy individuals (Figure 2G). This raises the 
hypothesis that, contrary to what happens with Congenital Agammaglobulinemia patients, who 
have severely impaired GC formation, CVID patients present a significant increase in the 
circulating population of follicular CXCR5+ CD4 T cells, possibly related to the impaired function 
of GCs and their hypercellularity8. These results are particularly interesting given the recent 
results on TACI-deficient mice showing that these animals have expanded populations of TFH cells 
and GC B cells, when immunized with T-dependent antigens9. AS previously mentioned, TACI 
deficiency is reported to be associated with 10% of CVID cases10. 
 
 
Concluding Remarks 
 
Overall, our data on the longitudinal assessment of CVID patients starting IgG 
replacement therapy suggests that the introduction of therapy was not associated with major 
immune alterations, and that the immune imbalances were stable and likely related to the 
clinical course of CVID patients. 
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Figure 2. T-cell populations in CVID patients before and up to 12 months after starting IgG replacement therapy. 
Frequencies of activated (HLA-DR
+
CD38
+
) CD4 (A) and CD8 (B) T cells, naive (CD45RA
+
CD27
+
) CD4 (C) and CD8 (D) T 
cells, terminally-differentiated (CD45RA
+
CD27
-
) CD8 T cells (E), and CXCR5
+
 CD4 T cells (F), ), in four CVID patients 
before (time 0) and after starting IgG replacement therapy. (G) Circulating CXCR5
+
 CD4 T cells in healthy individuals 
(filled circles) and CVID patients (open squares). Each symbol represents one individual. Bars represent the mean 
value. Data were compared using the Mann-Whitney test, and p values are shown. 
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The overall aim of this work was to study two clinical settings of primary B-cell 
immunodeficiencies, CVID and Congenital Agammaglobulinemia, in order to better understand 
the impact of B-cell dysfunction on the immune system. Ultimately, the study of these human 
clinical models was aimed not only to expand our knowledge on the function of the immune 
system as a whole, but also to help provide better tools to treat these patients.  
 
In summary, we found that ex vivo BAFF-R expression was reduced in CVID patients, 
particularly in those that present very low frequencies of memory B cells. In contrast, TACI 
expression was significantly increased. Both the decrease in BAFF-R expression and the increase 
in TACI were directly associated with high serum levels of BAFF found in the patients. In vitro 
studies showed that BAFF induced BAFF-R down-regulation, both in healthy individuals and in 
CVID patients. However, the degree of this modulation was impaired in CVID patients, 
suggesting that these dynamics are affected, with a possible impact in B-cell homeostasis. We 
also observed that CVID was associated with monocyte activation unrelated to plasma LPS 
levels, but in direct association with T-cell activation and B-cell imbalances. The search to 
understand the mechanisms underlying the increase in inflammatory manifestations observed in 
CVID patients led us to study the contribution of IL-17, a major pro-inflammatory cytokine 
implicated in autoimmunity and inflammatory conditions. However, no increase in TH17 cells was 
found in CVID and their frequency was inversely correlated with markers of GC dysfunction. TH17 
cells were severely reduced in Congenital Agammaglobulinemia and directly associated with 
switched-memory B cells in healthy subjects, which raises important questions regarding the 
impact of B-cell depleting therapies on this population. 
 
In section 1 of the chapter of Results, we showed that BAFF-R and TACI expression were 
altered in CVID patients, likely contributing to disease pathogenesis. It will be extremely useful 
to understand whether altered receptor expression translates into altered ligand-binding and 
consequently to perturbed ligand responsiveness. This can be achieved by studying BAFF-binding 
capacity in B cells from CVID patients with different levels of BAFF-R expression. We have also 
hypothesized that BAFF can modulate the levels of BAFF-R in a physiological context. Our data 
showing that BAFF-R expression decreases following 5 minutes of stimulation with BAFF is 
suggestive that BAFF-R is being internalized, but further experiments are necessary in order to 
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better evaluate this point, namely through the use of inhibitors of endocytosis. It will also be 
important to understand, in case internalization occurs, what is the fate of internalized BAFF-R. 
Whether it is a target for degradation or it recycles back to the cell membrane may have 
different biological significances and outcomes. This is particularly relevant given the fact that 
we found high BAFF serum levels in CVID patients, together with low BAFF-R expression on B 
cells. A scenario where BAFF ligation is targeting BAFF-R to degradation could explain our 
observations and imply that B cells from CVID patients are consequently less responsive to BAFF 
stimulation. However, a previous report has suggested, although through a distinct experimental 
approach, that this may not be the case1. Another possibility that can be responsible for the 
down-regulation of BAFF-R upon BAFF binding is that BAFF-R is being cleaved and shed into the 
extracellular space. This is a rather interesting possibility, since it would prevent BAFF from 
acting on its target B cells. BAFF-R shedding could then act as a buffer in situations where excess 
BAFF is present. This mechanism has been described to occur for TNF receptors and to be critical 
for the regulation of TNF activity in vivo2. Our results have thus revealed a new possibility in 
which BAFF regulates the levels of its receptor, BAFF-R. Understanding the mechanisms involved 
in this modulation will be particularly relevant to discern whether BAFF-depleting therapies3 may 
have a place in the treatment of CVID. In the case of applying such therapies in CVID patients, 
the main aim would not probably be the total depletion of circulating BAFF but rather the 
elimination of the excess BAFF, in order to allow B cells to regain a normal response to this 
homeostatic cytokine. In this sense, BAFF-depleting therapies would have to be tailored to each 
patient. 
 
In section 2 of the chapter of Results, we reported that the frequencies of TH17 cells and 
switched-memory B cells are directly associated in healthy subjects, and that Congenital 
Agammaglobulinemia patients, who lack peripheral B cells, have a severe reduction of this CD4 
T-cell population. In addition, in CVID patients, who present primary defects in mature B-cell 
differentiation, the frequency of TH17 cells was inversely correlated with markers of GC 
dysfunction, suggesting that B cells play a role in the homeostasis of the TH17 subset. These 
results raise important questions in what concerns the use of B-cell depleting therapies in clinical 
contexts where TH17 have a pathological role, and the beneficial impact that these therapies can 
by affecting this population. Concerning our findings of markedly reduced frequencies of IL-17-
producing CD4 T cells in patients with Congenital Agammaglobulinemia, it will be of greater 
importance to understand whether this is due to intrinsic T-cell defects or to a lack of adequate 
interactions in vivo. Our preliminary data on the assessment of the ability of naïve CD4 T cells 
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from Congenital Agammaglobulinemia patients to differentiate under TH17-polarizing conditions 
suggest that there is actually a cell-specific defect, but this point needs further evaluation. In the 
case this cell-specific defect is confirmed, it will be important to understand which phase of TH17 
differentiation is affected: induction, amplification or survival. Given that each of these phases 
has different molecular requirements, identifying which one is affected would shed light into the 
molecular mechanism underlying the differentiation defect. However, the recent data showing 
that B-cell depletion with rituximab in rheumatoid arthritis patients specifically inhibits the TH17 
response, without affecting other T-cell subsets4, appear to be against the view of Congenital 
Agammaglobulinemia patients having a cell-intrinsic defect in TH17 differentiation, and rather 
suggest that B cells themselves are involved in the development of TH17 responses. 
Nevertheless, we can also hypothesize that the fact that CD4 T cells from Congenital 
Agammaglobulinemia have not been exposed to interaction with B cells makes them less prone 
to develop into the TH17 population. 
 
Regarding the data we have generated on Treg cells, we show that the frequencies of Treg 
cells and TH17 cells are directly associated in CVID patients. These data support the view that the 
impairment of the GCs found in CVID may have an impact in both populations. In addition, we 
report dissociation between FOXP3 and CD25 expression in CVID patients, with severely 
impaired expression of CD25 in the presence of normal frequencies of FOXP3+ CD4 T cells. It will 
be important to clarify the putative Treg disturbances in CVID 
5-8. In what concerns our data, we 
can hypothesize that Treg cells are reduced, in which case expression of FOXP3 is mainly related 
to activation. However, the fact that we found no difference in the MFI of FOXP3 expression 
would be against this view, since high levels of FOXP3 expression are regarded as a good 
estimate of Treg function
9. Nevertheless, the fact that CVID patients with autoimmunity, 
lymphoid proliferation or chronic diarrhoea present a significant decrease in FOXP3 MFI may be 
pointing to a true decrease of Treg cells, at least in some groups of CVID patients. We can also put 
forward a different picture where Treg cells are not reduced in CVID, but their suppressive 
function is affected by the loss of CD25 expression. The expansion of FOXP3+CD25- CD4 T cells, 
which has also been described in SLE with conflicting data regarding their suppressive function10-
14, seems to be in favour of this hypothesis. A third situation can also be envisaged, in which Treg 
cells are not reduced in CVID and there is also no loss of suppressive function. This would mean 
that the low levels of CD25 expression would not impact on Treg function and would be likely 
related to either lack of appropriate stimulation in vivo or to an intrinsic defect to respond to, for 
instance, TCR stimulation or c cytokines.  
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Finally, in section 3 of the chapter of Results, we showed that CVID, contrary to 
Congenital Agammaglobulinemia, was associated with monocyte imbalances that directly 
correlated with T-cell activation markers and with B-cell imbalances, without an association with 
plasma LPS levels. A very recent report has corroborated our data, also showing that CVID 
patients present increased serum levels of sCD14 in direct correlation with T-cell activation, in 
the absence of increased levels of LPS15. We thus describe monocyte activation as being a 
feature of CVID, and hypothesize that a possible modulation of microbial translocation may be 
taking place by the action of the IgG replacement therapy. To properly evaluate this possibility, it 
will be crucial to assess the levels of LPS, LBP, sCD14 and anti-LPS antibodies, together with 
other more suitable indicators of microbial translocation, such as bacterial 16S ribosomal DNA, 
in the group of CVID patients that are being followed longitudinally prior to and after 
commencing IgG replacement therapy. Only through the study of these patients we will be able 
to ascertain whether IgG replacement therapy has a role in these processes. However, this 
seems to be an unlikely possibility, given the fact that we found a limited impact of IgG 
replacement therapy in parameters related to monocyte and T-cell activation in our longitudinal 
follow-up of CVID patients starting therapy, together with little impact on B- and T-cell 
compartments. It does seem that the immune imbalances that CVID patients present are stable 
and likely related to the clinical course of the disease, with little influence from the IgG 
replacement therapy. 
 
The schematic diagram shown in Figure 1 summarizes the immune system disturbances 
that we observed in primary B-cell immunodeficiencies. In Congenital Agammaglobulinemia 
patients, who lack B cells, we do not observe major alterations in the monocyte compartment, 
while the impairments in T cells appear to be restricted to a reduction in the levels of circulating 
TH17 and TFH cells. In contrast, in CVID patients, who have B cells that are dysfunctional, both 
lymphoid and myeloid compartments are affected. CVID patients present both monocyte and T-
cell activation, in direct association with B-cell imbalances. In addition, our preliminary data also 
suggest that CVID patients have increased frequencies of circulating TFH cells, underpinning the 
role of disturbed GC function in CVID pathogenesis. 
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Figure 1. Simplified schematic representation of the disturbances of the immune system associated with primary B-
cell immunodeficiencies. (A) Interaction between T cells, B cells and antigen-presenting cells (APC) in the normally-
functioning immune system. (B) In the absence of B cells, as exemplified by Congenital Agammaglobulinemia patients, 
no major alterations are seen in the monocyte (APC) compartment, and imbalances at the level of T cells appear to be 
confined to a reduction in circulating TH17 cells and TFH cells. (C) When B cells are present but dysfunctional, as in the 
case of CVID patients, monocyte activation is observed, in direct association with T-cell activation and with the 
expansion of pathogenic CD21
low
CD38
low
 B cells. 
 
Additionally, while patients with Congenital Agammaglobulinemia have clinical 
manifestations that are mostly related to the increased susceptibility to infections derived from 
the absence of B cells and antibody production, CVID patients have a much more complex 
clinical picture, with a high prevalence of autoimmunity and lymphoproliferation16. These clinical 
manifestations are sometimes difficult to treat and consequently there is a need for improved 
therapeutic strategies.  
Given the plethora of clinical complications and immune alterations present in CVID 
patients17, it can be argued that allogeneic haematopoietic stem cell transplantation (HSCT) 
might actually be considered a curative strategy. By wiping out the old compromised immune 
system and replacing it with a new one, normal immunity in CVID patients might be restored. 
HSCT has been reported as a treatment for CVID patients in the case of malignancy, for which 
patients are at a high risk16. Quite recently, the outcome of HSCT performed in four CVID 
patients, either for malignancy or for severe CVID with imminent organ failure, has been 
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reported, with promising results18. Even though only one of the four treated CVID patients has 
been clinically “cured”, resolving all CVID-related complications, including Ig production, in 
addition to the lymphoma for which the patient received allogeneic HSCT, the proof of principle 
has been made18. HSCT can thus be envisioned as a curative approach, even if great care must be 
taken when selecting patients and donors for this procedure. HSCT implies the use of 
conditioning, even if at low doses. In addition, graft-versus-host disease is always a risk19. 
Consequently, only patients with severe clinical manifestations that are refractory to 
conventional treatments should be considered, but it should also be bore in mind that once 
serious organ damage has occurred, HSCT has very little potential to revert the situation. Given 
the great improvements that have been made in HSCT, both in terms of conditioning and the 
treatment of complications arising from transplantation, HSCT may be considered a true option 
in the treatment of CVID in the near future. Nevertheless, HSCT should only be regarded in a 
limited number of cases, and so the need for therapeutic strategies that may target the 
complexity of immune defects present in CVID still prevails.  
 
 
In conclusion, we have shown that both B-cell intrinsic and extrinsic defects are 
underlying the pathogenesis of CVID. B-cell homeostasis is likely impaired, given that expression 
of BAFF-R is significantly reduced, while TACI expression is increased in CVID patients, both of 
which in direct correlation with high serum levels of BAFF. These data raise the possibility of 
BAFF-depleting therapies being envisaged in the treatment of CVID. In addition, we have 
reported that the homeostasis of the TH17 population is related to B-cell maturation, illustrated 
by the severe reduction of TH17 cells in patients with Congenital Agammaglobulinemia, with 
implications for the role of B-cell depleting therapies in this population. Finally, the finding of 
increased levels of monocyte activation in CVID patients that are directly associated with T-cell 
activation points out the need to design therapeutic strategies that target immune activation, in 
order to achieve better treatments for non-infectious complications. 
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